<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Droperidol for psychosis‐induced aggression or agitation - Khokhar, MA - 2016 | Cochrane Library</title> <meta content="Droperidol for psychosis‐induced aggression or agitation - Khokhar, MA - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002830.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Droperidol for psychosis‐induced aggression or agitation - Khokhar, MA - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002830.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD002830.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Droperidol for psychosis‐induced aggression or agitation" name="citation_title"/> <meta content="Mariam A Khokhar" name="citation_author"/> <meta content="University of Sheffield" name="citation_author_institution"/> <meta content="memzcasse@hotmail.com" name="citation_author_email"/> <meta content="John Rathbone" name="citation_author"/> <meta content="Bond University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD002830.pub3" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/12/15" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002830.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002830.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002830.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acute Disease; Aggression [drug effects]; Antipsychotic Agents [*therapeutic use]; Benzodiazepines [therapeutic use]; Droperidol [*therapeutic use]; Haloperidol [therapeutic use]; Midazolam [therapeutic use]; Olanzapine; Psychomotor Agitation [drug therapy]; Psychotic Disorders [*drug therapy]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002830.pub3&amp;doi=10.1002/14651858.CD002830.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002830.pub3&amp;doi=10.1002/14651858.CD002830.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002830.pub3&amp;doi=10.1002/14651858.CD002830.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002830.pub3&amp;doi=10.1002/14651858.CD002830.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002830.pub3&amp;doi=10.1002/14651858.CD002830.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002830.pub3&amp;doi=10.1002/14651858.CD002830.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002830.pub3&amp;doi=10.1002/14651858.CD002830.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002830.pub3&amp;doi=10.1002/14651858.CD002830.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002830.pub3&amp;doi=10.1002/14651858.CD002830.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002830.pub3&amp;doi=10.1002/14651858.CD002830.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002830.pub3&amp;doi=10.1002/14651858.CD002830.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002830.pub3&amp;doi=10.1002/14651858.CD002830.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002830.pub3&amp;doi=10.1002/14651858.CD002830.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002830.pub3&amp;doi=10.1002/14651858.CD002830.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002830.pub3&amp;doi=10.1002/14651858.CD002830.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002830.pub3&amp;doi=10.1002/14651858.CD002830.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002830.pub3&amp;doi=10.1002/14651858.CD002830.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002830.pub3&amp;doi=10.1002/14651858.CD002830.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002830.pub3&amp;doi=10.1002/14651858.CD002830.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002830.pub3&amp;doi=10.1002/14651858.CD002830.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002830.pub3&amp;doi=10.1002/14651858.CD002830.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002830.pub3&amp;doi=10.1002/14651858.CD002830.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002830.pub3&amp;doi=10.1002/14651858.CD002830.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="XwNPMGod";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD002830\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD002830\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002830\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002830\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","hr","fr","pl","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD002830.pub3",title:"Droperidol for psychosis\\u2010induced aggression or agitation",firstPublishedDate:"Dec 15, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Schizophrenia Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=XwNPMGod&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002830.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002830.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD002830.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD002830.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002830.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD002830.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD002830.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD002830.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD002830.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD002830.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5182 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD002830.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002830.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002830.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002830.pub3/full#CD002830-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002830.pub3/full#CD002830-sec-0237"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002830.pub3/full#CD002830-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002830.pub3/full#CD002830-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002830.pub3/full#CD002830-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002830.pub3/full#CD002830-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002830.pub3/full#CD002830-sec-0112"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002830.pub3/full#CD002830-sec-0213"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002830.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002830.pub3/appendices#CD002830-sec-0249"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002830.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002830.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/table_n/CD002830StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/table_n/CD002830StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002830.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002830.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002830.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002830.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002830.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD002830.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Droperidol for psychosis‐induced aggression or agitation</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002830.pub3/information#CD002830-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Mariam A Khokhar</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002830.pub3/information#CD002830-cr-0003">John Rathbone</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/information/en#CD002830-sec-0335">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 15 December 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD002830.pub3">https://doi.org/10.1002/14651858.CD002830.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD002830-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002830-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002830-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002830-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002830-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD002830-abs-0001" lang="en"> <section id="CD002830-sec-0001"> <h3 class="title" id="CD002830-sec-0001">Background</h3> <p>People experiencing acute psychotic illnesses, especially those associated with agitated or violent behaviour, may require urgent pharmacological tranquillisation or sedation. Droperidol, a butyrophenone antipsychotic, has been used for this purpose in several countries. </p> </section> <section id="CD002830-sec-0002"> <h3 class="title" id="CD002830-sec-0002">Objectives</h3> <p>To estimate the effects of droperidol, including its cost‐effectiveness, when compared to placebo, other 'standard' or 'non‐standard' treatments, or other forms of management of psychotic illness, in controlling acutely disturbed behaviour and reducing psychotic symptoms in people with schizophrenia‐like illnesses. </p> </section> <section id="CD002830-sec-0003"> <h3 class="title" id="CD002830-sec-0003">Search methods</h3> <p>We updated previous searches by searching the Cochrane Schizophrenia Group Register (18 December 2015). We searched references of all identified studies for further trial citations and contacted authors of trials. We supplemented these electronic searches by handsearching reference lists and contacting both the pharmaceutical industry and relevant authors. </p> </section> <section id="CD002830-sec-0004"> <h3 class="title" id="CD002830-sec-0004">Selection criteria</h3> <p>We included all randomised controlled trials (RCTs) with useable data that compared droperidol to any other treatment for people acutely ill with suspected acute psychotic illnesses, including schizophrenia, schizoaffective disorder, mixed affective disorders, the manic phase of bipolar disorder or a brief psychotic episode. </p> </section> <section id="CD002830-sec-0005"> <h3 class="title" id="CD002830-sec-0005">Data collection and analysis</h3> <p>For included studies, we assessed quality, risk of bias and extracted data. We excluded data when more than 50% of participants were lost to follow‐up. For binary outcomes, we calculated standard estimates of risk ratio (RR) and the corresponding 95% confidence intervals (CI). We created a 'Summary of findings' table using GRADE. </p> </section> <section id="CD002830-sec-0006"> <h3 class="title" id="CD002830-sec-0006">Main results</h3> <p>We identified four relevant trials from the update search (previous version of this review included only two trials). When droperidol was compared with placebo, for the outcome of tranquillisation or asleep by 30 minutes we found evidence of a clear difference (1 RCT, N = 227, RR 1.18, 95% CI 1.05 to 1.31, <i>high‐quality evidence</i> ). There was a clear demonstration of reduced risk of needing additional medication after 60 minutes for the droperidol group (1 RCT, N = 227, RR 0.55, 95% CI 0.36 to 0.85, <i>high‐quality evidence</i> ). There was no evidence that droperidol caused more cardiovascular arrhythmia (1 RCT, N = 227, RR 0.34, 95% CI 0.01 to 8.31, <i>moderate‐quality evidence</i> ) and respiratory airway obstruction (1 RCT, N = 227, RR 0.62, 95% CI 0.15 to 2.52, <i>low‐quality evidence</i> ) than placebo. For 'being ready for discharge', there was no clear difference between groups (1 RCT, N = 227, RR 1.16, 95% CI 0.90 to 1.48, <i>high‐quality evidence</i>). There were no data for mental state and costs. </p> <p>Similarly, when droperidol was compared to haloperidol, for the outcome of tranquillisation or asleep by 30 minutes we found evidence of a clear difference (1 RCT, N = 228, RR 1.01, 95% CI 0.93 to 1.09, <i>high‐quality evidence</i> ). There was a clear demonstration of reduced risk of needing additional medication after 60 minutes for participants in the droperidol group (2 RCTs, N = 255, RR 0.37, 95% CI 0.16 to 0.90, <i>high‐quality evidence</i> ). There was no evidence that droperidol caused more cardiovascular hypotension (1 RCT, N = 228, RR 2.80, 95% CI 0.30 to 26.49,<i>moderate‐quality evidence</i> ) and cardiovascular hypotension/desaturation (1 RCT, N = 228, RR 2.80, 95% CI 0.12 to 67.98, <i>low‐quality evidence</i> ) than haloperidol. There was no suggestion that use of droperidol was unsafe. For mental state, there was no evidence of clear difference between the efficacy of droperidol compared to haloperidol (Scale for Quantification of Psychotic Symptom Severity, 1 RCT, N = 40, mean difference (MD) 0.11, 95% CI ‐0.07 to 0.29, <i>low‐quality evidence</i>). There were no data for service use and costs. </p> <p>Whereas, when droperidol was compared with midazolam, for the outcome of tranquillisation or asleep by 30 minutes we found droperidol to be less acutely tranquillising than midazolam (1 RCT, N = 153, RR 0.96, 95% CI 0.72 to 1.28, <i>high‐quality evidence</i> ). As regards the 'need for additional medication by 60 minutes after initial adequate sedation, we found an effect (1 RCT, N = 153, RR 0.54, 95% CI 0.24 to 1.20, <i>moderate‐quality evidence</i> ). In terms of adverse effects, we found no statistically significant differences between the two drugs for either airway obstruction (1 RCT, N = 153, RR 0.13, 95% CI 0.01 to 2.55, <i>low‐quality evidence</i> ) or respiratory hypoxia (1 RCT, N = 153, RR 0.70, 95% CI 0.16 to 3.03, <i>moderate‐quality evidence</i>) ‐ but use of midazolam did result in three people (out of around 70) needing some sort of 'airway management' with no such events in the droperidol group. There were no data for mental state, service use and costs. </p> <p>Furthermore, when droperidol was compared to olanzapine, for the outcome of tranquillisation or asleep by any time point, we found no clear differences between the older drug (droperidol) and olanzapine (e.g. at 30 minutes: 1 RCT, N = 221, RR 1.02, 95% CI 0.94 to 1.11, <i>high‐quality evidence</i> ). There was a suggestion that participants allocated droperidol needed less additional medication after 60 minutes than people given the olanzapine (1 RCT, N = 221, RR 0.56, 95% CI 0.36 to 0.87, <i>high‐quality evidence</i> ). There was no evidence that droperidol caused more cardiovascular arrhythmia (1 RCT, N = 221, RR 0.32, 95% CI 0.01 to 7.88, <i>moderate‐quality evidence</i> ) and respiratory airway obstruction (1 RCT, N = 221, RR 0.97, 95% CI 0.20 to 4.72, <i>low‐quality evidence</i> ) than olanzapine. For 'being ready for discharge', there was no difference between groups (1 RCT, N = 221, RR 1.06, 95% CI 0.83 to 1.34, <i>high‐quality evidence</i>). There were no data for mental state and costs. </p> </section> <section id="CD002830-sec-0007"> <h3 class="title" id="CD002830-sec-0007">Authors' conclusions</h3> <p>Previously, the use of droperidol was justified based on experience rather than evidence from well‐conducted and reported randomised trials. However, this update found high‐quality evidence with minimal risk of bias to support the use of droperidol for acute psychosis. Also, we found no evidence to suggest that droperidol should not be a treatment option for people acutely ill and disturbed because of serious mental illnesses. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD002830-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002830-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002830-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002830-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002830-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD002830-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/pl#CD002830-abs-0008">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD002830-abs-0005">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD002830-abs-0004" lang="en"> <h3>Droperidol for psychosis‐induced aggression or agitation</h3> <p>Is droperidol effective for managing people who are aggressive or agitated due to psychosis? </p> <p><b>Background</b> </p> <p>People with psychosis can experience symptoms such as hallucinations (seeing or hearing things that are not there) or delusions (belief in things that are bizarre or obviously not true). These symptoms are often disturbing and frightening, and can lead to people with psychosis becoming very disturbed, violent or agitated. Droperidol is one of the medicines normally used to help calm (tranquillise) people in this situation. Previously, the use of this drug was based on results from small clinical trials with no firm conclusion regarding its effects. Larger trials were needed. </p> <p><b>Searching</b> </p> <p>In 2015, the Information Specialist of the Cochrane Schizophrenia Group updated previous searches of their specialised register of studies. The review authors identified and screened 21 records. </p> <p><b>Description of studies</b> </p> <p>Six randomised controlled studies are now included in the review. All the studies randomised people who were aggressive or agitated due to psychosis to receive either droperidol or placebo (a pretend medicine), haloperidol, olanzapine or midazolam. The size of the studies ranged from 40 to 221 participants. All took place in within a hospital. Four of the six studies were under two hours of duration. </p> <p><b>Main results</b> </p> <p>Compared to placebo, droperidol was more effective at tranquillising agitated participants 30 minutes after taking it. Similar results were found for tranquillisation when droperidol was compared with haloperidol but this effect was less clear, and not evident when droperidol was compared to midazolam or olanzapine. Droperidol did not cause more side effects than the other drugs in the studies. The studies did not look at costs. </p> <p><b>Review authors' conclusions</b> </p> <p>Although we could only include six studies, they provided high‐quality evidence suggesting that droperidol is effective and can be used to control people with very disturbed and aggressive behaviours caused by psychosis. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD002830-sec-0237" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD002830-sec-0237"></div> <h3 class="title" id="CD002830-sec-0238">Implications for practice</h3> <section id="CD002830-sec-0238"> <section id="CD002830-sec-0239"> <h5 class="title">1 For people with psychotic illness</h5> <p>Acute psychotic illness, especially with agitated, aggressive or violent behaviours, may require rapid tranquillisation or sedation. Droperidol, a butyrophenone neuroleptic that is no longer commercially promoted or manufactured, remains a viable option for this purpose based on more evidence from randomised controlled trials in this 2016 update. </p> </section> <section id="CD002830-sec-0240"> <h5 class="title">2 For clinicians</h5> <p>Intramuscular droperidol was once a popular choice for the acute management of very psychotic aggressive and agitated people. The first version of this review thought that evidence relating to use of droperidol was of historical interest only (<a href="./references#CD002830-bbs2-0082" title="CureS , RathboneJ , CarpenterS . Droperidol for acute psychosis. Cochrane Database of Systematic Reviews2004, Issue 4. [DOI: 10.1002/14651858.CD002830.pub2; PUBMED: 15495037] ">Cure 2004</a>). This seems to be untrue. Droperidol is still used. There remains compelling evidence that droperidol has a place in short‐term management of psychotic aggressive people. The evidence presented in this review allows conclusions to be drawn about its comparative efficacy to haloperidol, midazolam and olanzapine that concur with the impressions of the effectiveness of these other compounds from other sources. Clinicians could help evaluate these different approaches by supporting clinically relevant randomised controlled trials. We found no evidence of reasons for any more concern over cardiac problems than with other approaches, and less for respiratory difficulties than midazolam. </p> </section> <section id="CD002830-sec-0241"> <h5 class="title">3 For managers/policy makers</h5> <p>Currently it seems that people in Australia, Belgium, Brazil, Czech Republic, Denmark, Finland, Greece, India, Italy, Netherlands, New Zealand, South Africa, Spain, Sweden, Thailand, and the USA have droperidol as one option for treatment of aggression thought due to psychosis. Much evidence for other compounds or approaches is no stronger than for this old drug. </p> </section> </section> <h3 class="title" id="CD002830-sec-0242">Implications for research</h3> <section id="CD002830-sec-0242"> <section id="CD002830-sec-0243"> <h5 class="title">1 General</h5> <p>As with all similar studies, public registration of a study before randomisation commences would ensure that participants could be confident that people would know that the study had at least taken place. Better reporting of data would have allowed us to determine the effects of this compound in emergency situations. Newer trials tended to comply with <a href="http://www.consort-statement.org/" target="_blank">CONSORT</a> making it much easier to understand the methods of the studies. We hope that trials in the next version of this review will go that one last and important step and allow full access to all data (<a href="http://www.alltrials.net/" target="_blank">AllTrials</a>; <a href="http://opentrials.net/" target="_blank">OpenTrials</a>). </p> </section> <section id="CD002830-sec-0244"> <h5 class="title">2 Specific</h5> <section id="CD002830-sec-0245"> <h6 class="title">2.1 Reviews</h6> <p>Several of the excluded studies in this review would be relevant for inclusion in related Cochrane reviews (<a href="#CD002830-tbl-0010">Table 6</a>). </p> </section> <section id="CD002830-sec-0246"> <h6 class="title">2.2 Trials</h6> <p>This review highlights the urgent need for more good quality controlled trials of other compounds for management of acute psychosis that address outcomes of major importance such as quality of life, economic costs and satisfaction of carers. We realise that design of such studies takes time and a great deal of thought and commitment. However, we have given this area some thought and suggest the broad outline of a trial in <a href="#CD002830-tbl-0011">Table 7</a>. </p> <div class="table" id="CD002830-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Design of a future study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised (clearly described).</p> <p>Blinding: single blind (outcomes assessor).</p> <p>Duration: up to 2 weeks.</p> <p>Design: parallel.</p> <p>Setting: emergency settings.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diagnosis: people whose aggressive behaviour is thought due to psychotic illness.</p> <p>N = 300.</p> <p>Age: &gt; 18 years.</p> <p>Sex: not applicable.</p> <p>Inclusion criteria: other measures failed.</p> <p>Exclusion criteria: specific contraindication to evaluated treatments.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Droperidol. N = 150.</p> <p>2. Drug intervention of choice. N = 150.</p> <p>Both drugs should be known to be effective, but the comparative effectiveness be unclear.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tranquil/asleep: binary outcomes, time.</p> <p>Behaviour: need for additional medication, additional aggressive episode.</p> <p>Adverse effects.</p> <p>Acceptability of treatment.</p> <p>Costs: cost of services, cost of care.</p> <p>Quality of life.</p> <p>Service outcomes: days in hospital, discharged, transfer to secure unit.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Notes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study should comply with <a href="http://www.consort-statement.org/" target="_blank">CONSORT</a> and <a href="http://www.alltrials.net/" target="_blank">AllTrials</a>. </p> </td> </tr> </tbody> </table> </div> </section> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD002830-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD002830-sec-0022"></div> <div class="table" id="CD002830-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Droperidol versus placebo</span></div> <tbody> <tr class="table-header separated"> <td align="left" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b>Droperidol versus placebo</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> acute psychosis </p> <p><b>Setting:</b> inpatient </p> <p><b>Intervention:</b> droperidol </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with droperidol</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tranquillisation or asleep: tranquillised/sleep ‐ by around 30 minutes</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.18<br/> (1.05 to 1.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>227<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>'Moderate' control risk approximately that of trial population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>800 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>944 per 1000<br/> (840 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Global state: use of additional medication ‐ by 60 minutes after initial adequate sedation until ED discharge (various psychotropic drugs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.55<br/> (0.36 to 0.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>227<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>'Moderate' control risk approximately that of trial population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>400 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>220 per 1000<br/> (144 to 340) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects ‐ cardiovascular ‐ arrhythmia</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.34<br/> (0.01 to 8.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>227<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>'Moderate' control risk approximately that of trial population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000<br/> (0 to 83) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects ‐ respiratory ‐ airway obstruction</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.62<br/> (0.15 to 2.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>227<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low <sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>'Moderate' control risk approximately that of trial population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000<br/> (6 to 101) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Service use: person able to be discharged home</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.16<br/> (0.90 to 1.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>227<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>'Moderate' control risk approximately that of trial population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>580 per 1000<br/> (450 to 740) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mental state ‐ improvement</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No trial reported this important outcome.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Economic: direct costs</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No trial reported this important outcome.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>ED:</b> emergency department; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: rated 'not serious' (no downgrade) ‐ clear reporting of good methods. </p> <p><sup>2</sup> Indirectness: rated 'not serious' (no downgrade) ‐ but proxy outcome for 'Another episode of aggression by 24 hours'. </p> <p><sup>3</sup> Imprecision: rated 'serious' (downgraded by 1) ‐ few events, wide confidence intervals. </p> <p><sup>4</sup> Indirectness: rated 'serious' (downgraded by 1) ‐ respiratory obstruction proxy measure ‐ not 'death'. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002830-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Droperidol versus haloperidol</span></div> <tbody> <tr class="table-header separated"> <td align="left" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b>Droperidol versus haloperidol</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> acute psychosis </p> <p><b>Setting:</b> inpatient </p> <p><b>Intervention:</b> droperidol </p> <p><b>Comparison:</b> haloperidol </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with haloperidol</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with droperidol</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tranquillisation or asleep: tranquillised/sleep ‐ by around 30 minutes</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.01<br/> (0.93 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>228<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>'Moderate' control risk approximately that of trial population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>920 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>929 per 1000<br/> (856 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Global state: use of additional medication ‐ by 60 minutes after initial adequate sedation until ED discharge (various psychotropic drugs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.37<br/> (0.16 to 0.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>255<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>'Moderate' control risk approximately that of trial population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>160 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>59 per 1000<br/> (26 to 144) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects ‐ cardiovascular ‐ hypotension</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.80<br/> (0.30 to 26.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>228<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>'Moderate' control risk approximately that of trial population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000<br/> (3 to 265) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects ‐ cardiovascular ‐ hypotension/desaturation</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.80 (0.12 to 67.98)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>228<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low <sup>1,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>'Moderate' control risk approximately that of trial population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Service use: person able to be discharged home</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not pooled</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No trial reported this important outcome.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mental state: mean score by 13 days (Scale for Quantification of Psychotic Symptom Severity, high = poor) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: mean score by 13 days (Scale for Quantification of Psychotic Symptom Severity, high = poor) was 0 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: mean score by 13 days (Scale for Quantification of Psychotic Symptom Severity, high = poor) in the intervention group was 0.11 undefined more (0.07 fewer to 0.29 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.11</p> <p>CI ‐0.07 to 0.29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low <sup>1,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>'Moderate' control risk approximately that of trial population.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Economic: direct costs</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No trial reported this important outcome.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>ED:</b> emergency department; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: rated 'not serious' (no downgrade) ‐ clear reporting of good methods. </p> <p><sup>2</sup> Indirectness: rated 'not serious' (no downgrade) ‐ but proxy outcome for 'Another episode of aggression by 24 hours'. </p> <p><sup>3</sup> Imprecision: rated 'serious' (downgraded by 1) ‐ few events, wide confidence intervals. </p> <p><sup>4</sup> Indirectness: rated 'serious' (downgraded by 1) ‐ hypotension/desaturation proxy measure ‐ not 'death'. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002830-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Droperidol versus midazolam</span></div> <tbody> <tr class="table-header separated"> <td align="left" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b>Droperidol versus midazolam</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> acute psychosis </p> <p><b>Setting:</b> inpatient </p> <p><b>Intervention:</b> droperidol </p> <p><b>Comparison:</b> midazolam </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with midazolam</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with droperidol</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tranquillisation or asleep: tranquillised/asleep ‐ by 30 minutes (at 10 minutes)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.96<br/> (0.72 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>153<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>'Moderate' control risk approximately that of trial population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>550 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>528 per 1000<br/> (396 to 704) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Global state: use of additional medication ‐ by 60 minutes after initial adequate sedation until ED discharge (various psychotropic drugs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.54 (0.24 to 1.20)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>153<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>'Moderate' control risk approximately that of trial population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>190 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>101 per 1000<br/> (42 to 224) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects ‐ respiratory ‐ airway obstruction</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.13<br/> (0.01 to 2.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>153<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low <sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>'Moderate' control risk approximately that of trial population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000<br/> (0 to 102) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects ‐ respiratory ‐ hypoxia</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.70<br/> (0.16 to 3.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>153<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>'Moderate' control risk approximately that of trial population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>35 per 1000<br/> (8 to 143) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Service use: person able to be discharged home</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No trial reported this important outcome.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mental state ‐ improvement</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No trial reported this important outcome.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Economic: direct costs</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No trial reported this important outcome.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>ED:</b> emergency department; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: rated 'not serious' (no downgrade) ‐ clear reporting of good methods. </p> <p><sup>2</sup> Imprecision: rated 'serious' (downgraded by 1) ‐ few events, wide confidence intervals. </p> <p><sup>3</sup> Indirectness: rated 'serious' (downgraded by 1) ‐ respiratory obstruction proxy measure ‐ not 'death'. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002830-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Droperidol versus olanzapine</span></div> <tbody> <tr class="table-header separated"> <td align="left" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b>Droperidol versus olanzapine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> acute psychosis </p> <p><b>Setting:</b> inpatient </p> <p><b>Intervention:</b> droperidol </p> <p><b>Comparison:</b> olanzapine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with olanzapine</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with droperidol</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tranquillisation or asleep: tranquillised/asleep ‐ by around 30 minutes</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.02<br/> (0.94 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>221<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>'Moderate' control risk approximately that of trial population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>900 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>918 per 1000<br/> (846 to 999) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Global state: use of additional medication ‐ by 60 minutes after initial adequate sedation until ED discharge (various psychotropic drugs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.56<br/> (0.36 to 0.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>221<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>'Moderate' control risk approximately that of trial population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>370 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>207 per 1000<br/> (133 to 322) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects ‐ cardiovascular ‐ arrhythmia</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.32<br/> (0.01 to 7.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>221<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>'Moderate' control risk approximately that of trial population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000<br/> (0 to 79) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects ‐ respiratory ‐ airway obstruction</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.97<br/> (0.20 to 4.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>221<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low <sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>'Moderate' control risk approximately that of trial population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000<br/> (6 to 142) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Service use: person able to be discharged home</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.06<br/> (0.83 to 1.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>221<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>'Moderate' control risk approximately that of trial population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>530 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>562 per 1000<br/> (440 to 710) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mental state ‐ improvement</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No trial reported this important outcome.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Economic: direct costs</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No trial reported this important outcome.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>ED:</b> emergency department; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: rated 'not serious' (no downgrade) ‐ clear reporting of good methods. </p> <p><sup>2</sup> Imprecision: rated 'serious' (downgraded by 1) ‐ few events, wide confidence intervals. </p> <p><sup>3</sup> Indirectness: rated 'serious' (downgraded by 1) ‐ respiratory obstruction proxy measure ‐ not 'death'. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD002830-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD002830-sec-0023"></div> <section id="CD002830-sec-0024"> <h3 class="title" id="CD002830-sec-0024">Description of the condition</h3> <p>Violent or acutely disturbed people pose a risk to themselves and to others, as well as a diagnostic dilemma (<a href="./references#CD002830-bbs2-0018" title="ThomasHJr , SchwartzE , PetrilliR . Droperidol versus haloperidol for chemical restraint of agitated and combative patients. Annals of Emergency Medicine1992;21(4):407‐13. ">Thomas 1992</a>). The actual prevalence of violent behaviour is high although percentages differ according to setting, definition, client group and measure (<a href="./references#CD002830-bbs2-0052" title="LatalovaK . Violence and duration of untreated psychosis in first‐episode patients. International Journal of Clinical Practice2014;68(3):330‐5. [PUBMED: 24471741] ">Latalova 2014</a>). For people presenting with first episode of illness, serious violence has been reported in anything between 2% and nearly 30% (<a href="./references#CD002830-bbs2-0052" title="LatalovaK . Violence and duration of untreated psychosis in first‐episode patients. International Journal of Clinical Practice2014;68(3):330‐5. [PUBMED: 24471741] ">Latalova 2014</a>). Violent behaviour may be more prevalent at this point in a person's illness, when their symptoms may have gone unnoticed for some time, and they are more vigorous than later on in life (<a href="./references#CD002830-bbs2-0078" title="WinsperC , SinghSP , MarwahaS , AmosT , LesterH , EverardL , et al. Pathways to violent behavior during first‐episode psychosis: a report from the UK National EDEN Study. JAMA Psychiatry2013;70(12):1287‐93. [PUBMED: 24089149] ">Winsper 2013</a>). </p> <p>Ideally, to ensure a safe and therapeutic environment, attempts should be made to calm the person either through verbal de‐escalation or intensive nursing techniques. Behaviour may frequently be too disturbed or agitated for 'verbal tranquillisation' to be effective, and further action, in the form of rapid tranquillisation, may be necessary. </p> </section> <section id="CD002830-sec-0025"> <h3 class="title" id="CD002830-sec-0025">Description of the intervention</h3> <p>Various drug regimens are used in such emergency situations, and clinical practice differs. One survey from the USA found that the medical directors of 20 emergency rooms preferred drug management for aggressive people to be a haloperidol‐lorazepam mixture (<a href="#CD002830-tbl-0005">Table 1</a>) (<a href="./references#CD002830-bbs2-0027" title="BinderRL , McNielDE . Contemporary practices in managing acute violent patients in 20 psychiatric emergency rooms. Psychiatric Services1999;50(12):1553‐4. ">Binder 1999</a>). In 1993, a similar survey of clinicians' preferences in the UK found that chlorpromazine was the most common choice (<a href="./references#CD002830-bbs2-0032" title="CunnaneJG . Drug management of disturbed behaviour by psychiatrists. Psychiatric Bulletin1994;18:138‐9. ">Cunnane 1994</a>). Another survey of emergency rooms in Rio de Janeiro found that a haloperidol‐promethazine mixture was commonly used for emergency intramuscular (IM) sedation of severely agitated/aggressive people (70 to 100 people with suspected psychotic illness per week per 3.5 million; <a href="#CD002830-tbl-0006">Table 2</a>) (<a href="./references#CD002830-bbs2-0047" title="HufG , daSilva Freire CoutinhoE , FagundesHMJr , OliveiraES , LopezJR , GewandszajderM , et al. Current practices in managing acutely disturbed patients at three hospitals in Rio de Janeiro‐Brazil: a prevalence study. BMC Psychiatry2002;1:4. ">Huf 2002</a>). A survey of frequency of emergency prescribing in a general psychiatric hospital in South London (UK) showed that rapid medical tranquillisation was required 102 times in 160 days (<a href="./references#CD002830-bbs2-0065" title="PilowskyLS , RingH , ShinePJ , BattersbyM , LaderM . Rapid tranquillisation. A survey of emergency prescribing in a general psychiatric hospital. British Journal of Psychiatry1992;160:831‐5. ">Pilowsky 1992</a>). Eight different drugs were used, amongst which diazepam, haloperidol and droperidol were used most often (<a href="#CD002830-tbl-0007">Table 3</a>). </p> <div class="table" id="CD002830-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Survey of 20 medical directors of emergency departments in the USA</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Favoured drug</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol + lorazepam ± benztropine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Droperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Benzodiazepine (unspecified) alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Droperidol + lorazepam + diphenhydramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol + benztropine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD002830-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Preferred medication for rapid tranquillisation in Rio de Janeiro</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Drug of choice</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean dose (mg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Frequency of use</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol + promethazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (2.5 to 10) + 50 (25 to 100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol + promethazine + diazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (2.5 to 10) + 50 (25 to 100) +10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol + promethazine + chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 + 50 + 25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine + diazepam + promethazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 + 10 + 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine + promethazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 + 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diazepam + promethazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 + 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol + diazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 + 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Promethazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1%</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD002830-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Drugs for rapid tranquillisation in London survey</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Drug of choice</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean dose (mg)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diazepam*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27 (10 to 80)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 (10 to 60)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>162 (50 to 400)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Droperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 (10 to 20)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paraldehyde</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>U/K</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amytal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>U/K</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lorazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>U/K</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nitrazepam**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>U/K</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>* most frequent; **least frequent; U/K: unknown.</p> </div> </div> <p>Droperidol (marketed as Dehydrobenzperidol, Dridol, Droleptan, Droperidols, Inapsin, Inapsine, Leptanal comp, Leptofen, Paxical or Sintodian) has been widely used in Europe by psychiatrists since the 1960s for treating acute or chronic psychoses (<a href="./references#CD002830-bbs2-0007" title="CocitoE , AmbrosiniG , ArataA , BevilacquaP , TortoraE . Clinical evaluation of 112 psychiatric patients of a butyrophenone neuroleptic, dehydrobenzperidol (R 4749). Arzneimittelforschung1970;20(8):1119‐25. ">Cocito 1970</a>; <a href="./references#CD002830-bbs2-0005" title="ResnickM , BurtonBT . Droperidol versus haloperidol in the initial management of acutely agitated patients. Journal of Clinical Psychiatry1984;45(7):298‐9. ">Resnick 1984</a>). It inhibits the effects of dopamine. In the USA, it is used primarily in conjunction with anaesthetics because of its sedative and antiemetic properties (<a href="./references#CD002830-bbs2-0005" title="ResnickM , BurtonBT . Droperidol versus haloperidol in the initial management of acutely agitated patients. Journal of Clinical Psychiatry1984;45(7):298‐9. ">Resnick 1984</a>). Reported advantages of droperidol over haloperidol (another inhibitor of the effects of dopamine) include: a faster onset of action when given IM, swifter elimination from the body and fewer adverse effects (<a href="./references#CD002830-bbs2-0016" title="RichardsJR , DerletRW , DuncanDR . Chemical restraint for the agitated patient in the emergency department: lorazepam versus droperidol. Journal of Emergency Medicine1998;16(4):567‐73. ">Richards 1998</a>). The most commonly reported adverse effects for droperidol include hypotension (abnormally low blood pressure) and tachycardia (above normal heart rate). Other adverse effects include restlessness, hyperactivity, anxiety and dysphoria (feeling ill at ease). The frequency of adverse effects involving movement disorders is reported to be 20% to 40% (<a href="./references#CD002830-bbs2-0007" title="CocitoE , AmbrosiniG , ArataA , BevilacquaP , TortoraE . Clinical evaluation of 112 psychiatric patients of a butyrophenone neuroleptic, dehydrobenzperidol (R 4749). Arzneimittelforschung1970;20(8):1119‐25. ">Cocito 1970</a>). Droperidol has been associated only rarely with serious adverse effects such as neuroleptic malignant syndrome (altered consciousness, muscle rigidity and autonomic instability) and sudden death. Sudden death has been reported to be associated with high doses of droperidol (25 mg or more) in people at risk for cardiac dysrhythmia, such as people with severe electrolyte disturbances or alcohol withdrawal (<a href="./references#CD002830-bbs2-0069" title="RxList.com , Inc . RxList ‐ Internet Drug Index. www.rxlist.com Accessed 26 July 2000. ">RxList 2000</a>). Droperidol should not be given to people with severe depression as it may aggravate their symptoms (<a href="./references#CD002830-bbs2-0059" title="MartindaleW , Pharmaceutical Society of Great Britain. Martindale: The Extra Pharmacopoeia. 28th Edition. London: Pharmaceutical Press, 1982. ">Martindale 1982</a>). </p> <p>Following an extensive risk‐benefit assessment requested by the Medicines Control Agency, Janssen‐Cilag, the pharmaceutical company who market droperidol, concluded that the oral form of droperidol should be discontinued and that the injectable form would no longer be commercially viable. The Medical Director of Janssen‐Cilag told PharmaTimes (<a href="http://www.pharmatimes.co.uk/" target="_blank">www.pharmatimes.co.uk/</a>) that the decision had been taken because many people who receive droperidol also receive other medications that extend QT prolongation, and are more likely to have background illnesses that may exacerbate the problem. He added that the company intended to implement a world‐wide withdrawal of droperidol, and supplies would stop entering the distribution chain at the end of March 2001. This seems not to have happened and droperidol has been used for this and other purposes (<a href="./references#CD002830-bbs2-0039" title="FurykJS , MeekRA , Egerton‐WarburtonD . Drugs for the treatment of nausea and vomiting in adults in the emergency department setting. Cochrane Database of Systematic Reviews2015, Issue 9. [DOI: 10.1002/14651858.CD010106.pub2; PUBMED: 26411330] ">Furyk 2015</a>; <a href="./references#CD002830-bbs2-0071" title="StorrarJ , HitchensM , PlattT , DormanS . Droperidol for treatment of nausea and vomiting in palliative care patients. Cochrane Database of Systematic Reviews2014, Issue 11. [DOI: 10.1002/14651858.CD006938.pub3; CD006938] ">Storrar 2014</a>), and research has continued. Some authoritative findings are not supportive of the original decision regarding QT prolongation (<a href="./references#CD002830-bbs2-0001" title="CalverL , DrinkwaterV , GuptaR , PageCB , IsbisterGK . Droperidol v. haloperidol for sedation of aggressive behaviour in acute mental health: randomized controlled trial. British Journal of Psychiatry2015;206(3):223‐8. ">Calver 2015</a>), and call into question the original Food and Drugs Authority decision and their decision‐making process (<a href="./references#CD002830-bbs2-0063" title="NewmanDH . Training the mind, and the Food and Drug Administration, on droperidol. Annals of Emergency Medicine2015; Vol. 66, issue 3:243‐5. [PUBMED: 26116221] ">Newman 2015</a>). </p> </section> <section id="CD002830-sec-0026"> <h3 class="title" id="CD002830-sec-0026">How the intervention might work</h3> <p>Droperidol, 1‐(1‐3‐(p‐fluorobenzoyl)propyl‐1,2,3,6‐tetrahydro‐4‐pyridyl)‐2‐benzimidazolinone, is a butyrophenone neuroleptic drug (<a href="#CD002830-fig-0001">Figure 1</a>). Butyrophenones inhibit the effects of dopamine and resemble phenothiazines such as trifluoperazine. They have fewer sedative and antimuscarinic effects than other phenothiazine derived antipsychotic drugs, but exhibit more pronounced adverse effects upon the extrapyramidal nerve system. Back in March 2000, the cost of medication with droperidol (Droleptan) in Great Britain was GBP0.90 for a 2 mL amp injection, or GBP0.25 for a 10 mg tablet (<a href="./references#CD002830-bbs2-0029" title="British Medical Association. British National Formulary. 9th Edition. London: British Medical Association, 2000. ">BNF 2000</a>). Droperidol may be taken orally (5 mg to 20 mg repeated every four to six hours, as necessary) or as an IM or intravenous (IV) injection (dosages: up to 10 mg repeated every four to six hours for IM; and 5 mg to 15 mg repeated every four to six hours for IV). The onset of action from injection is 3 to 10 minutes, although the peak effect may not be apparent for 30 minutes. The duration of sedation and tranquillisation may last for two to four hours, although alteration of alertness may persist for up to 12 hours (<a href="./references#CD002830-bbs2-0069" title="RxList.com , Inc . RxList ‐ Internet Drug Index. www.rxlist.com Accessed 26 July 2000. ">RxList 2000</a>). </p> <div class="figure" id="CD002830-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Droperidol structure." data-id="CD002830-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Droperidol structure.</p> </div> </div> </div> </section> <section id="CD002830-sec-0027"> <h3 class="title" id="CD002830-sec-0027">Why it is important to do this review</h3> <p>Droperidol is still in use. We think it is still being used in Australia, Belgium, Brazil, Czech Republic, Denmark, Finland, Greece, India, Italy, Netherlands, New Zealand, South Africa, Spain, Sweden, Thailand, and the USA. It is of interest to researchers and clinicians in the area of management of acute aggression. Previous versions of this review are out of date (<a href="./references#CD002830-bbs2-0081" title="CureS , CarpenterS . Droperidol for acute psychosis. Cochrane Database of Systematic Reviews2001, Issue 2. [DOI: 10.1002/14651858.CD002830; PUBMED: 11406047] ">Cure 2001</a>; <a href="./references#CD002830-bbs2-0082" title="CureS , RathboneJ , CarpenterS . Droperidol for acute psychosis. Cochrane Database of Systematic Reviews2004, Issue 4. [DOI: 10.1002/14651858.CD002830.pub2; PUBMED: 15495037] ">Cure 2004</a>), and this review forms one of a family of related work (<a href="#CD002830-tbl-0008">Table 4</a>). </p> <div class="table" id="CD002830-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Other relevant Cochrane reviews</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Focus of review</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Completed and maintained reviews</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>'As required' medication regimens for seriously mentally ill people in hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002830-bbs2-0031" title="ChakrabartiA , WhicherEV , MorrisonM , Douglas‐HallP . 'As required' medication regimens for seriously mentally ill people in hospital. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD003441.pub2] ">Chakrabarti 2007</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Benzodiazepines for psychosis‐induced aggression or agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002830-bbs2-0041" title="GilliesD , BeckA , McCloudA , RathboneJ . Benzodiazepines for psychosis‐induced aggression or agitation. Cochrane Database of Systematic Reviews2005, Issue 4. [DOI: 10.1002/14651858.CD003079.pub2] ">Gillies 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlorpromazine for psychosis‐induced aggression or agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002830-bbs2-0021" title="AhmedU , JonesH , AdamsCE . Chlorpromazine for psychosis induced aggression or agitation. Cochrane Database of Systematic Reviews2010, Issue 4. [DOI: 10.1002/14651858.CD007445.pub2; PUBMED: 20393959] ">Ahmed 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clotiapine for acute psychotic illnesses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002830-bbs2-0026" title="BerkM , RathboneJ , Mandriota‐CarpenterSL . Clotiapine for acute psychotic illnesses. Cochrane Database of Systematic Reviews2004, Issue 4. [DOI: 10.1002/14651858.CD002304.pub2; CD002304] ">Berk 2004</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Containment strategies for people with serious mental illness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002830-bbs2-0062" title="MuralidharanS , FentonM . Containment strategies for people with serious mental illness. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD002084.pub2] ">Muralidharan 2006</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Droperidol for acute psychosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This review</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002830-bbs2-0066" title="PowneyMJ , AdamsCE , JonesH . Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation). Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD009377.pub2; PUBMED: 23152276] ">Powney 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol + promethazine for psychosis‐induced aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002830-bbs2-0048" title="HufG , AlexanderJ , Allen MichaelH , Raveendran NirmalS . Haloperidol plus promethazine for psychosis‐induced aggression. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD005146.pub2; CD005146] ">Huf 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Olanzapine IM or olanzapine orodispersible tablet for acutely disturbed/agitated people with suspected serious mental illnesses </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002830-bbs2-0025" title="BelgamwarRB , FentonM . Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD003729.pub2] ">Belgamwar 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Seclusion and restraint for serious mental illnesses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002830-bbs2-0070" title="SailasE , FentonM . Seclusion and restraint for people with serious mental illnesses. Cochrane Database of Systematic Reviews2000, Issue 2. [DOI: 10.1002/14651858.CD001163] ">Sailas 2000</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002830-bbs2-0040" title="GibsonRC , FentonM , CoutinhoES , CampbellC . Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. Cochrane Database of Systematic Reviews2004, Issue 3. [DOI: 10.1002/14651858.CD000525.pub2] ">Gibson 2004</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Reviews in the process of being completed or updated</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone for psychosis‐induced aggression or agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002830-bbs2-0022" title="AhmedU , RehmanF , JonesH , AdamsCE . Risperidone for psychosis induced aggression or agitation. Cochrane Database of Systematic Reviews2011, Issue 11. [DOI: 10.1002/14651858.CD009412; CD009412] ">Ahmed 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol for long‐term aggression in psychosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002830-bbs2-0051" title="KhushuA , PowneyMJ , AdamsCE . Haloperidol for long‐term aggression in psychosis. Cochrane Database of Systematic Reviews2012, Issue 5. [DOI: 10.1002/14651858.CD009830] ">Khushu 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Loxapine inhaler for psychosis‐induced aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002830-bbs2-0076" title="VangalaR , AhmedU , AhmedR . Loxapine inhaler for psychosis‐induced aggression or agitation. Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD010190] ">Vangala 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clozapine for people with schizophrenia and recurrent physical aggression (Title)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002830-bbs2-0073" title="ToalF , RobertsK . Clozapine for people with schizophrenia and recurrent physical aggression. Cochrane Database of Systematic Reviews: Registered title. ">Toal 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine for psychosis‐induced aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002830-bbs2-0077" title="WilkieF , FentonM . Quetiapine for psychosis‐induced aggression or agitation. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD009801] ">Wilkie 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>De‐escalation techniques for psychosis‐induced aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002830-bbs2-0067" title="RaoH , YeungWL , JayaramMB . De‐escalation techniques for psychosis‐induced aggression or agitation. Cochrane Database of Systematic Reviews2012, Issue 7. [DOI: 10.1002/14651858.CD009922] ">Rao 2012</a> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>IM: intramuscular.</p> </div> </div> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD002830-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD002830-sec-0028"></div> <p>To estimate the effects of droperidol, including its cost‐effectiveness, when compared to placebo, other 'standard' or 'non‐standard' treatments, or other forms of management of psychotic illness, in controlling acutely disturbed behaviour and reducing psychotic symptoms in people with schizophrenia‐like illnesses. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD002830-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD002830-sec-0029"></div> <section id="CD002830-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD002830-sec-0031"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs). If a trial had been described as 'double‐blind' but implied randomisation, we would have included such trials in a sensitivity analysis (see <a href="#CD002830-sec-0106">Sensitivity analysis</a>). We excluded quasi‐randomised studies, such as those allocating by alternate days of the week. </p> </section> <section id="CD002830-sec-0032"> <h4 class="title">Types of participants</h4> <p>Any people with acutely disturbed/aggressive/agitated behaviour secondary to psychotic illnesses such as schizophrenia, schizoaffective disorder, mixed affective disorders, the manic phase of bipolar disorder or a brief psychotic episode, irrespective of age and sex. The definition of 'acute' adopted for the purposes of this review was determined by the statements and implications made by the authors of the trials that the behavioural disturbances of the participants were of sudden onset or extreme in nature, or both. If trial participants were included who were not clearly acutely disturbed, we analysed data together and separately to see what effect the results had on the summated outcome. If there were differences, we presented data separately. We only included trials of people with organic illnesses or people abusing substances if participants were exhibiting disturbed behaviour resulting from a psychotic episode, and we analysed these data separately. For the 2015 update, we decided to slightly widen our inclusion criteria by including studies where the <i>majority</i> of people in the study had some form of mental illness that was thought to be fuelling their aggression/agitation ‐ even if their data were 'contaminated' by data relating to people who were aggressive for reasons thought to not be because of mental illness. </p> </section> <section id="CD002830-sec-0033"> <h4 class="title">Types of interventions</h4> <section id="CD002830-sec-0034"> <h5 class="title">1 Droperidol</h5> <p>Any dose, given orally, or by IM or IV injection</p> <p>Compared with:</p> </section> <section id="CD002830-sec-0035"> <h5 class="title">a. Standard medication</h5> <p>Drug treatments that fit with normal 'custom and practice': this may have involved increasing the dose of standard medication or addition of another 'standard' psychotropic drug, such as an antipsychotic, an anxiolytic (benzodiazepine or other) or a mood stabiliser. We proposed to report the effects of separate preparations distinctly. </p> </section> <section id="CD002830-sec-0036"> <h5 class="title">b. Non‐standard medication</h5> <p>Drug treatments that were evaluated as a new type of intervention. We proposed to report the effects of separate preparations distinctly. </p> </section> <section id="CD002830-sec-0037"> <h5 class="title">c. Placebo</h5> </section> <section id="CD002830-sec-0038"> <h5 class="title">d. Any other means of management</h5> </section> </section> <section id="CD002830-sec-0039"> <h4 class="title">Types of outcome measures</h4> <p>We planned to divide outcomes into immediate (within two hours), short term (longer than two hours to 24 hours), medium term (longer than 24 hours to two weeks) and long term (beyond two weeks). </p> <section id="CD002830-sec-0040"> <h5 class="title">Primary outcomes</h5> <section id="CD002830-sec-0041"> <h6 class="title">1. Tranquilisation or asleep: tranquillised/sleep ‐ by up to 30 minutes</h6> </section> <section id="CD002830-sec-0042"> <h6 class="title">2. Specific behaviours: aggression ‐ another episode of aggression by 24 hours</h6> </section> <section id="CD002830-sec-0043"> <h6 class="title">3. Adverse effect: specific and serious adverse effects by 24 hours</h6> </section> </section> <section id="CD002830-sec-0044"> <h5 class="title">Secondary outcomes</h5> <section id="CD002830-sec-0045"> <h6 class="title">1. Tranquillisation or asleep</h6> <p>1.1 Tranquil/asleep ‐ after 30 minutes<br/> 1.2 Time to tranquillisation/sleep. </p> </section> <section id="CD002830-sec-0046"> <h6 class="title">2. Specific behaviours</h6> <p>2.1 Self‐harm, including suicide.<br/> 2.2 Injury to others.<br/> 2.3 Aggression.<br/> 2.3.1 Clinically important change in aggression.<br/> 2.3.2 Any change in aggression.<br/> 2.3.3 Average endpoint aggression score.<br/> 2.3.4 Average change in aggression scores. </p> </section> <section id="CD002830-sec-0047"> <h6 class="title">3. Global state</h6> <p>3.1 Overall improvement.<br/> 3.2 Use of additional medication.<br/> 3.3 Use of restraints/seclusion.<br/> 3.4 Relapse ‐ as defined by each study.<br/> 3.5 Recurrence of violent incidents.<br/> 3.6 Needing extra visits from the doctor.<br/> 3.7 Refusing oral medication.<br/> 3.8 Accepting treatment.<br/> 3.9 Average endpoint acceptance score.<br/> 3.10 Average change in acceptance score. </p> </section> <section id="CD002830-sec-0048"> <h6 class="title">4. Adverse effects</h6> <p>4.1 Death.<br/> 4.2 Other clinically important general adverse effects.<br/> 4.3 Any general adverse effects.<br/> 4.4 Any serious, specific adverse effects ‐ after 24 hours.<br/> 4.5 Average endpoint general adverse effect score.<br/> 4.6 Average change in general adverse effect scores.<br/> 4.7 Clinically important change in specific adverse effects.<br/> 4.8 Any change in specific adverse effects.<br/> 4.9 Average endpoint‐specific adverse effects.<br/> 4.10 Average change in specific adverse effects. </p> </section> <section id="CD002830-sec-0049"> <h6 class="title">5. Service outcomes</h6> <p>5.1 Duration of hospital stay.<br/> 5.2 Re‐admission.<br/> 5.3 No clinically important engagement with services.<br/> 5.4 Not any engagement with services.<br/> 5.5 Average endpoint engagement score.<br/> 5.6 Average change in engagement scores. </p> </section> <section id="CD002830-sec-0050"> <h6 class="title">6. Mental state</h6> <p>6.1 Clinically important change in general mental state.<br/> 6.2 Any change in general mental state.<br/> 6.3 Average endpoint general mental state score.<br/> 6.4 Average change in general mental state scores. </p> </section> <section id="CD002830-sec-0051"> <h6 class="title">7. Leaving the study early</h6> <p>7.1 For specific reasons.<br/> 7.2 For general reasons. </p> </section> <section id="CD002830-sec-0052"> <h6 class="title">8. Satisfaction with treatment</h6> <p>8.1 Recipient of treatment not satisfied with treatment.<br/> 8.2 Recipient of treatment average satisfaction score.<br/> 8.3 Recipient of treatment average change in satisfaction scores.<br/> 8.4 Informal treatment provider not satisfied with treatment.<br/> 8.5 Informal treatment providers' average satisfaction score.<br/> 8.6 Informal treatment providers' average change in satisfaction scores.<br/> 8.7 Professional providers not satisfied with treatment.<br/> 8.8 Professional providers' average satisfaction score.<br/> 8.9 Professional providers' average change in satisfaction scores. </p> </section> <section id="CD002830-sec-0053"> <h6 class="title">9. Acceptance of treatment</h6> <p>9.1 Accepting treatment.<br/> 9.2 Average endpoint acceptance score.<br/> 9.3 Average change in acceptance score. </p> </section> <section id="CD002830-sec-0054"> <h6 class="title">10. Quality of life</h6> <p>10.1 Clinically important change in quality of life.<br/> 10.2 Any change in quality of life.<br/> 10.3 Average endpoint quality of life score.<br/> 10.4 Average change in quality of life scores.<br/> 10.5 Clinically important change in specific aspects of quality of life.<br/> 10.6 Any change in specific aspects of quality of life.<br/> 10.7 Average endpoint‐specific aspects of quality of life.<br/> 10.8 Average change in specific aspects of quality of life. </p> </section> <section id="CD002830-sec-0055"> <h6 class="title">11. Economic outcomes</h6> <p>11.1 Direct costs.<br/> 11.2 Indirect costs. </p> </section> <section id="CD002830-sec-0056"> <h6 class="title">'Summary of findings' table</h6> <p>We used the GRADE approach to interpret findings (<a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011709/full#CD011709-bbs2-0034" target="_blank">Schünemann 2008</a>), and GRADE profiler (<a href="http://www.ims.cochrane.org/revman/gradepro" target="_blank">GRADEpro</a>) to import data from Review Manager 5 (<a href="http://www.ims.cochrane.org/revman" target="_blank">Review Manager</a>) to create 'Summary of findings' tables. These tables provide outcome‐specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined and the sum of available data on all outcomes that we rated as important to patient care and decision making. We aimed to select the following main outcomes for inclusion in the 'Summary of findings' tables. </p> <p> <ul id="CD002830-list-0001"> <li> <p>Tranquillisation or asleep: tranquillised/sleep ‐ by up to 30 minutes.</p> </li> <li> <p>Specific behaviours: aggression ‐ another episode of aggression ‐ by 24 hours.</p> </li> <li> <p>Adverse effect ‐ specific and serious adverse effects by 24 hours (not death).</p> </li> <li> <p>Adverse effect ‐ specific and serious adverse effects (death).</p> </li> <li> <p>Service outcome ‐ satisfaction with treatment (not discharged).</p> </li> <li> <p>Mental state ‐ improvement.</p> </li> <li> <p>Economic outcomes ‐ direct costs.</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD002830-sec-0057"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD002830-sec-0058"> <h4 class="title">Electronic searches</h4> <p>On 18 December 2015, we searched the Cochrane Schizophrenia Group's Register of Trials using the following search string: </p> <p>*Droperidol* in Intervention Field of STUDY</p> <p>In such a study‐based register, searching the major concept retrieves all the synonym keywords and relevant studies because all the studies have already been organised based on their interventions and linked to the relevant topics. </p> <p>The Cochrane Schizophrenia Group's Register of Trials is compiled by systematic searches of major resources (including AMED, BIOSIS, CINAHL, Embase, MEDLINE, PsycINFO, PubMed, and registries of clinical trials) and their monthly updates, handsearches, grey literature and conference proceedings (see <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html" target="_blank">Group's Module</a>). The register as no language, date, document type or publication status limitations for inclusion of records. </p> <p>For previous searches, see <a href="./appendices#CD002830-sec-0250">Appendix 1</a>. </p> </section> <section id="CD002830-sec-0059"> <h4 class="title">Searching other resources</h4> <section id="CD002830-sec-0060"> <h5 class="title">1 Reference searching</h5> <p>We inspected references of all included studies for further relevant studies.</p> </section> <section id="CD002830-sec-0061"> <h5 class="title">2 Personal contact</h5> <p>We contacted the first author of each included study for information regarding unpublished trials. </p> </section> </section> </section> <section id="CD002830-sec-0062"> <h3 class="title" id="CD002830-sec-0062">Data collection and analysis</h3> <p>For previous data collection and analysis see <a href="./appendices#CD002830-sec-0285">Appendix 2</a>. </p> <section id="CD002830-sec-0063"> <h4 class="title">Selection of studies</h4> <p>Review authors (MAK) and CEA (see <a href="#CD002830-sec-0247">Acknowledgements</a>) independently inspected citations from the 2015 search and identified relevant abstracts. We compared findings to ensure reliability. In case of disputes, we would have acquired the full report for more detailed scrutiny. One review author (MAK) obtained and inspected full reports of the abstracts meeting the review criteria, which CEA re‐inspected to ensure a reliable selection. We did not disagree on selection. In future versions, if it is not possible to resolve disagreements by discussion, we will attempt to contact the study authors for clarification. </p> </section> <section id="CD002830-sec-0064"> <h4 class="title">Data extraction and management</h4> <section id="CD002830-sec-0065"> <h5 class="title">1 Extraction</h5> <p>Review author (MAK) independently extracted data from all included studies and CA independently extracted data from a random 20% sample. We discussed any disagreements and documented decisions; if necessary, we contacted authors of studies for clarification. We extracted data presented only in graphs and figures whenever possible, but included these data in the review only if two review authors independently had the same result. We attempted to contact authors through an open‐ended request to obtain missing information or for clarification whenever necessary. If studies were multicentre, we would have extracted data relevant to each component centre separately. Where possible, we reported total end‐scale measures, as opposed to subscale measures. </p> </section> <section id="CD002830-sec-0066"> <h5 class="title">2 Management</h5> <section id="CD002830-sec-0067"> <h6 class="title">2.1 Forms</h6> <p>We extracted data onto simple standard forms.</p> </section> <section id="CD002830-sec-0068"> <h6 class="title">2.2 Scale‐derived data</h6> <p>We included continuous data from rating scales only if:</p> <p> <ul id="CD002830-list-0002"> <li> <p>the psychometric properties of the measuring instrument were described in a peer‐reviewed journal (<a href="./references#CD002830-bbs2-0058" title="MarshallM , LockwoodA , BradleyC , AdamsC , JoyC , FentonM . Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry2000;176:249‐52. ">Marshall 2000</a>); and </p> </li> <li> <p>the measuring instrument had not been written or modified by one of the trialists for that trial. </p> </li> </ul> </p> <p>Ideally, the measuring instrument should have been either a self‐report or completed by an independent rater or relative (not the therapist). We realise that this is not often reported clearly; in <a href="#CD002830-sec-0113">Description of studies</a> we noted if this was the case. </p> </section> <section id="CD002830-sec-0069"> <h6 class="title">2.3 Endpoint versus change data</h6> <p>Both endpoint and change data have advantages. Change data can remove a component of between‐person variability from the analysis. However, calculation of change needs two assessments (baseline and endpoint), which can be difficult in unstable and difficult‐to‐measure conditions such as schizophrenia. We decided to use primarily endpoint data, and only use change data if the former were not available. We combined endpoint and change data in the analysis, as we preferred to use mean differences (MD) rather than standardised mean differences throughout (<a href="./references#CD002830-bbs2-0046" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD002830-sec-0070"> <h6 class="title">2.4 Skewed data</h6> <p>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non‐parametric data, we applied the following standards to all data before inclusion. </p> <section id="CD002830-sec-0071"> <p><b>For change data</b></p> <p> <ul id="CD002830-list-0003"> <li> <p>We entered change data, as when continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not. We presented and entered change data into statistical analyses. </p> </li> </ul> </p> </section> <section id="CD002830-sec-0072"> <p><b>For endpoint data</b></p> <p> <ul id="CD002830-list-0004"> <li> <p>When a scale started from the finite number 0, we subtracted the lowest possible value from the mean and divided this by the standard deviation (SD). If this value was lower than 1, it strongly suggested a skew, and we would have excluded the study. If this ratio was higher than 1 but below 2, there was suggestion of skew. We would have entered the study and tested whether its inclusion or exclusion would have changed the results substantially. Finally, if the ratio was larger than 2, we would have included the study, because skew was less likely (<a href="./references#CD002830-bbs2-0023" title="AltmanDG , BlandJM . Detecting skewness from summary information. BMJ1996;313:1200. ">Altman 1996</a>; <a href="./references#CD002830-bbs2-0046" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </li> <li> <p>If a scale started from a positive value (such as the Positive and Negative Syndrome Scale, which can have values from 30 to 210) (<a href="./references#CD002830-bbs2-0050" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>), we would have modified the calculation described above to take into account the scale starting point. In such cases, skew is present if 2 SD &gt; (S ‐ S<sub>min</sub>), where S is the mean score and S<sub>min</sub> is the minimum score. </p> </li> </ul> </p> <p>(Please note, irrespective of the above rules, we would enter endpoint data from studies of at least 200 participants in the analysis because skewed data pose less of a problem in large studies.) </p> </section> </section> <section id="CD002830-sec-0073"> <h6 class="title">2.5 Common measure</h6> <p>To facilitate comparison between trials, we intended to convert variables that could be reported in different metrics, such as days in hospital (e.g. mean days per year, per week or per month) to a common metric (e.g. mean days per month). </p> </section> <section id="CD002830-sec-0074"> <h6 class="title">2.6 Conversion of continuous to binary data</h6> <p>Where possible, we attempted to convert outcome measures to dichotomous data. We did this by identifying cutoff points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there is a 50% reduction in a scale‐derived score such as the Brief Psychiatric Rating Scale (BPRS), in <a href="./references#CD002830-bbs2-0064" title="OverallJE , GorhamDR . The Brief Psychiatric Rating Scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>, or the Positive and Negative Syndrome Scale, in <a href="./references#CD002830-bbs2-0050" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>, this could be considered to be a clinically significant response (<a href="./references#CD002830-bbs2-0054" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelRR . What does the PANSS mean?. Schizophrenia Research2005;79(2‐3):231‐8. [PUBMED: 15982856] ">Leucht 2005a</a>; <a href="./references#CD002830-bbs2-0055" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . Clinical implications of Brief Psychiatric Rating Scale scores. British Journal of Psychiatry2005;187:366‐71. [PUBMED: 16199797] ">Leucht 2005b</a>). If data based on these thresholds were not available, we used the primary cutoff presented by the original authors. </p> </section> <section id="CD002830-sec-0075"> <h6 class="title">2.7 Direction of graphs</h6> <p>Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for droperidol intervention. Where keeping to this made it impossible to avoid outcome titles with clumsy double‐negatives (e.g. 'not un‐improved'), we reported data where the left of the line indicated an unfavourable outcome. We noted this in the relevant graphs. </p> </section> </section> </section> <section id="CD002830-sec-0076"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>One review author (MAK) assessed risk of bias by using criteria described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> to assess trial quality (<a href="./references#CD002830-bbs2-0046" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). This set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting. </p> <p>Where a study provided inadequate details of randomisation and other characteristics of the trial, she attempted to contact the study authors to obtain further information. </p> <p>We noted the level of risk of bias in both the text of the review and in the 'Risk of bias' table within the <a href="./references#CD002830-sec-0342" title="">Characteristics of included studies</a> table; <a href="./full#CD002830-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD002830-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD002830-tbl-0003">summary of findings Table 3</a>; and <a href="./full#CD002830-tbl-0004">summary of findings Table 4</a>. </p> </section> <section id="CD002830-sec-0077"> <h4 class="title">Measures of treatment effect</h4> <section id="CD002830-sec-0078"> <h5 class="title">1 Binary data</h5> <p>For binary outcomes, we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive than odds ratios, and that odds ratios tend to be interpreted as RR by clinicians (<a href="./references#CD002830-bbs2-0030" title="BoisselJP , CucheratM , LiW , ChatellierG , GueyffierF , BuyseM , et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie1999;54(4):405‐11. [PUBMED: 10667106] ">Boissel 1999</a>; <a href="./references#CD002830-bbs2-0033" title="DeeksJ . Issues in the selection for meta‐analyses of binary data. 8th International Cochrane Colloquium, 2000 Oct 25‐28; Cape Town: The Cochrane Collaboration. 2000. ">Deeks 2000</a>). The number needed to treat for an additional beneficial outcome/number needed to treat for an additional harmful outcome statistic with its CIs is intuitively attractive to clinicians but is problematic both in its accurate calculation in meta‐analyses and its interpretation (<a href="./references#CD002830-bbs2-0049" title="HuttonJL . Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology2009;146(1):27‐30. ">Hutton 2009</a>). For binary data presented in the <a href="./full#CD002830-tbl-0001">summary of findings Table for the main comparison</a>, where possible, we calculated illustrative comparative risks. </p> </section> <section id="CD002830-sec-0079"> <h5 class="title">2 Continuous data</h5> <p>For continuous outcomes, we estimated MD between groups with 95% CI. We preferred not to calculate effect size measures (standardised mean difference). However, if scales of very considerable similarity had been used, we presumed there was a small difference in measurement, and we calculated effect size and transformed the effect back to the units of one or more of the specific instruments. </p> </section> </section> <section id="CD002830-sec-0080"> <h4 class="title">Unit of analysis issues</h4> <section id="CD002830-sec-0081"> <h5 class="title">1 Cluster trials</h5> <p>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice), but analysis and pooling of clustered data pose problems. Authors often fail to account for intraclass correlation in clustered studies, leading to a 'unit of analysis' error (<a href="./references#CD002830-bbs2-0034" title="DivineGW , BrownJT , FrazerLM . The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine1992;7:623‐9. ">Divine 1992</a>), whereby P values are spuriously low, CIs unduly narrow, and statistical significance overestimated. This causes type I errors (<a href="./references#CD002830-bbs2-0028" title="BlandJM , KerrySM . Statistics notes. Trials randomised in clusters. BMJ1997;315:600. ">Bland 1997</a>; <a href="./references#CD002830-bbs2-0043" title="GullifordMC , UkoumunneOC , ChinnS . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149:876‐83. ">Gulliford 1999</a>). </p> <p>If clustering had not been accounted for in primary studies, we would have presented data in a table, with an asterisk symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review, we will seek to contact first authors of studies to obtain intraclass correlation coefficients (ICCs) for their clustered data and to adjust for this by using accepted methods (<a href="./references#CD002830-bbs2-0043" title="GullifordMC , UkoumunneOC , ChinnS . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149:876‐83. ">Gulliford 1999</a>). If clustering was incorporated into the analysis of primary studies, we would have presented these data as if from a non‐cluster randomised study, but adjusted for the clustering effect. </p> <p>We sought statistical advice and were advised that the binary data as presented in a report should be divided by a 'design effect'. We calculated this using the mean number of participants per cluster (m) and the ICC (design effect = 1 + (m ‐ 1) × ICC) (<a href="./references#CD002830-bbs2-0035" title="DonnerA , KlarN . Issues in the meta‐analysis of cluster randomized trials. Statistics in Medicine2002;21:2971‐80. ">Donner 2002</a>). If the ICC was not reported, we would have assumed it to be 0.1 (<a href="./references#CD002830-bbs2-0075" title="UkoumunneOC , GullifordMC , ChinnS , SterneJAC , BurneyPGJ . Methods for evaluating area‐wide and organisation‐based interventions in health and health care: a systematic review. Health Technology Assessment1999;3(5):iii‐92. [MEDLINE: 10982317] ">Ukoumunne 1999</a>). </p> <p>If cluster studies had been appropriately analysed taking into account ICCs and relevant data documented in the report, we would have synthesised these with other studies using the generic inverse‐variance technique. </p> </section> <section id="CD002830-sec-0082"> <h5 class="title">2 Cross‐over trials</h5> <p>A major concern of cross‐over trials is the carry‐over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase, the participants can differ systematically from their initial state despite a washout phase. For the same reason, cross‐over trials are not appropriate if the condition of interest is unstable (<a href="./references#CD002830-bbs2-0037" title="ElbourneD , AltmanDG , HigginsJPT , CurtinaF , WorthingtondHV , VaileA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). As both effects are very likely in severe mental illness, we had planned to use only the data of the first phase of cross‐over studies. </p> </section> <section id="CD002830-sec-0083"> <h5 class="title">3 Studies with multiple treatment groups</h5> <p>Where a study involved more than two treatment arms, if relevant, we presented the additional treatment arms in comparisons. If data were binary, we simply added these and combined them within the two‐by‐two table. If data were continuous, we combined data following the formula in Section 7.7.3.8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD002830-bbs2-0046" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). Where the additional treatment arms were not relevant, we did not use these data. </p> </section> </section> <section id="CD002830-sec-0084"> <h4 class="title">Dealing with missing data</h4> <section id="CD002830-sec-0085"> <h5 class="title">1 Overall loss of credibility</h5> <p>At some degree of loss of follow‐up data must lose credibility (<a href="./references#CD002830-bbs2-0080" title="XiaJ , AdamsCE , BhagatN , BhagatV , BhoopathiP , El‐SayehH , et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin2009;33(7):254‐7. ">Xia 2009</a>). We chose that, for any outcome, should more than 50% of the data be unaccounted for, we would not reproduce these data or use them within analyses (except for the outcome 'leaving the study early'). However, if more than 50% of those in one arm of a study were lost, but the total loss was less than 50%, we would have marked such data with an asterisk to indicate that such a result may well be prone to bias. </p> </section> <section id="CD002830-sec-0086"> <h5 class="title">2 Binary</h5> <p>In the case where attrition for a binary outcome was between 0% and 50% and where these data were not clearly described, we presented data on a 'once‐randomised‐always‐analyse' basis (an intention‐to‐treat analysis). We assumed all participants leaving the study early to have the same rates of negative outcome as participants who completed, except for the outcomes of death and adverse effects. For these outcomes, we used the rate of participants who stayed in the study ‐ in that arm of the trial ‐ for participants who did not. We undertook a sensitivity analysis to test how prone the primary outcomes were to change when data only from people who completed the study to that point were compared to the intention‐to‐treat analysis using the above assumptions. </p> </section> <section id="CD002830-sec-0087"> <h5 class="title">3 Continuous</h5> <section id="CD002830-sec-0088"> <h6 class="title">3.1 Attrition</h6> <p>In the case where attrition for a continuous outcome was between 0% and 50%, and data only from people who completed the study to that point were reported, we used these data. </p> </section> <section id="CD002830-sec-0089"> <h6 class="title">3.2 Standard deviations</h6> <p>If in future updates SDs are not reported, we will first try to obtain the missing values from the authors. If these are not available, where measures of variance for continuous data are missing, but an exact standard error (SE) and CIs are available for group means, and either P value or t value is available for differences in mean, we can calculate them according to the rules described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD002830-bbs2-0046" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). When only the SE is reported, SDs can be calculated by the formula SD = SE × square root (n). Sections 7.7.3 and 16.1.3 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> present detailed formulae for estimating SDs from P values, t or F values, CIs, ranges or other statistics (<a href="./references#CD002830-bbs2-0046" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). If these formulae do not apply, we will calculate the SDs according to a validated imputation method that is based on the SDs of the other included studies (<a href="./references#CD002830-bbs2-0038" title="FurukawaTA , BarbuiC , CiprianiA , BrambillaP , WatanabeN . Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology2006;59(7):7‐10. ">Furukawa 2006</a>). Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study's outcome and thus to lose information. We nevertheless will examine the validity of the imputations in a sensitivity analysis excluding imputed values. </p> </section> <section id="CD002830-sec-0090"> <h6 class="title">3.3 Last observation carried forward</h6> <p>We anticipated that in some studies the method of last observation carried forward (LOCF) would be employed within the study report. As with all methods of imputation to deal with missing data, LOCF introduces uncertainty about the reliability of the results (<a href="./references#CD002830-bbs2-0056" title="LeuchtS , EngelRR , BaumlJ , DavisJM . Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin2007;33(1):183‐91. [PUBMED: 16905632] ">Leucht 2007</a>). Therefore, where LOCF data were used in the trial, if less than 50% of the data were assumed, we presented and used these data and indicated that they were the product of LOCF assumptions. </p> </section> </section> </section> <section id="CD002830-sec-0091"> <h4 class="title">Assessment of heterogeneity</h4> <section id="CD002830-sec-0092"> <h5 class="title">1 Clinical heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We simply inspected all studies for clearly outlying people or situations that we had not predicted would arise. If such situations or participant groups arose, we would have fully discussed these. </p> </section> <section id="CD002830-sec-0093"> <h5 class="title">2 Methodological heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods that we had not predicted would arise. If such methodological outliers had been present, we would have fully discussed these. </p> </section> <section id="CD002830-sec-0094"> <h5 class="title">3 Statistical heterogeneity</h5> <section id="CD002830-sec-0095"> <h6 class="title">3.1 Visual inspection</h6> <p>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</p> </section> <section id="CD002830-sec-0096"> <h6 class="title">3.2 Employing the I<sup>2</sup> statistic </h6> <p>We investigated heterogeneity between studies by considering the I<sup>2</sup> method alongside the Chi<sup>2</sup> P value. The I<sup>2</sup> statistic provides an estimate of the percentage of inconsistency thought to be due to chance (<a href="./references#CD002830-bbs2-0045" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>). The importance of the observed value of the I<sup>2</sup> statistic depends on the magnitude and direction of effects and the strength of evidence for heterogeneity (e.g. P value from Chi<sup>2</sup> test, or a CI for the I<sup>2</sup> statistic). We interpreted an I<sup>2</sup> statistic estimate of 50% or greater accompanied by a statistically significant Chi<sup>2</sup> statistic as evidence of substantial levels of heterogeneity (<a href="./references#CD002830-bbs2-0046" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). When we found substantial levels of heterogeneity in the primary outcome, we explored reasons for heterogeneity (<a href="#CD002830-sec-0101">Subgroup analysis and investigation of heterogeneity</a>). </p> </section> </section> </section> <section id="CD002830-sec-0097"> <h4 class="title">Assessment of reporting biases</h4> <section id="CD002830-sec-0098"> <h5 class="title">1 Protocol versus full study</h5> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results. These are described in Section 10.1 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD002830-bbs2-0046" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We tried to locate protocols of included RCTs. If the protocol was available, we compared outcomes in the protocol with those in the published report. If the protocol was not available, we compared outcomes listed in the methods section of the trial report with reported results. </p> </section> <section id="CD002830-sec-0099"> <h5 class="title">2 Funnel plot</h5> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<a href="./references#CD002830-bbs2-0036" title="EggerM , SmithGD , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315:629‐34. ">Egger 1997</a>). These are described in Chapter 10 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD002830-bbs2-0046" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small‐study effects. We did not use funnel plots for outcomes where there were 10 or fewer studies, or where all studies were of similar size. In future updates of this review, if funnel plots are possible, we will seek statistical advice in their interpretation. </p> </section> </section> <section id="CD002830-sec-0100"> <h4 class="title">Data synthesis</h4> <p>We understand that there is no closed argument for preference for use of fixed‐effect or random‐effects models. The random‐effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seemed to be true to us, and the random‐effects model takes into account differences between studies even if there is no statistically significant heterogeneity. However, there is a disadvantage to the random‐effects model, in that it puts added weight on to small studies, which often are the most biased ones. Depending on the direction of effect, these studies can either inflate or deflate the effect size. We chose the fixed‐effect model for all analyses. </p> </section> <section id="CD002830-sec-0101"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <section id="CD002830-sec-0102"> <h5 class="title">1 Subgroup analyses</h5> <section id="CD002830-sec-0103"> <h6 class="title">1.1 Primary outcomes</h6> <p>We did not anticipate a need for any subgroup analysis.</p> </section> <section id="CD002830-sec-0104"> <h6 class="title">1.2 Clinical state, stage or problem</h6> <p>We proposed to undertake this review as part of a family of similar reviews that will provide an overview of the effects of droperidol for people with psychosis induced aggression or agitation in general. In addition, we aimed to report data on subgroups of people in the same clinical state, stage and with similar problems. </p> </section> </section> <section id="CD002830-sec-0105"> <h5 class="title">2 Investigation of heterogeneity</h5> <p>If inconsistency was high, we reported this. We first investigated whether data had been entered correctly. Second, if data were correct, we visually inspected the graph and successively removed outlying studies to see if homogeneity was restored. For this review, we decided that should this occur with data contributing to the summary finding of no more than around 10% of the total weighting, we would present the data. If not, we would not pool the data and we would discuss these issues. We know of no supporting research for this 10% cutoff, but we used prediction intervals as an alternative to this unsatisfactory state. </p> <p>If in future updates of this review unanticipated clinical or methodological heterogeneity is obvious, we will simply state hypotheses regarding these. We do not anticipate undertaking analyses relating to such situations. </p> </section> </section> <section id="CD002830-sec-0106"> <h4 class="title">Sensitivity analysis</h4> <section id="CD002830-sec-0107"> <h5 class="title">1 Implication of randomisation</h5> <p>We aimed to include trials in a sensitivity analysis if they were described in such a way as to imply randomisation. For the primary outcomes, we would have included these studies, and if there was no substantive difference when the implied randomised studies were added to those with better description of randomisation, then we would have employed all data from these studies. </p> </section> <section id="CD002830-sec-0108"> <h5 class="title">2 Assumptions for lost binary data</h5> <p>Where we had to make assumptions regarding people lost to follow‐up (see <a href="#CD002830-sec-0084">Dealing with missing data</a>), we compared the findings of the primary outcomes when we used our assumption(s) and when we used data only from people who completed the study to that point. If there was a substantial difference, we would have reported results and discussed them but continued to employ our assumption. </p> <p>If we had needed to make assumptions regarding missing SDs data (see <a href="#CD002830-sec-0084">Dealing with missing data</a>), we would have compared the findings of the primary outcomes when we used our assumption(s) and when we used data only from people who completed the study to that point. We would have undertaken a sensitivity analysis testing how prone results were to change when completer‐only data only were compared to imputed data using the above assumption. If there was a substantial difference, we would have reported results and discussed them but continued to employ our assumption. </p> </section> <section id="CD002830-sec-0109"> <h5 class="title">3 Risk of bias</h5> <p>For the primary outcome, we analysed the effects of excluding trials that we judged to be at high risk of bias across one or more of the domains of randomisation (implied as randomised with no further details available) allocation concealment, blinding and outcome reporting. If the exclusion of trials at high risk of bias had substantially altered the direction of effect or the precision of the effect estimates, then we would not have included data from these trials in the analysis. </p> </section> <section id="CD002830-sec-0110"> <h5 class="title">4 Imputed values</h5> <p>We had intended to undertake a sensitivity analysis to assess, if necessary, the effects of including data from trials where we used imputed values for ICC in calculating the design effect in cluster randomised trials. </p> <p>If we had noted substantial differences in the direction or precision of effect estimates in any of the sensitivity analyses listed above, we would not have pooled data from the excluded trials with the other trials contributing to the outcome, but would have presented them separately. </p> </section> <section id="CD002830-sec-0111"> <h5 class="title">5 Fixed effect and random effects</h5> <p>We synthesised all data using a fixed‐effect model, however we also aimed to synthesise data for the primary outcome using a random‐effects model to evaluate whether this altered the significance of the results. If the significance of results changed, we would have noted this in the text. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD002830-sec-0112" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD002830-sec-0112"></div> <section id="CD002830-sec-0113"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD002830-sec-0342" title="">Characteristics of included studies</a> and <a href="./references#CD002830-sec-0343" title="">Characteristics of excluded studies</a> tables. </p> <section id="CD002830-sec-0114"> <h4 class="title">Results of the search</h4> <p>We included six studies in this review. In the update search, we undertook for this review, we found 14 records that were potentially relevant. We identified no duplicates. We screened these 14 records and removed two records. We assessed 12 full‐text articles for eligibility and excluded six from the review with reasons. Three of these studies were already included in the previous version of the review and we added three new studies. The PRISMA table shows results of our search (<a href="#CD002830-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD002830-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="2015 study flow diagram." data-id="CD002830-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>2015 study flow diagram.</p> </div> </div> </div> </section> <section id="CD002830-sec-0115"> <h4 class="title">Included studies</h4> <section id="CD002830-sec-0116"> <h5 class="title">1 Methods</h5> <p>All the included trials were randomised including one study that employed block randomisation (<a href="./references#CD002830-bbs2-0001" title="CalverL , DrinkwaterV , GuptaR , PageCB , IsbisterGK . Droperidol v. haloperidol for sedation of aggressive behaviour in acute mental health: randomized controlled trial. British Journal of Psychiatry2015;206(3):223‐8. ">Calver 2015</a>). Five out of six included trials were double‐blind (<a href="./references#CD002830-bbs2-0002" title="ChanE , TaylorD , KongD , KnottJ , PhillipsG , CastleD . IV droperidol or olanzapine as adjuncts to midazolam for the acutely agitated patient: a multi‐centre, randomised, double‐blind, placebo‐controlled, clinical trial. Schizophrenia Research2012;136:S259. ChanEW , TaylorDM , KnottJC , PhillipsGA , CastleDJ , KongDCM . Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Annals of Emergency Medicine2013;61(1):72‐81. ">Chan 2013</a>; <a href="./references#CD002830-bbs2-0003" title="CocchiA , FondaP , PerosinoN . Droperidol: a double‐blind clinical study [Droperidol: studio clinico in doppio cieco]. Rivista Sperimentale di Freniatria e Medicina Legale Delle Alienazioni Mentali1971;95(6):1109‐25. ">Cocchi 1971</a>; <a href="./references#CD002830-bbs2-0004" title="KnottJC , TaylorD , CastleDJ . Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Annals of Emergency Medicine2006; Vol. 47, issue 1:61‐7. ">Knott 2006</a>; <a href="./references#CD002830-bbs2-0005" title="ResnickM , BurtonBT . Droperidol versus haloperidol in the initial management of acutely agitated patients. Journal of Clinical Psychiatry1984;45(7):298‐9. ">Resnick 1984</a>; <a href="./references#CD002830-bbs2-0006" title="VanLeeuwenAMH , MoldersJ , SterkmansP , MielantsP , MartensC , ToussaintC , et al. Brief communication: droperidol in acutely agitated patients. A double blind placebo‐controlled study. Journal of Nervous and Mental Disease1977;164(4):280‐3. ">Van Leeuwen 1977</a>), while <a href="./references#CD002830-bbs2-0005" title="ResnickM , BurtonBT . Droperidol versus haloperidol in the initial management of acutely agitated patients. Journal of Clinical Psychiatry1984;45(7):298‐9. ">Resnick 1984</a> gave no clear details of blinding. In an effort to minimise bias, three of the included studies stated that the outcome assessor was blind to group allocation (<a href="./references#CD002830-bbs2-0001" title="CalverL , DrinkwaterV , GuptaR , PageCB , IsbisterGK . Droperidol v. haloperidol for sedation of aggressive behaviour in acute mental health: randomized controlled trial. British Journal of Psychiatry2015;206(3):223‐8. ">Calver 2015</a>; <a href="./references#CD002830-bbs2-0002" title="ChanE , TaylorD , KongD , KnottJ , PhillipsG , CastleD . IV droperidol or olanzapine as adjuncts to midazolam for the acutely agitated patient: a multi‐centre, randomised, double‐blind, placebo‐controlled, clinical trial. Schizophrenia Research2012;136:S259. ChanEW , TaylorDM , KnottJC , PhillipsGA , CastleDJ , KongDCM . Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Annals of Emergency Medicine2013;61(1):72‐81. ">Chan 2013</a>; <a href="./references#CD002830-bbs2-0004" title="KnottJC , TaylorD , CastleDJ . Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Annals of Emergency Medicine2006; Vol. 47, issue 1:61‐7. ">Knott 2006</a>), one study reported no detail of blinding the outcome assessor (<a href="./references#CD002830-bbs2-0006" title="VanLeeuwenAMH , MoldersJ , SterkmansP , MielantsP , MartensC , ToussaintC , et al. Brief communication: droperidol in acutely agitated patients. A double blind placebo‐controlled study. Journal of Nervous and Mental Disease1977;164(4):280‐3. ">Van Leeuwen 1977</a>). </p> </section> <section id="CD002830-sec-0117"> <h5 class="title">2 Length of trials</h5> <p>The overall duration of the included trials varied in length from immediate (within two hours), short term (more than two hours to 24 hours) to long term (beyond 2 weeks) as listed in <a href="#CD002830-tbl-0009">Table 5</a>. </p> <div class="table" id="CD002830-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Length of included studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Immediate (&lt; 2 hours)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Short term (&gt; 2 hours to 24 hours)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Medium term (&gt; 24 hours to 2 weeks)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Long term (&gt; 2 weeks)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002830-bbs2-0006" title="VanLeeuwenAMH , MoldersJ , SterkmansP , MielantsP , MartensC , ToussaintC , et al. Brief communication: droperidol in acutely agitated patients. A double blind placebo‐controlled study. Journal of Nervous and Mental Disease1977;164(4):280‐3. ">Van Leeuwen 1977</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ (3 and 30 min)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002830-bbs2-0002" title="ChanE , TaylorD , KongD , KnottJ , PhillipsG , CastleD . IV droperidol or olanzapine as adjuncts to midazolam for the acutely agitated patient: a multi‐centre, randomised, double‐blind, placebo‐controlled, clinical trial. Schizophrenia Research2012;136:S259. ChanEW , TaylorDM , KnottJC , PhillipsGA , CastleDJ , KongDCM . Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Annals of Emergency Medicine2013;61(1):72‐81. ">Chan 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ (5, 10 and 60 min)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002830-bbs2-0001" title="CalverL , DrinkwaterV , GuptaR , PageCB , IsbisterGK . Droperidol v. haloperidol for sedation of aggressive behaviour in acute mental health: randomized controlled trial. British Journal of Psychiatry2015;206(3):223‐8. ">Calver 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ (10 min)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ (120 min)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002830-bbs2-0004" title="KnottJC , TaylorD , CastleDJ . Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Annals of Emergency Medicine2006; Vol. 47, issue 1:61‐7. ">Knott 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ (within 60 min)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ (2 hours)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002830-bbs2-0005" title="ResnickM , BurtonBT . Droperidol versus haloperidol in the initial management of acutely agitated patients. Journal of Clinical Psychiatry1984;45(7):298‐9. ">Resnick 1984</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ (15 and 30 min)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ (24 hours)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002830-bbs2-0003" title="CocchiA , FondaP , PerosinoN . Droperidol: a double‐blind clinical study [Droperidol: studio clinico in doppio cieco]. Rivista Sperimentale di Freniatria e Medicina Legale Delle Alienazioni Mentali1971;95(6):1109‐25. ">Cocchi 1971</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ (30 days)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>min: minute.</p> </div> </div> </section> <section id="CD002830-sec-0118"> <h5 class="title">3 Participants</h5> <p>A total of 733 people participated in the six studies. Three of the included studies included more than 100 participants (<a href="./references#CD002830-bbs2-0001" title="CalverL , DrinkwaterV , GuptaR , PageCB , IsbisterGK . Droperidol v. haloperidol for sedation of aggressive behaviour in acute mental health: randomized controlled trial. British Journal of Psychiatry2015;206(3):223‐8. ">Calver 2015</a>; <a href="./references#CD002830-bbs2-0002" title="ChanE , TaylorD , KongD , KnottJ , PhillipsG , CastleD . IV droperidol or olanzapine as adjuncts to midazolam for the acutely agitated patient: a multi‐centre, randomised, double‐blind, placebo‐controlled, clinical trial. Schizophrenia Research2012;136:S259. ChanEW , TaylorDM , KnottJC , PhillipsGA , CastleDJ , KongDCM . Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Annals of Emergency Medicine2013;61(1):72‐81. ">Chan 2013</a>; <a href="./references#CD002830-bbs2-0004" title="KnottJC , TaylorD , CastleDJ . Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Annals of Emergency Medicine2006; Vol. 47, issue 1:61‐7. ">Knott 2006</a>); the remaining studies included 40 (<a href="./references#CD002830-bbs2-0003" title="CocchiA , FondaP , PerosinoN . Droperidol: a double‐blind clinical study [Droperidol: studio clinico in doppio cieco]. Rivista Sperimentale di Freniatria e Medicina Legale Delle Alienazioni Mentali1971;95(6):1109‐25. ">Cocchi 1971</a>), 27 (<a href="./references#CD002830-bbs2-0005" title="ResnickM , BurtonBT . Droperidol versus haloperidol in the initial management of acutely agitated patients. Journal of Clinical Psychiatry1984;45(7):298‐9. ">Resnick 1984</a>), and 41 (<a href="./references#CD002830-bbs2-0006" title="VanLeeuwenAMH , MoldersJ , SterkmansP , MielantsP , MartensC , ToussaintC , et al. Brief communication: droperidol in acutely agitated patients. A double blind placebo‐controlled study. Journal of Nervous and Mental Disease1977;164(4):280‐3. ">Van Leeuwen 1977</a>) participants. Only three studies specified inclusion of both male and female participants (<a href="./references#CD002830-bbs2-0001" title="CalverL , DrinkwaterV , GuptaR , PageCB , IsbisterGK . Droperidol v. haloperidol for sedation of aggressive behaviour in acute mental health: randomized controlled trial. British Journal of Psychiatry2015;206(3):223‐8. ">Calver 2015</a>; <a href="./references#CD002830-bbs2-0003" title="CocchiA , FondaP , PerosinoN . Droperidol: a double‐blind clinical study [Droperidol: studio clinico in doppio cieco]. Rivista Sperimentale di Freniatria e Medicina Legale Delle Alienazioni Mentali1971;95(6):1109‐25. ">Cocchi 1971</a>; <a href="./references#CD002830-bbs2-0006" title="VanLeeuwenAMH , MoldersJ , SterkmansP , MielantsP , MartensC , ToussaintC , et al. Brief communication: droperidol in acutely agitated patients. A double blind placebo‐controlled study. Journal of Nervous and Mental Disease1977;164(4):280‐3. ">Van Leeuwen 1977</a>). </p> <p>All trials included people with psychoses. <a href="./references#CD002830-bbs2-0005" title="ResnickM , BurtonBT . Droperidol versus haloperidol in the initial management of acutely agitated patients. Journal of Clinical Psychiatry1984;45(7):298‐9. ">Resnick 1984</a> did not specify beyond stating that participants were admitted involuntarily to the emergency department of a psychiatric unit. <a href="./references#CD002830-bbs2-0006" title="VanLeeuwenAMH , MoldersJ , SterkmansP , MielantsP , MartensC , ToussaintC , et al. Brief communication: droperidol in acutely agitated patients. A double blind placebo‐controlled study. Journal of Nervous and Mental Disease1977;164(4):280‐3. ">Van Leeuwen 1977</a> included people with schizophrenia, manic depression or in a 'confusional state'; however, 10 participants had no specific diagnosis. <a href="./references#CD002830-bbs2-0003" title="CocchiA , FondaP , PerosinoN . Droperidol: a double‐blind clinical study [Droperidol: studio clinico in doppio cieco]. Rivista Sperimentale di Freniatria e Medicina Legale Delle Alienazioni Mentali1971;95(6):1109‐25. ">Cocchi 1971</a> stated that all participants had schizophrenia. </p> <p>All studies included people with acutely disturbed/aggressive/agitated behaviour secondary to psychotic illnesses such as schizophrenia, schizoaffective disorder, mixed affective disorders, the manic phase of bipolar disorder or a brief psychotic episode, irrespective of age and sex. For the 2015 update, we widened the criteria to include studies where the <i>majority</i> of people in the study had some form of mental illness that was thought to be fuelling their aggression/agitation. We included these studies even if their data were 'contaminated' by data relating to people who were aggressive for reasons other than mental illness. Therefore, we included <a href="./references#CD002830-bbs2-0004" title="KnottJC , TaylorD , CastleDJ . Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Annals of Emergency Medicine2006; Vol. 47, issue 1:61‐7. ">Knott 2006</a> (60% of participants had mental illness) in the review. However, none of the studies employed diagnostic criteria; it is unknown whether this influenced the validity of findings. </p> <p>Five out of six trials referred to the current clinical state of participants: agitation or aggression (<a href="./references#CD002830-bbs2-0001" title="CalverL , DrinkwaterV , GuptaR , PageCB , IsbisterGK . Droperidol v. haloperidol for sedation of aggressive behaviour in acute mental health: randomized controlled trial. British Journal of Psychiatry2015;206(3):223‐8. ">Calver 2015</a>; <a href="./references#CD002830-bbs2-0002" title="ChanE , TaylorD , KongD , KnottJ , PhillipsG , CastleD . IV droperidol or olanzapine as adjuncts to midazolam for the acutely agitated patient: a multi‐centre, randomised, double‐blind, placebo‐controlled, clinical trial. Schizophrenia Research2012;136:S259. ChanEW , TaylorDM , KnottJC , PhillipsGA , CastleDJ , KongDCM . Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Annals of Emergency Medicine2013;61(1):72‐81. ">Chan 2013</a>); schizophrenic ‐ acutely exacerbated (<a href="./references#CD002830-bbs2-0003" title="CocchiA , FondaP , PerosinoN . Droperidol: a double‐blind clinical study [Droperidol: studio clinico in doppio cieco]. Rivista Sperimentale di Freniatria e Medicina Legale Delle Alienazioni Mentali1971;95(6):1109‐25. ">Cocchi 1971</a>); marked agitation requiring chemical restraint (<a href="./references#CD002830-bbs2-0004" title="KnottJC , TaylorD , CastleDJ . Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Annals of Emergency Medicine2006; Vol. 47, issue 1:61‐7. ">Knott 2006</a>); unspecified psychosis (<a href="./references#CD002830-bbs2-0005" title="ResnickM , BurtonBT . Droperidol versus haloperidol in the initial management of acutely agitated patients. Journal of Clinical Psychiatry1984;45(7):298‐9. ">Resnick 1984</a>); and a combination of schizophrenia, mania, confusional state and miscellaneous disorders (<a href="./references#CD002830-bbs2-0006" title="VanLeeuwenAMH , MoldersJ , SterkmansP , MielantsP , MartensC , ToussaintC , et al. Brief communication: droperidol in acutely agitated patients. A double blind placebo‐controlled study. Journal of Nervous and Mental Disease1977;164(4):280‐3. ">Van Leeuwen 1977</a>). </p> </section> <section id="CD002830-sec-0119"> <h5 class="title">4 Setting</h5> <p>Two trials took place in large metropolitan emergency departments (<a href="./references#CD002830-bbs2-0002" title="ChanE , TaylorD , KongD , KnottJ , PhillipsG , CastleD . IV droperidol or olanzapine as adjuncts to midazolam for the acutely agitated patient: a multi‐centre, randomised, double‐blind, placebo‐controlled, clinical trial. Schizophrenia Research2012;136:S259. ChanEW , TaylorDM , KnottJC , PhillipsGA , CastleDJ , KongDCM . Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Annals of Emergency Medicine2013;61(1):72‐81. ">Chan 2013</a>; <a href="./references#CD002830-bbs2-0004" title="KnottJC , TaylorD , CastleDJ . Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Annals of Emergency Medicine2006; Vol. 47, issue 1:61‐7. ">Knott 2006</a>), and <a href="./references#CD002830-bbs2-0001" title="CalverL , DrinkwaterV , GuptaR , PageCB , IsbisterGK . Droperidol v. haloperidol for sedation of aggressive behaviour in acute mental health: randomized controlled trial. British Journal of Psychiatry2015;206(3):223‐8. ">Calver 2015</a> was in a psychiatric intensive care unit of a large tertiary specialist mental health facility in Australia. One trial was conducted in an Emergency Department and Psychiatric crisis unit, Oregon Health Sciences University, Portland (<a href="./references#CD002830-bbs2-0005" title="ResnickM , BurtonBT . Droperidol versus haloperidol in the initial management of acutely agitated patients. Journal of Clinical Psychiatry1984;45(7):298‐9. ">Resnick 1984</a>). The setting of <a href="./references#CD002830-bbs2-0006" title="VanLeeuwenAMH , MoldersJ , SterkmansP , MielantsP , MartensC , ToussaintC , et al. Brief communication: droperidol in acutely agitated patients. A double blind placebo‐controlled study. Journal of Nervous and Mental Disease1977;164(4):280‐3. ">Van Leeuwen 1977</a> was unclear and <a href="./references#CD002830-bbs2-0003" title="CocchiA , FondaP , PerosinoN . Droperidol: a double‐blind clinical study [Droperidol: studio clinico in doppio cieco]. Rivista Sperimentale di Freniatria e Medicina Legale Delle Alienazioni Mentali1971;95(6):1109‐25. ">Cocchi 1971</a> stated the trial took place in a hospital setting. </p> </section> <section id="CD002830-sec-0120"> <h5 class="title">5 Interventions</h5> <p> <div class="table" id="CD002830-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial drug</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5 mg IM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5 mg IV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>10 mg IM</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>10 mg IV</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Droperidol</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ (<a href="./references#CD002830-bbs2-0005" title="ResnickM , BurtonBT . Droperidol versus haloperidol in the initial management of acutely agitated patients. Journal of Clinical Psychiatry1984;45(7):298‐9. ">Resnick 1984</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ (<a href="./references#CD002830-bbs2-0004" title="KnottJC , TaylorD , CastleDJ . Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Annals of Emergency Medicine2006; Vol. 47, issue 1:61‐7. ">Knott 2006</a>; <a href="./references#CD002830-bbs2-0002" title="ChanE , TaylorD , KongD , KnottJ , PhillipsG , CastleD . IV droperidol or olanzapine as adjuncts to midazolam for the acutely agitated patient: a multi‐centre, randomised, double‐blind, placebo‐controlled, clinical trial. Schizophrenia Research2012;136:S259. ChanEW , TaylorDM , KnottJC , PhillipsGA , CastleDJ , KongDCM . Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Annals of Emergency Medicine2013;61(1):72‐81. ">Chan 2013</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ (<a href="./references#CD002830-bbs2-0001" title="CalverL , DrinkwaterV , GuptaR , PageCB , IsbisterGK . Droperidol v. haloperidol for sedation of aggressive behaviour in acute mental health: randomized controlled trial. British Journal of Psychiatry2015;206(3):223‐8. ">Calver 2015</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ (<a href="./references#CD002830-bbs2-0006" title="VanLeeuwenAMH , MoldersJ , SterkmansP , MielantsP , MartensC , ToussaintC , et al. Brief communication: droperidol in acutely agitated patients. A double blind placebo‐controlled study. Journal of Nervous and Mental Disease1977;164(4):280‐3. ">Van Leeuwen 1977</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Haloperidol</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ (<a href="./references#CD002830-bbs2-0005" title="ResnickM , BurtonBT . Droperidol versus haloperidol in the initial management of acutely agitated patients. Journal of Clinical Psychiatry1984;45(7):298‐9. ">Resnick 1984</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ (<a href="./references#CD002830-bbs2-0001" title="CalverL , DrinkwaterV , GuptaR , PageCB , IsbisterGK . Droperidol v. haloperidol for sedation of aggressive behaviour in acute mental health: randomized controlled trial. British Journal of Psychiatry2015;206(3):223‐8. ">Calver 2015</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Olanzapine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ (<a href="./references#CD002830-bbs2-0002" title="ChanE , TaylorD , KongD , KnottJ , PhillipsG , CastleD . IV droperidol or olanzapine as adjuncts to midazolam for the acutely agitated patient: a multi‐centre, randomised, double‐blind, placebo‐controlled, clinical trial. Schizophrenia Research2012;136:S259. ChanEW , TaylorDM , KnottJC , PhillipsGA , CastleDJ , KongDCM . Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Annals of Emergency Medicine2013;61(1):72‐81. ">Chan 2013</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Midazolam</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ (<a href="./references#CD002830-bbs2-0004" title="KnottJC , TaylorD , CastleDJ . Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Annals of Emergency Medicine2006; Vol. 47, issue 1:61‐7. ">Knott 2006</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ (<a href="./references#CD002830-bbs2-0002" title="ChanE , TaylorD , KongD , KnottJ , PhillipsG , CastleD . IV droperidol or olanzapine as adjuncts to midazolam for the acutely agitated patient: a multi‐centre, randomised, double‐blind, placebo‐controlled, clinical trial. Schizophrenia Research2012;136:S259. ChanEW , TaylorDM , KnottJC , PhillipsGA , CastleDJ , KongDCM . Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Annals of Emergency Medicine2013;61(1):72‐81. ">Chan 2013</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ (<a href="./references#CD002830-bbs2-0006" title="VanLeeuwenAMH , MoldersJ , SterkmansP , MielantsP , MartensC , ToussaintC , et al. Brief communication: droperidol in acutely agitated patients. A double blind placebo‐controlled study. Journal of Nervous and Mental Disease1977;164(4):280‐3. ">Van Leeuwen 1977</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>IM: intramuscular; IV: intravenous.</p> </td> </tr> </tbody> </table> </div> </p> </section> <section id="CD002830-sec-0121"> <h5 class="title">6 Outcomes</h5> <section id="CD002830-sec-0122"> <h6 class="title">6.1 Overall</h6> <p>The outcomes for which we could obtain useable data were: tranquillisation or asleep, global state, service use, mental state and Adverse effects. </p> </section> <section id="CD002830-sec-0123"> <h6 class="title">6.2 Outcome scales</h6> <p>The scales used by trials that provided useable data are described below.</p> <section id="CD002830-sec-0124"> <p><b>6.1.1 Mental state</b></p> <p>i. Scale for Quantification of Psychotic Symptom Severity, high = poor) (<a href="./references#CD002830-bbs2-0042" title="GoodrichDW . Quantification of the severity of overt psychotic symptoms. American Journal of Psychiatry1953;110:334. ">Goodrich 1953</a>) </p> <p>A research rating scale for use by hospital psychiatrists to express quantitatively the severity of 'incapacitation' due to psychotic symptoms. A rating of from 1.0 to 2.0, extreme behaviour disorganisation requiring vigilance by hospital staff; from 2.0 to 3.0, severity requiring "security ward" care; from 3.0 to 3.7, severity requiring open convalescent ward care; and from 3.8 to 4.0, not requiring hospitalisation, or person ready for discharge. </p> <p>ii. Glasgow Coma Scale (<a href="./references#CD002830-bbs2-0072" title="TeasdaleG , JennettB . Assessment of coma and impaired consciousness. A practical scale. Lancet (London, England)1974;2(7872):81‐4. [PUBMED: 4136544] ">Teasdale 1974</a>) </p> <p>The Glasgow Coma Scale (GCS) is a scoring system used to describe the level of consciousness in a person following a traumatic brain injury. The test is simple, reliable, correlates well with outcome and is an objective way of recording the initial and subsequent level of consciousness in a person after a brain injury. It is used by trained staff at the site of an injury (e.g. at a car crash or sports injury), and in the emergency department and intensive care units. Clinicians use this scale to rate the best eye opening response, the best verbal response and the best motor response aperson makes. Generally, brain injury is classified as 'severe' (GCS 3 to 8, cannot score lower than 3), 'moderate' (GCS 9 to 12) and mild (GCS 13 to 15). </p> <p>iii. Brief Psychiatric Rating Scale (<a href="./references#CD002830-bbs2-0064" title="OverallJE , GorhamDR . The Brief Psychiatric Rating Scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>) </p> <p>The BPRS is used to assess the severity of a range of psychiatric symptoms, including psychotic symptoms. The original scale has 16 items, although a revised 18‐item scale is commonly used. Each item is defined on a 7‐point scale varying from 'not present' to 'extremely severe', scoring from 0 to 6 or 1 to 7. Total scores can range from 0 to 126, with high scores indicating more severe symptoms. </p> </section> </section> <section id="CD002830-sec-0125"> <h6 class="title">6.3 Missing outcomes</h6> <p>No trial reported outcomes directly relevant to satisfaction with treatment, acceptance of treatment, quality of life or economics. </p> </section> </section> </section> <section id="CD002830-sec-0126"> <h4 class="title">Excluded studies</h4> <p>See <a href="./references#CD002830-sec-0343" title="">Characteristics of excluded studies</a> table for details of excluded studies and <a href="#CD002830-tbl-0010">Table 6</a> for details of randomised excluded studies which are potentially relevant to other reviews. </p> <div class="table" id="CD002830-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Randomised excluded studies relevant to other reviews</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Excluded study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b> Participants</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Suggested comparison</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Existing review</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> People with serious mental illness</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> People without mental illness</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002830-bbs2-0012" title="胡光涛 , 李志宏 , 王国威 , 黄一 , 贺英 . Mesylate injection of acute agitation in schizophrenia symptoms. Efficacy of ziprasidone treatment [Google translate] [注射用甲磺酸齐拉西酮治疗精神分裂症急性激越症状疗效观察]. 中国新药与临床杂志2014;33(1):57‐60. ">Hu 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute agitation and schizophrenia.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haloperidol vs. ziprasidone for acute agitation and schizophrenia.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002830-bbs2-0066" title="PowneyMJ , AdamsCE , JonesH . Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation). Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD009377.pub2; PUBMED: 23152276] ">Powney 2012</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002830-bbs2-0007" title="CocitoE , AmbrosiniG , ArataA , BevilacquaP , TortoraE . Clinical evaluation of 112 psychiatric patients of a butyrophenone neuroleptic, dehydrobenzperidol (R 4749). Arzneimittelforschung1970;20(8):1119‐25. ">Cocito 1970</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>With psychosis in hospital, not acutely ill.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Droperidol for (non‐acute) psychosis.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD002830-bbs2-0013" title="IsbisterGK , CalverLA , PageCB , StokesB , BryantJL , DownesMA . Randomized controlled trial of intramuscular droperidol versus midazolam for violence and acute behavioral disturbance: the DORM study. Annals of Emergency Medicine2010;56(4):392‐401. ">Isbister 2010</a>; <a href="./references#CD002830-bbs2-0017" title="RosenCL , RatliffAF , WolfeRE , BranneySW , RoeEJ , PonsPT . The efficacy of intravenous droperidol in the prehospital setting. Journal of Emergency Medicine1997;15(1):13‐7. ">Rosen 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with violent and acute behavioural disturbance. No mention of any underlying psychiatric illness. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Droperidol for acute non‐psychiatric disturbance.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mostly people with trauma and medical reasons for their disturbance (total 46), 1 with 'psychiatric' diagnosis. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002830-bbs2-0015" title="RichardsJR , DerletRW , DuncanDR . Metamphetamine toxicity: treatment with a benzodiazepine versus a butyrophenone. European Journal of Emergency Medicine1997;4:130‐5. ">Richards 1997</a>; <a href="./references#CD002830-bbs2-0016" title="RichardsJR , DerletRW , DuncanDR . Chemical restraint for the agitated patient in the emergency department: lorazepam versus droperidol. Journal of Emergency Medicine1998;16(4):567‐73. ">Richards 1998</a>; </p> <p><a href="./references#CD002830-bbs2-0018" title="ThomasHJr , SchwartzE , PetrilliR . Droperidol versus haloperidol for chemical restraint of agitated and combative patients. Annals of Emergency Medicine1992;21(4):407‐13. ">Thomas 1992</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with drug‐induced toxicity, not people with severe mental illnesses.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Droperidol for drug‐induced toxicity.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002830-bbs2-0009" title="FosterPN , StickleBR , DaleM , LaurenceAS . Akathisia after low‐dose droperidol. British Journal of Anaesthesia1995;74:477P. ">Foster 1995</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Healthy women attending day hospital for minor surgery.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Droperidol for minor surgery.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> </table> </div> <p>We excluded 14 studies, four of which were not randomised. <a href="./references#CD002830-bbs2-0010" title="GirardR , BlondelF . Clinical evaluation of oral droperidol in psychiatry [Interet du droperidol en psychiatrie]. Psychologie Medicale1972;4(6):1169‐75. ">Girard 1972</a> and <a href="./references#CD002830-bbs2-0014" title="LilburnJK , DundeeJW , NairSG . Attenuation of psychic sequelae from ketamine. British Journal of Clinical Pharmacology1977; Vol. 4, issue 5:641P‐2P. ">Lilburn 1977</a> were case‐control studies, and <a href="./references#CD002830-bbs2-0019" title="WeiserG . Initial treatment of schizophrenia using droperidol [Initialbehandlung der Schizophrenie mit Droperidol]. Wiener Zeitschrift fur Nervenheilkunde und deren Grenzgebiete1973;31:176‐88. ">Weiser 1973</a> was a case series. After emails from Dr Hooper it was clear that his study also had to be excluded, as allocation to groups had not been random, with participants being alternately allocated to either the treatment or the control intervention (<a href="./references#CD002830-bbs2-0011" title="HooperJF , MinterG . Droperidol in the management of psychiatric emergencies. Journal of Clinical Psychopharmacology1983;3(4):262‐3. ">Hooper 1983</a>). Most of the remaining trials were excluded because participants were not clearly experiencing psychotic illnesses. <a href="./references#CD002830-bbs2-0009" title="FosterPN , StickleBR , DaleM , LaurenceAS . Akathisia after low‐dose droperidol. British Journal of Anaesthesia1995;74:477P. ">Foster 1995</a> included female participants undergoing minor gynaecological surgery. <a href="./references#CD002830-bbs2-0016" title="RichardsJR , DerletRW , DuncanDR . Chemical restraint for the agitated patient in the emergency department: lorazepam versus droperidol. Journal of Emergency Medicine1998;16(4):567‐73. ">Richards 1998</a> and <a href="./references#CD002830-bbs2-0018" title="ThomasHJr , SchwartzE , PetrilliR . Droperidol versus haloperidol for chemical restraint of agitated and combative patients. Annals of Emergency Medicine1992;21(4):407‐13. ">Thomas 1992</a> both included predominantly 'intoxicated' people. <a href="./references#CD002830-bbs2-0018" title="ThomasHJr , SchwartzE , PetrilliR . Droperidol versus haloperidol for chemical restraint of agitated and combative patients. Annals of Emergency Medicine1992;21(4):407‐13. ">Thomas 1992</a> also included people experiencing trauma, an underlying medical condition or who were undiagnosed, as did <a href="./references#CD002830-bbs2-0017" title="RosenCL , RatliffAF , WolfeRE , BranneySW , RoeEJ , PonsPT . The efficacy of intravenous droperidol in the prehospital setting. Journal of Emergency Medicine1997;15(1):13‐7. ">Rosen 1997</a>. Both <a href="./references#CD002830-bbs2-0016" title="RichardsJR , DerletRW , DuncanDR . Chemical restraint for the agitated patient in the emergency department: lorazepam versus droperidol. Journal of Emergency Medicine1998;16(4):567‐73. ">Richards 1998</a> and <a href="./references#CD002830-bbs2-0017" title="RosenCL , RatliffAF , WolfeRE , BranneySW , RoeEJ , PonsPT . The efficacy of intravenous droperidol in the prehospital setting. Journal of Emergency Medicine1997;15(1):13‐7. ">Rosen 1997</a> included some people with a 'psychiatric' diagnosis but their studies had to be excluded because outcomes for these participants, a small minority of the total, were not separately analysed. <a href="./references#CD002830-bbs2-0007" title="CocitoE , AmbrosiniG , ArataA , BevilacquaP , TortoraE . Clinical evaluation of 112 psychiatric patients of a butyrophenone neuroleptic, dehydrobenzperidol (R 4749). Arzneimittelforschung1970;20(8):1119‐25. ">Cocito 1970</a> included only people with psychosis, but not necessarily with acute illnesses, while <a href="./references#CD002830-bbs2-0013" title="IsbisterGK , CalverLA , PageCB , StokesB , BryantJL , DownesMA . Randomized controlled trial of intramuscular droperidol versus midazolam for violence and acute behavioral disturbance: the DORM study. Annals of Emergency Medicine2010;56(4):392‐401. ">Isbister 2010</a>, although randomised, did not mention any underlying psychiatric illness. <a href="./references#CD002830-bbs2-0020" title="WeiserG , TahedlA , ReiseckerF , MeyerH . Advantages of the initial therapy of acute schizophrenia with large doses of droperidol: a comparative study [Vorteile der Initialbehandlung akuter Schizophrenien mit hochdosiertem Droperidol. Eine Vergleichsstudie]. Arzneimittel Forschung1975;25(11):1845‐8. ">Weiser 1975</a> would have been included, except for the addition of five people to replace those who left the study early. It is not clear to which group(s) those leaving early belonged, so the remaining data were rendered of little value once data from the non‐random replacements had been incorporated. </p> <section id="CD002830-sec-0127"> <h5 class="title">Awaiting assessment</h5> <p>No studies are currently awaiting assessment.</p> </section> <section id="CD002830-sec-0128"> <h5 class="title">Ongoing studies</h5> <p>We are not aware of any ongoing studies.</p> </section> </section> </section> <section id="CD002830-sec-0129"> <h3 class="title">Risk of bias in included studies</h3> <p>See also 'Risk of bias' tables in the <a href="./references#CD002830-sec-0342" title="">Characteristics of included studies</a> table and <a href="#CD002830-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD002830-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD002830-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD002830-sec-0130"> <h4 class="title">Allocation</h4> <p>All the included trials were randomised including one study (<a href="./references#CD002830-bbs2-0001" title="CalverL , DrinkwaterV , GuptaR , PageCB , IsbisterGK . Droperidol v. haloperidol for sedation of aggressive behaviour in acute mental health: randomized controlled trial. British Journal of Psychiatry2015;206(3):223‐8. ">Calver 2015</a>) that employed block randomisation. <a href="./references#CD002830-bbs2-0006" title="VanLeeuwenAMH , MoldersJ , SterkmansP , MielantsP , MartensC , ToussaintC , et al. Brief communication: droperidol in acutely agitated patients. A double blind placebo‐controlled study. Journal of Nervous and Mental Disease1977;164(4):280‐3. ">Van Leeuwen 1977</a> specified that treatment was "randomly assigned" with participants listed in chronological order and assigned individually numbered vials. Therefore, it was unclear whether those randomising could have ascertained the order of prescribing. <a href="./references#CD002830-bbs2-0005" title="ResnickM , BurtonBT . Droperidol versus haloperidol in the initial management of acutely agitated patients. Journal of Clinical Psychiatry1984;45(7):298‐9. ">Resnick 1984</a> did not specify the explicit means of allocation, although he stated that participants received treatment on a 'randomised basis', and that the codes identifying the packages of medication were "kept in the pharmacy until the conclusion of the study". <a href="./references#CD002830-bbs2-0003" title="CocchiA , FondaP , PerosinoN . Droperidol: a double‐blind clinical study [Droperidol: studio clinico in doppio cieco]. Rivista Sperimentale di Freniatria e Medicina Legale Delle Alienazioni Mentali1971;95(6):1109‐25. ">Cocchi 1971</a> specified only that the study was randomised, with no details regarding the means of allocation. </p> </section> <section id="CD002830-sec-0131"> <h4 class="title">Blinding</h4> <p>Five out of six included trials were double‐blind (<a href="./references#CD002830-bbs2-0002" title="ChanE , TaylorD , KongD , KnottJ , PhillipsG , CastleD . IV droperidol or olanzapine as adjuncts to midazolam for the acutely agitated patient: a multi‐centre, randomised, double‐blind, placebo‐controlled, clinical trial. Schizophrenia Research2012;136:S259. ChanEW , TaylorDM , KnottJC , PhillipsGA , CastleDJ , KongDCM . Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Annals of Emergency Medicine2013;61(1):72‐81. ">Chan 2013</a>; <a href="./references#CD002830-bbs2-0003" title="CocchiA , FondaP , PerosinoN . Droperidol: a double‐blind clinical study [Droperidol: studio clinico in doppio cieco]. Rivista Sperimentale di Freniatria e Medicina Legale Delle Alienazioni Mentali1971;95(6):1109‐25. ">Cocchi 1971</a>; <a href="./references#CD002830-bbs2-0004" title="KnottJC , TaylorD , CastleDJ . Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Annals of Emergency Medicine2006; Vol. 47, issue 1:61‐7. ">Knott 2006</a>; <a href="./references#CD002830-bbs2-0005" title="ResnickM , BurtonBT . Droperidol versus haloperidol in the initial management of acutely agitated patients. Journal of Clinical Psychiatry1984;45(7):298‐9. ">Resnick 1984</a>; <a href="./references#CD002830-bbs2-0006" title="VanLeeuwenAMH , MoldersJ , SterkmansP , MielantsP , MartensC , ToussaintC , et al. Brief communication: droperidol in acutely agitated patients. A double blind placebo‐controlled study. Journal of Nervous and Mental Disease1977;164(4):280‐3. ">Van Leeuwen 1977</a>). To minimise bias, three of the included studies stated that the outcome assessor was blinded to group allocation (<a href="./references#CD002830-bbs2-0001" title="CalverL , DrinkwaterV , GuptaR , PageCB , IsbisterGK . Droperidol v. haloperidol for sedation of aggressive behaviour in acute mental health: randomized controlled trial. British Journal of Psychiatry2015;206(3):223‐8. ">Calver 2015</a>; <a href="./references#CD002830-bbs2-0002" title="ChanE , TaylorD , KongD , KnottJ , PhillipsG , CastleD . IV droperidol or olanzapine as adjuncts to midazolam for the acutely agitated patient: a multi‐centre, randomised, double‐blind, placebo‐controlled, clinical trial. Schizophrenia Research2012;136:S259. ChanEW , TaylorDM , KnottJC , PhillipsGA , CastleDJ , KongDCM . Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Annals of Emergency Medicine2013;61(1):72‐81. ">Chan 2013</a>; <a href="./references#CD002830-bbs2-0004" title="KnottJC , TaylorD , CastleDJ . Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Annals of Emergency Medicine2006; Vol. 47, issue 1:61‐7. ">Knott 2006</a>). One study reported no detail of blinding the outcome assessor (<a href="./references#CD002830-bbs2-0006" title="VanLeeuwenAMH , MoldersJ , SterkmansP , MielantsP , MartensC , ToussaintC , et al. Brief communication: droperidol in acutely agitated patients. A double blind placebo‐controlled study. Journal of Nervous and Mental Disease1977;164(4):280‐3. ">Van Leeuwen 1977</a>), while <a href="./references#CD002830-bbs2-0005" title="ResnickM , BurtonBT . Droperidol versus haloperidol in the initial management of acutely agitated patients. Journal of Clinical Psychiatry1984;45(7):298‐9. ">Resnick 1984</a> gave no clear details of blinding. </p> </section> <section id="CD002830-sec-0132"> <h4 class="title">Incomplete outcome data</h4> <p>We rated only three studies at low risk bias with regard to attrition bias, as all participants were continued to follow‐up (<a href="./references#CD002830-bbs2-0001" title="CalverL , DrinkwaterV , GuptaR , PageCB , IsbisterGK . Droperidol v. haloperidol for sedation of aggressive behaviour in acute mental health: randomized controlled trial. British Journal of Psychiatry2015;206(3):223‐8. ">Calver 2015;</a><a href="./references#CD002830-bbs2-0002" title="ChanE , TaylorD , KongD , KnottJ , PhillipsG , CastleD . IV droperidol or olanzapine as adjuncts to midazolam for the acutely agitated patient: a multi‐centre, randomised, double‐blind, placebo‐controlled, clinical trial. Schizophrenia Research2012;136:S259. ChanEW , TaylorDM , KnottJC , PhillipsGA , CastleDJ , KongDCM . Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Annals of Emergency Medicine2013;61(1):72‐81. ">Chan 2013;</a><a href="./references#CD002830-bbs2-0005" title="ResnickM , BurtonBT . Droperidol versus haloperidol in the initial management of acutely agitated patients. Journal of Clinical Psychiatry1984;45(7):298‐9. ">Resnick 1984</a>), and only one study with high risk of attrition bias as it did not include all randomised participants in the final analysis (<a href="./references#CD002830-bbs2-0004" title="KnottJC , TaylorD , CastleDJ . Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Annals of Emergency Medicine2006; Vol. 47, issue 1:61‐7. ">Knott 2006</a>). We rated two studies as having unclear risk of bias (<a href="./references#CD002830-bbs2-0003" title="CocchiA , FondaP , PerosinoN . Droperidol: a double‐blind clinical study [Droperidol: studio clinico in doppio cieco]. Rivista Sperimentale di Freniatria e Medicina Legale Delle Alienazioni Mentali1971;95(6):1109‐25. ">Cocchi 1971</a>; <a href="./references#CD002830-bbs2-0006" title="VanLeeuwenAMH , MoldersJ , SterkmansP , MielantsP , MartensC , ToussaintC , et al. Brief communication: droperidol in acutely agitated patients. A double blind placebo‐controlled study. Journal of Nervous and Mental Disease1977;164(4):280‐3. ">Van Leeuwen 1977</a>). </p> </section> <section id="CD002830-sec-0133"> <h4 class="title">Selective reporting</h4> <p>All studies reported data for all outcomes listed. We rated five studies at low risk of bias and one study at unclear risk of reporting bias (<a href="./references#CD002830-bbs2-0004" title="KnottJC , TaylorD , CastleDJ . Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Annals of Emergency Medicine2006; Vol. 47, issue 1:61‐7. ">Knott 2006</a>). </p> </section> <section id="CD002830-sec-0134"> <h4 class="title">Other potential sources of bias</h4> <p>We identified no other potential sources of bias.</p> </section> </section> <section id="CD002830-sec-0135"> <h3 class="title" id="CD002830-sec-0135">Effects of interventions</h3> <p>See: <a href="./full#CD002830-tbl-0001"><b>Summary of findings for the main comparison</b> Droperidol versus placebo</a>; <a href="./full#CD002830-tbl-0002"><b>Summary of findings 2</b> Droperidol versus haloperidol</a>; <a href="./full#CD002830-tbl-0003"><b>Summary of findings 3</b> Droperidol versus midazolam</a>; <a href="./full#CD002830-tbl-0004"><b>Summary of findings 4</b> Droperidol versus olanzapine</a> </p> <p>There are four comparisons: droperidol compared with placebo, droperidol compared with haloperidol, droperidol compared with midazolam and droperidol compared with olanzapine. The studies reported outcomes for intervals within the 'immediate' time frame as defined in <a href="#CD002830-sec-0030">Criteria for considering studies for this review</a>. We reported these immediate outcomes individually. </p> <section id="CD002830-sec-0136"> <h4 class="title">1 Comparison 1: Droperidol versus placebo</h4> <p>Two studies provided data for the comparison of droperidol versus placebo (<a href="./references#CD002830-bbs2-0002" title="ChanE , TaylorD , KongD , KnottJ , PhillipsG , CastleD . IV droperidol or olanzapine as adjuncts to midazolam for the acutely agitated patient: a multi‐centre, randomised, double‐blind, placebo‐controlled, clinical trial. Schizophrenia Research2012;136:S259. ChanEW , TaylorDM , KnottJC , PhillipsGA , CastleDJ , KongDCM . Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Annals of Emergency Medicine2013;61(1):72‐81. ">Chan 2013</a>, N = 227; <a href="./references#CD002830-bbs2-0006" title="VanLeeuwenAMH , MoldersJ , SterkmansP , MielantsP , MartensC , ToussaintC , et al. Brief communication: droperidol in acutely agitated patients. A double blind placebo‐controlled study. Journal of Nervous and Mental Disease1977;164(4):280‐3. ">Van Leeuwen 1977</a>, N = 41). </p> <section id="CD002830-sec-0137"> <h5 class="title">1.1 Tranquillisation or asleep: 1. tranquilised/asleep (minutes)</h5> <p>One study provided data for tranquillisation or asleep (<a href="./references#CD002830-bbs2-0002" title="ChanE , TaylorD , KongD , KnottJ , PhillipsG , CastleD . IV droperidol or olanzapine as adjuncts to midazolam for the acutely agitated patient: a multi‐centre, randomised, double‐blind, placebo‐controlled, clinical trial. Schizophrenia Research2012;136:S259. ChanEW , TaylorDM , KnottJC , PhillipsGA , CastleDJ , KongDCM . Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Annals of Emergency Medicine2013;61(1):72‐81. ">Chan 2013</a>). </p> <section id="CD002830-sec-0138"> <h6 class="title">1.1.1 By five minutes</h6> <p>There was no clear difference between droperidol and placebo for by five minutes (1 RCT, N = 227, RR 1.32, 95% CI 0.90 to 1.96; <a href="./references#CD002830-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD002830-sec-0139"> <h6 class="title">1.1.2 By 10 minutes</h6> <p>By 10 minutes, there was evidence that droperidol was clearly different in its effects compared with placebo (1 RCT, N = 227, RR 1.36, 95% CI 1.08 to 1.71; <a href="./references#CD002830-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD002830-sec-0140"> <h6 class="title">1.1.3 By 30 minutes</h6> <p>By 30 minutes, we found evidence of a clear difference between droperidol and placebo (1 RCT, N = 227, RR 1.18, 95% CI 1.05 to 1.31; <a href="./references#CD002830-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD002830-sec-0141"> <h6 class="title">1.1.4 By 60 minutes</h6> <p>By 60 minutes, we found evidence of a clear difference between droperidol and placebo (1 RCT, N = 227, RR 1.09, 95% CI 1.00 to 1.18; <a href="./references#CD002830-fig-0004" title="">Analysis 1.1</a>). </p> </section> </section> <section id="CD002830-sec-0142"> <h5 class="title">1.2 Tranquillisation or asleep: 2. difficulty in achieving tranquillisation/sleep</h5> <p><a href="./references#CD002830-bbs2-0002" title="ChanE , TaylorD , KongD , KnottJ , PhillipsG , CastleD . IV droperidol or olanzapine as adjuncts to midazolam for the acutely agitated patient: a multi‐centre, randomised, double‐blind, placebo‐controlled, clinical trial. Schizophrenia Research2012;136:S259. ChanEW , TaylorDM , KnottJC , PhillipsGA , CastleDJ , KongDCM . Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Annals of Emergency Medicine2013;61(1):72‐81. ">Chan 2013</a> provided data for difficulty in achieving tranquillisation/sleep. There was no clear difference between droperidol and placebo (1 RCT, N = 227, RR 0.51, 95% CI 0.10 to 2.75; <a href="./references#CD002830-fig-0005" title="">Analysis 1.2</a>). </p> </section> <section id="CD002830-sec-0143"> <h5 class="title">1.3 Tranquillisation or asleep: 3. time to tranquillisation/sleep</h5> <p><a href="./references#CD002830-bbs2-0002" title="ChanE , TaylorD , KongD , KnottJ , PhillipsG , CastleD . IV droperidol or olanzapine as adjuncts to midazolam for the acutely agitated patient: a multi‐centre, randomised, double‐blind, placebo‐controlled, clinical trial. Schizophrenia Research2012;136:S259. ChanEW , TaylorDM , KnottJC , PhillipsGA , CastleDJ , KongDCM . Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Annals of Emergency Medicine2013;61(1):72‐81. ">Chan 2013</a> provided data for time to tranquillisation/sleep. We found evidence of a clear difference between droperidol and placebo in the mean time (in minutes) taken to become tranquil or asleep (1 RCT, N = 227, MD ‐46.50, 95% CI ‐86.83 to ‐6.17; <a href="./references#CD002830-fig-0006" title="">Analysis 1.3</a>). </p> </section> <section id="CD002830-sec-0144"> <h5 class="title">1.4 Global state: use of additional medication</h5> <p>Two studies provided data on use of additional medication (<a href="./references#CD002830-bbs2-0002" title="ChanE , TaylorD , KongD , KnottJ , PhillipsG , CastleD . IV droperidol or olanzapine as adjuncts to midazolam for the acutely agitated patient: a multi‐centre, randomised, double‐blind, placebo‐controlled, clinical trial. Schizophrenia Research2012;136:S259. ChanEW , TaylorDM , KnottJC , PhillipsGA , CastleDJ , KongDCM . Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Annals of Emergency Medicine2013;61(1):72‐81. ">Chan 2013</a>; <a href="./references#CD002830-bbs2-0006" title="VanLeeuwenAMH , MoldersJ , SterkmansP , MielantsP , MartensC , ToussaintC , et al. Brief communication: droperidol in acutely agitated patients. A double blind placebo‐controlled study. Journal of Nervous and Mental Disease1977;164(4):280‐3. ">Van Leeuwen 1977</a>). </p> <section id="CD002830-sec-0145"> <h6 class="title">1.4.1 "To reach initial adequate sedation"</h6> <p><a href="./references#CD002830-bbs2-0002" title="ChanE , TaylorD , KongD , KnottJ , PhillipsG , CastleD . IV droperidol or olanzapine as adjuncts to midazolam for the acutely agitated patient: a multi‐centre, randomised, double‐blind, placebo‐controlled, clinical trial. Schizophrenia Research2012;136:S259. ChanEW , TaylorDM , KnottJC , PhillipsGA , CastleDJ , KongDCM . Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Annals of Emergency Medicine2013;61(1):72‐81. ">Chan 2013</a> provided data for numbers needing additional medication to reach initial adequate sedation. We found evidence that droperidol was clearly different in its effects compared with placebo (1 RCT, N = 227, RR 0.50, 95% CI 0.28 to 0.89; <a href="./references#CD002830-fig-0007" title="">Analysis 1.4</a>). </p> </section> <section id="CD002830-sec-0146"> <h6 class="title">1.4.2 By three minutes (haloperidol)</h6> <p><a href="./references#CD002830-bbs2-0006" title="VanLeeuwenAMH , MoldersJ , SterkmansP , MielantsP , MartensC , ToussaintC , et al. Brief communication: droperidol in acutely agitated patients. A double blind placebo‐controlled study. Journal of Nervous and Mental Disease1977;164(4):280‐3. ">Van Leeuwen 1977</a> provided data for numbers needing additional haloperidol by three minutes. We found evidence of a clear difference between droperidol and placebo for use of additional medication (1 RCT, N = 41, RR 0.37, 95% CI 0.18 to 0.72; <a href="./references#CD002830-fig-0007" title="">Analysis 1.4</a>). </p> </section> <section id="CD002830-sec-0147"> <h6 class="title">1.4.3 By 30 minutes (any psychotropic drug)</h6> <p><a href="./references#CD002830-bbs2-0006" title="VanLeeuwenAMH , MoldersJ , SterkmansP , MielantsP , MartensC , ToussaintC , et al. Brief communication: droperidol in acutely agitated patients. A double blind placebo‐controlled study. Journal of Nervous and Mental Disease1977;164(4):280‐3. ">Van Leeuwen 1977</a> provided data for numbers needing any additional psychotropic drug by 30 minutes. We found no evidence of a clear difference between droperidol and placebo (1 RCT, N = 41, RR 0.46, 95% CI 0.17 to 1.24; <a href="./references#CD002830-fig-0007" title="">Analysis 1.4</a>). </p> </section> <section id="CD002830-sec-0148"> <h6 class="title">1.4.4 By 60 minutes (midazolam, droperidol, olanzapine, haloperidol)</h6> <p><a href="./references#CD002830-bbs2-0002" title="ChanE , TaylorD , KongD , KnottJ , PhillipsG , CastleD . IV droperidol or olanzapine as adjuncts to midazolam for the acutely agitated patient: a multi‐centre, randomised, double‐blind, placebo‐controlled, clinical trial. Schizophrenia Research2012;136:S259. ChanEW , TaylorDM , KnottJC , PhillipsGA , CastleDJ , KongDCM . Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Annals of Emergency Medicine2013;61(1):72‐81. ">Chan 2013</a> provided data for use of additional medication. By 60 minutes, there was evidence of a clear difference favouring droperidol (1 RCT, N = 227, RR 0.64, 95% CI 0.42 to 0.96; <a href="./references#CD002830-fig-0007" title="">Analysis 1.4</a>). </p> </section> <section id="CD002830-sec-0149"> <h6 class="title">1.4.5 From 60 minutes after initial adequate sedation until emergency department discharge (various psychotropic drugs) </h6> <p>We found evidence of a clear difference for use of additional medication favouring droperidol (1 RCT, N = 227, RR 0.55, 95% CI 0.36 to 0.85; <a href="./references#CD002830-fig-0007" title="">Analysis 1.4</a>). </p> </section> </section> <section id="CD002830-sec-0150"> <h5 class="title">1.5 Adverse effects</h5> <p>Two studies provided adverse effect data (<a href="./references#CD002830-bbs2-0002" title="ChanE , TaylorD , KongD , KnottJ , PhillipsG , CastleD . IV droperidol or olanzapine as adjuncts to midazolam for the acutely agitated patient: a multi‐centre, randomised, double‐blind, placebo‐controlled, clinical trial. Schizophrenia Research2012;136:S259. ChanEW , TaylorDM , KnottJC , PhillipsGA , CastleDJ , KongDCM . Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Annals of Emergency Medicine2013;61(1):72‐81. ">Chan 2013</a>; <a href="./references#CD002830-bbs2-0006" title="VanLeeuwenAMH , MoldersJ , SterkmansP , MielantsP , MartensC , ToussaintC , et al. Brief communication: droperidol in acutely agitated patients. A double blind placebo‐controlled study. Journal of Nervous and Mental Disease1977;164(4):280‐3. ">Van Leeuwen 1977</a>). </p> <section id="CD002830-sec-0151"> <h6 class="title">1.5.1 Cardiovascular ‐ arrhythmia</h6> <p><a href="./references#CD002830-bbs2-0002" title="ChanE , TaylorD , KongD , KnottJ , PhillipsG , CastleD . IV droperidol or olanzapine as adjuncts to midazolam for the acutely agitated patient: a multi‐centre, randomised, double‐blind, placebo‐controlled, clinical trial. Schizophrenia Research2012;136:S259. ChanEW , TaylorDM , KnottJC , PhillipsGA , CastleDJ , KongDCM . Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Annals of Emergency Medicine2013;61(1):72‐81. ">Chan 2013</a> provided data for arrhythmia. There was no clear difference between droperidol and placebo (1 RCT, N = 227, RR 0.34, 95% CI 0.01 to 8.31; <a href="./references#CD002830-fig-0008" title="">Analysis 1.5</a>). </p> </section> <section id="CD002830-sec-0152"> <h6 class="title">1.5.2 Cardiovascular ‐ hypotension</h6> <p><a href="./references#CD002830-bbs2-0002" title="ChanE , TaylorD , KongD , KnottJ , PhillipsG , CastleD . IV droperidol or olanzapine as adjuncts to midazolam for the acutely agitated patient: a multi‐centre, randomised, double‐blind, placebo‐controlled, clinical trial. Schizophrenia Research2012;136:S259. ChanEW , TaylorDM , KnottJC , PhillipsGA , CastleDJ , KongDCM . Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Annals of Emergency Medicine2013;61(1):72‐81. ">Chan 2013</a> provided data for hypotension. We found no evidence of a clear difference between droperidol and placebo (1 RCT, N = 227, RR 0.68, 95% CI 0.20 to 2.36; <a href="./references#CD002830-fig-0008" title="">Analysis 1.5</a>). </p> </section> <section id="CD002830-sec-0153"> <h6 class="title">1.5.3 Central nervous system ‐ oversedation (decreased Glasgow Coma Score of 6)</h6> <p><a href="./references#CD002830-bbs2-0002" title="ChanE , TaylorD , KongD , KnottJ , PhillipsG , CastleD . IV droperidol or olanzapine as adjuncts to midazolam for the acutely agitated patient: a multi‐centre, randomised, double‐blind, placebo‐controlled, clinical trial. Schizophrenia Research2012;136:S259. ChanEW , TaylorDM , KnottJC , PhillipsGA , CastleDJ , KongDCM . Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Annals of Emergency Medicine2013;61(1):72‐81. ">Chan 2013</a> provided data for oversedation. We found no evidence of a clear difference between droperidol and placebo (1 RCT, N = 227, RR 0.34, 95% CI 0.01 to 8.31; <a href="./references#CD002830-fig-0008" title="">Analysis 1.5</a>). </p> </section> <section id="CD002830-sec-0154"> <h6 class="title">1.5.4 Respiratory ‐ airway obstruction</h6> <p><a href="./references#CD002830-bbs2-0002" title="ChanE , TaylorD , KongD , KnottJ , PhillipsG , CastleD . IV droperidol or olanzapine as adjuncts to midazolam for the acutely agitated patient: a multi‐centre, randomised, double‐blind, placebo‐controlled, clinical trial. Schizophrenia Research2012;136:S259. ChanEW , TaylorDM , KnottJC , PhillipsGA , CastleDJ , KongDCM . Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Annals of Emergency Medicine2013;61(1):72‐81. ">Chan 2013</a> provided data for airway obstruction. There was noclear difference between droperidol and placebo (1 RCT, N = 227, RR 0.62, 95% CI 0.15 to 2.52; <a href="./references#CD002830-fig-0008" title="">Analysis 1.5</a>). </p> </section> <section id="CD002830-sec-0155"> <h6 class="title">1.5.5 Respiratory ‐ oxygen desaturation</h6> <p><a href="./references#CD002830-bbs2-0002" title="ChanE , TaylorD , KongD , KnottJ , PhillipsG , CastleD . IV droperidol or olanzapine as adjuncts to midazolam for the acutely agitated patient: a multi‐centre, randomised, double‐blind, placebo‐controlled, clinical trial. Schizophrenia Research2012;136:S259. ChanEW , TaylorDM , KnottJC , PhillipsGA , CastleDJ , KongDCM . Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Annals of Emergency Medicine2013;61(1):72‐81. ">Chan 2013</a> provided data for oxygen desaturation. We found no evidence of a clear difference between droperidol and placebo (1 RCT, N = 227, RR 1.03, 95% CI 0.42 to 2.49; <a href="./references#CD002830-fig-0008" title="">Analysis 1.5</a>). </p> </section> <section id="CD002830-sec-0156"> <h6 class="title">1.5.6 Unspecified ‐ by three minutes</h6> <p>One trial provided data for unspecified Adverse effects by three minutes (<a href="./references#CD002830-bbs2-0006" title="VanLeeuwenAMH , MoldersJ , SterkmansP , MielantsP , MartensC , ToussaintC , et al. Brief communication: droperidol in acutely agitated patients. A double blind placebo‐controlled study. Journal of Nervous and Mental Disease1977;164(4):280‐3. ">Van Leeuwen 1977</a>, N = 41). There were no events in either the droperidol or placebo group (<a href="./references#CD002830-fig-0008" title="">Analysis 1.5</a>). </p> </section> </section> <section id="CD002830-sec-0157"> <h5 class="title">1.6 Service use: person able to be discharged home</h5> <p><a href="./references#CD002830-bbs2-0002" title="ChanE , TaylorD , KongD , KnottJ , PhillipsG , CastleD . IV droperidol or olanzapine as adjuncts to midazolam for the acutely agitated patient: a multi‐centre, randomised, double‐blind, placebo‐controlled, clinical trial. Schizophrenia Research2012;136:S259. ChanEW , TaylorDM , KnottJC , PhillipsGA , CastleDJ , KongDCM . Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Annals of Emergency Medicine2013;61(1):72‐81. ">Chan 2013</a> provided data for discharge. There was no clear difference between droperidol and placebo (N = 227, RR 1.16, 95% CI 0.90 to 1.48; <a href="./references#CD002830-fig-0009" title="">Analysis 1.6</a>). </p> </section> <section id="CD002830-sec-0158"> <h5 class="title">1.7 Service use: emergency department length of stay</h5> <p><a href="./references#CD002830-bbs2-0002" title="ChanE , TaylorD , KongD , KnottJ , PhillipsG , CastleD . IV droperidol or olanzapine as adjuncts to midazolam for the acutely agitated patient: a multi‐centre, randomised, double‐blind, placebo‐controlled, clinical trial. Schizophrenia Research2012;136:S259. ChanEW , TaylorDM , KnottJC , PhillipsGA , CastleDJ , KongDCM . Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Annals of Emergency Medicine2013;61(1):72‐81. ">Chan 2013</a> (N = 227) provided data for length of stay in emergency department. Data were skewed and can be viewed in <a href="./references#CD002830-fig-0010" title="">Analysis 1.7</a>). There was no suggestion of a difference between droperidol and placebo (median stay was around 10 hours for both groups). </p> </section> </section> <section id="CD002830-sec-0159"> <h4 class="title">2 Comparison 2: Droperidol versus haloperidol</h4> <p>Three studies provided data for the comparison of droperidol versus haloperidol (<a href="./references#CD002830-bbs2-0001" title="CalverL , DrinkwaterV , GuptaR , PageCB , IsbisterGK . Droperidol v. haloperidol for sedation of aggressive behaviour in acute mental health: randomized controlled trial. British Journal of Psychiatry2015;206(3):223‐8. ">Calver 2015</a>, N = 228; <a href="./references#CD002830-bbs2-0003" title="CocchiA , FondaP , PerosinoN . Droperidol: a double‐blind clinical study [Droperidol: studio clinico in doppio cieco]. Rivista Sperimentale di Freniatria e Medicina Legale Delle Alienazioni Mentali1971;95(6):1109‐25. ">Cocchi 1971</a>, N = 40; <a href="./references#CD002830-bbs2-0005" title="ResnickM , BurtonBT . Droperidol versus haloperidol in the initial management of acutely agitated patients. Journal of Clinical Psychiatry1984;45(7):298‐9. ">Resnick 1984</a>, N = 27). </p> <section id="CD002830-sec-0160"> <h5 class="title">2.1 Tranquillisation or asleep: 1. tranquillised/sleep within 120 minutes</h5> <p><a href="./references#CD002830-bbs2-0001" title="CalverL , DrinkwaterV , GuptaR , PageCB , IsbisterGK . Droperidol v. haloperidol for sedation of aggressive behaviour in acute mental health: randomized controlled trial. British Journal of Psychiatry2015;206(3):223‐8. ">Calver 2015</a> provided useable data for tranquillised/sleep within 120 minutes. We found no evidence of a clear difference between droperidol and haloperidol(1 RCT, N = 228, RR 1.01, 95% CI 0.93 to 1.09). </p> </section> <section id="CD002830-sec-0161"> <h5 class="title">2.2 Tranquillisation or asleep: 2. time to tranquillisation/sleep</h5> <p><a href="./references#CD002830-bbs2-0001" title="CalverL , DrinkwaterV , GuptaR , PageCB , IsbisterGK . Droperidol v. haloperidol for sedation of aggressive behaviour in acute mental health: randomized controlled trial. British Journal of Psychiatry2015;206(3):223‐8. ">Calver 2015</a> provided data for time to tranquillisation/sleep, we have presented them in <a href="./references#CD002830-fig-0012" title="">Analysis 2.2</a>. There was no suggestion of clear difference between droperidol and haloperidol (median time was around 25 minutes for both groups). </p> </section> <section id="CD002830-sec-0162"> <h5 class="title">2.3 Global state: use of additional medication</h5> <section id="CD002830-sec-0163"> <h6 class="title">2.3.1 Midazolam administered initially</h6> <p><a href="./references#CD002830-bbs2-0001" title="CalverL , DrinkwaterV , GuptaR , PageCB , IsbisterGK . Droperidol v. haloperidol for sedation of aggressive behaviour in acute mental health: randomized controlled trial. British Journal of Psychiatry2015;206(3):223‐8. ">Calver 2015</a> provided data that showed no clear difference between droperidol and haloperidol for use of additional medication (1 RCT, N = 228, RR 3.26, 95% CI 0.69 to 15.37; <a href="./references#CD002830-fig-0013" title="">Analysis 2.3</a>). </p> </section> <section id="CD002830-sec-0164"> <h6 class="title">2.3.2 By 30 minutes</h6> <p><a href="./references#CD002830-bbs2-0005" title="ResnickM , BurtonBT . Droperidol versus haloperidol in the initial management of acutely agitated patients. Journal of Clinical Psychiatry1984;45(7):298‐9. ">Resnick 1984</a> provided data for use of additional medication by 30 minutes. We found no clear difference between droperidol and haloperidol (1 RCT, N = 27, RR 0.45, 95% CI 0.20 to 1.01; <a href="./references#CD002830-fig-0013" title="">Analysis 2.3</a>). </p> </section> <section id="CD002830-sec-0165"> <h6 class="title">2.3.3 By 60 minutes</h6> <p>Two trials provided data for use of additional medication by 60 minutes (<a href="./references#CD002830-bbs2-0001" title="CalverL , DrinkwaterV , GuptaR , PageCB , IsbisterGK . Droperidol v. haloperidol for sedation of aggressive behaviour in acute mental health: randomized controlled trial. British Journal of Psychiatry2015;206(3):223‐8. ">Calver 2015</a>; <a href="./references#CD002830-bbs2-0005" title="ResnickM , BurtonBT . Droperidol versus haloperidol in the initial management of acutely agitated patients. Journal of Clinical Psychiatry1984;45(7):298‐9. ">Resnick 1984</a>). There was evidence of a clear effect, favouring droperidol for this outcome. (2 RCTs, N = 255, RR 0.37, 95% CI 0.16 to 0.9; <a href="./references#CD002830-fig-0013" title="">Analysis 2.3</a>). </p> </section> <section id="CD002830-sec-0166"> <h6 class="title">2.3.4 By 90 minute</h6> <p><a href="./references#CD002830-bbs2-0005" title="ResnickM , BurtonBT . Droperidol versus haloperidol in the initial management of acutely agitated patients. Journal of Clinical Psychiatry1984;45(7):298‐9. ">Resnick 1984</a> provided data for use of additional medication by 90 minutes. There was no evidence of a clear difference between droperidol and haloperidol(1 RCT, N = 27, RR 0.47, 95% CI 0.02 to 10.63; <a href="./references#CD002830-fig-0013" title="">Analysis 2.3</a>). </p> </section> </section> <section id="CD002830-sec-0167"> <h5 class="title">2.4 Global state: no overall improvement ‐ by 30 days</h5> <p><a href="./references#CD002830-bbs2-0003" title="CocchiA , FondaP , PerosinoN . Droperidol: a double‐blind clinical study [Droperidol: studio clinico in doppio cieco]. Rivista Sperimentale di Freniatria e Medicina Legale Delle Alienazioni Mentali1971;95(6):1109‐25. ">Cocchi 1971</a> provided data for overall improvement. There was no clear difference between droperidol and haloperidol (1 RCT, N = 40, RR 0.67, 95% CI 0.29 to 1.52; <a href="./references#CD002830-fig-0014" title="">Analysis 2.4</a>). </p> </section> <section id="CD002830-sec-0168"> <h5 class="title">2.5 Adverse effects</h5> <p>One study provided adverse effect data (<a href="./references#CD002830-bbs2-0001" title="CalverL , DrinkwaterV , GuptaR , PageCB , IsbisterGK . Droperidol v. haloperidol for sedation of aggressive behaviour in acute mental health: randomized controlled trial. British Journal of Psychiatry2015;206(3):223‐8. ">Calver 2015</a>, N = 228). </p> <section id="CD002830-sec-0169"> <h6 class="title">2.5.1 Cardiovascular ‐ hypotension</h6> <p>There was no clear difference between droperidol and haloperidol for hypotension (RR 2.80, 95% CI 0.30 to 26.49; <a href="./references#CD002830-fig-0015" title="">Analysis 2.5</a>). </p> </section> <section id="CD002830-sec-0170"> <h6 class="title">2.5.2 Cardiovascular ‐ hypotension/desaturation</h6> <p>We found no evidence of a clear difference between the two treatments for hypotension/desaturation (RR 2.80, 95% CI 0.12 to 67.98; <a href="./references#CD002830-fig-0015" title="">Analysis 2.5</a>). </p> </section> <section id="CD002830-sec-0171"> <h6 class="title">2.5.3 Central nervous system ‐ extrapyramidal adverse effects</h6> <p>There was no clear difference in extrapyramidal adverse effects between droperidol and haloperidol (RR 2.80, 95% CI 0.12 to 67.98; <a href="./references#CD002830-fig-0015" title="">Analysis 2.5</a>). </p> </section> <section id="CD002830-sec-0172"> <h6 class="title">2.5.4 Central nervous system ‐ oversedation</h6> <p>There was no clear difference between droperidol and haloperidol for oversedation (RR 2.80, 95% CI 0.12 to 67.98; <a href="./references#CD002830-fig-0015" title="">Analysis 2.5</a>). </p> </section> <section id="CD002830-sec-0173"> <h6 class="title">2.5.5 Staff injuries</h6> <p>There was no evidence of a clear difference in staff injuries between droperidol and haloperidol (RR 0.56, 95% CI 0.14 to 2.29; <a href="./references#CD002830-fig-0015" title="">Analysis 2.5</a>). </p> </section> </section> <section id="CD002830-sec-0174"> <h5 class="title">2.6 Mental state: mean score by 13 days (Scale for Quantification of Psychotic Symptom Severity, high = poor) </h5> <p><a href="./references#CD002830-bbs2-0003" title="CocchiA , FondaP , PerosinoN . Droperidol: a double‐blind clinical study [Droperidol: studio clinico in doppio cieco]. Rivista Sperimentale di Freniatria e Medicina Legale Delle Alienazioni Mentali1971;95(6):1109‐25. ">Cocchi 1971</a>, N = 40 provided mental state data and we found no evidence of a clear difference between droperidol and haloperidol (MD 0.11, 95% CI ‐0.07 to 0.29; <a href="./references#CD002830-fig-0016" title="">Analysis 2.6</a>). </p> </section> </section> <section id="CD002830-sec-0175"> <h4 class="title">3 Comparison 3: Droperidol versus midazolam</h4> <p>One study provided data for the comparison of droperidol versus midazolam (<a href="./references#CD002830-bbs2-0004" title="KnottJC , TaylorD , CastleDJ . Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Annals of Emergency Medicine2006; Vol. 47, issue 1:61‐7. ">Knott 2006</a>, N = 153). </p> <section id="CD002830-sec-0176"> <h5 class="title">3.1 Tranquillisation or asleep: 1. tranquillised/asleep</h5> <p>We identified one study relevant to this outcome and categorised data into two subsets: by 5 minutes and by 10 minutes. </p> <section id="CD002830-sec-0177"> <h6 class="title">3.2.1 By five minutes</h6> <p>We found evidence of a clear difference between droperidol and midazolam by five minutes (RR 0.37, 95% CI 0.21 to 0.64; <a href="./references#CD002830-fig-0017" title="">Analysis 3.1</a>). </p> </section> <section id="CD002830-sec-0178"> <h6 class="title">3.2.2 By 10 minutes</h6> <p>There was no clear difference between droperidol and midazolam by 10 minutes (RR 0.96, 95% CI 0.72 to 1.28; <a href="./references#CD002830-fig-0017" title="">Analysis 3.1</a>). </p> </section> </section> <section id="CD002830-sec-0179"> <h5 class="title">3.2 Tranquillisation or asleep: 2. time to tranquillisation/sleep</h5> <p>There was no suggestion of a clear difference between droperidol and midazolam (median time was around 10 minutes for both groups; <a href="./references#CD002830-fig-0018" title="">Analysis 3.2</a>). </p> </section> <section id="CD002830-sec-0180"> <h5 class="title">3.3 Global state: use of additional medication</h5> <p>We found one study reporting data on use of additional medication and categorised data into one subset involving 153 participants (<a href="./references#CD002830-bbs2-0004" title="KnottJC , TaylorD , CastleDJ . Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Annals of Emergency Medicine2006; Vol. 47, issue 1:61‐7. ">Knott 2006</a>). </p> <section id="CD002830-sec-0181"> <h6 class="title">3.3.1 By 60 minutes</h6> <p>There was no clear difference between droperidol and midazolam by 60 minutes (RR 0.54, 95% CI 0.24 to 1.20; <a href="./references#CD002830-fig-0019" title="">Analysis 3.3</a>). </p> </section> </section> <section id="CD002830-sec-0182"> <h5 class="title">3.4 Adverse effects</h5> <p>One study provided adverse effect data (<a href="./references#CD002830-bbs2-0004" title="KnottJC , TaylorD , CastleDJ . Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Annals of Emergency Medicine2006; Vol. 47, issue 1:61‐7. ">Knott 2006</a>, N = 153). </p> <section id="CD002830-sec-0183"> <h6 class="title">3.4.1 Cardiovascular ‐ arrhythmia (bradycardia)</h6> <p>There was no evidence of a clear difference between droperidol and midazolam for arrhythmia (RR 2.81, 95% CI 0.12 to 67.98; <a href="./references#CD002830-fig-0020" title="">Analysis 3.4</a>). </p> </section> <section id="CD002830-sec-0184"> <h6 class="title">3.4.2 Cardiovascular ‐ hypotension</h6> <p>There was no clear difference between droperidol and midazolam for hypotension (RR 0.70, 95% CI 0.16 to 3.03; <a href="./references#CD002830-fig-0020" title="">Analysis 3.4</a>). </p> </section> <section id="CD002830-sec-0185"> <h6 class="title">3.4.3 Central nervous system ‐ dystonic reaction</h6> <p>There was no evidence of a clear difference between droperidol and midazolam for dystonic reaction (RR 6.56, 95% CI 0.34 to 124.93; <a href="./references#CD002830-fig-0020" title="">Analysis 3.4</a>). </p> </section> <section id="CD002830-sec-0186"> <h6 class="title">3.4.4 Central nervous system ‐ seizure</h6> <p>There were no seizures in either the droperidol or midazolam group (<a href="./references#CD002830-fig-0020" title="">Analysis 3.4</a>). </p> </section> <section id="CD002830-sec-0187"> <h6 class="title">3.4.5 Gastric ‐ aspiration</h6> <p>There were no aspirations in either the droperidol or midazolam group (<a href="./references#CD002830-fig-0020" title="">Analysis 3.4</a>). </p> </section> <section id="CD002830-sec-0188"> <h6 class="title">3.4.6 Gastric ‐ vomiting</h6> <p>There were no vomiting episodes in either the droperidol or midazolam group (<a href="./references#CD002830-fig-0020" title="">Analysis 3.4</a>). </p> </section> <section id="CD002830-sec-0189"> <h6 class="title">3.4.7 Respiratory ‐ airway management</h6> <p>There was no evidence of a clear difference between droperidol and midazolam (RR 0.13, 95% CI 0.01 to 2.55; <a href="./references#CD002830-fig-0020" title="">Analysis 3.4</a>). </p> </section> <section id="CD002830-sec-0190"> <h6 class="title">3.4.8 Respiratory ‐ assistance with ventilation</h6> <p>There was no need for assistance with ventilation with either droperidol or midazolam (<a href="./references#CD002830-fig-0020" title="">Analysis 3.4</a>). </p> </section> <section id="CD002830-sec-0191"> <h6 class="title">3.4.9 Respiratory ‐ hypoxia</h6> <p>There was no clear difference between droperidol and midazolam for hypoxia (RR 0.70, 95% CI 0.16 to 3.03; <a href="./references#CD002830-fig-0020" title="">Analysis 3.4</a>) </p> </section> </section> </section> <section id="CD002830-sec-0192"> <h4 class="title">4 Comparison 4: Droperidol versus olanzapine</h4> <p>One study provided data for the comparison of droperidol versus olanzapine (<a href="./references#CD002830-bbs2-0002" title="ChanE , TaylorD , KongD , KnottJ , PhillipsG , CastleD . IV droperidol or olanzapine as adjuncts to midazolam for the acutely agitated patient: a multi‐centre, randomised, double‐blind, placebo‐controlled, clinical trial. Schizophrenia Research2012;136:S259. ChanEW , TaylorDM , KnottJC , PhillipsGA , CastleDJ , KongDCM . Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Annals of Emergency Medicine2013;61(1):72‐81. ">Chan 2013</a>). In this comparison, there were seven outcomes. </p> <section id="CD002830-sec-0193"> <h5 class="title">4.3 Tranquillisation or asleep: 3. tranquillised/asleep</h5> <p>We divided the data into four subsets, with a total of 884 people. There was no clear difference between droperidol and olanzapine (RR 1.00, 95% CI 0.93 to 1.07). </p> <section id="CD002830-sec-0194"> <h6 class="title">4.3.1 At five minutes</h6> <p>There was no clear difference between droperidol and olanzapine at five minutes (RR 1.00, 95% CI 0.70 to 1.42; <a href="./references#CD002830-fig-0021" title="">Analysis 4.1</a>). </p> </section> <section id="CD002830-sec-0195"> <h6 class="title">4.3.2 At 10 minutes</h6> <p>There was no evidence of a clear difference between droperidol and olanzapine at 10 minutes (RR 0.97, 95% CI 0.81 to 1.17; <a href="./references#CD002830-fig-0021" title="">Analysis 4.1</a>). </p> </section> <section id="CD002830-sec-0196"> <h6 class="title">4.3.3 At 30 minutes</h6> <p>There was no clear difference between droperidol and olanzapine at 30 minutes (RR 1.02, 95% CI 0.94 to 1.11; <a href="./references#CD002830-fig-0021" title="">Analysis 4.1</a>). </p> </section> <section id="CD002830-sec-0197"> <h6 class="title">4.3.4 At 60 minutes</h6> <p>There was no clear difference between droperidol and olanzapine at 60 minutes (RR 0.99, 95% CI 0.93 to 1.05; <a href="./references#CD002830-fig-0021" title="">Analysis 4.1</a>). </p> </section> </section> <section id="CD002830-sec-0198"> <h5 class="title">4.2 Tranquillisation or asleep: 2. difficulty in achieving tranquillisation/sleep</h5> <p>We found no evidence of a clear difference between droperidol and olanzapine for difficulty in achieving tranquillisation/sleep (RR 0.65, 95% CI 0.11 to 3.81; <a href="./references#CD002830-fig-0022" title="">Analysis 4.2</a>). </p> </section> <section id="CD002830-sec-0199"> <h5 class="title">4.3 Tranquillisation or asleep: 3. time to tranquillisation/sleep</h5> <p>There was no clear difference between droperidol and olanzapine for time to tranquillisation/sleep (in minutes) (1 RCT, N = 221, MD 7.3 95% CI ‐11.74 to 26.34; <a href="./references#CD002830-fig-0023" title="">Analysis 4.3</a>). </p> </section> <section id="CD002830-sec-0200"> <h5 class="title">4.4 Global state: use of additional medication</h5> <p>We identified one study reporting use of additional medication and categorised data into three subsets (<a href="./references#CD002830-bbs2-0002" title="ChanE , TaylorD , KongD , KnottJ , PhillipsG , CastleD . IV droperidol or olanzapine as adjuncts to midazolam for the acutely agitated patient: a multi‐centre, randomised, double‐blind, placebo‐controlled, clinical trial. Schizophrenia Research2012;136:S259. ChanEW , TaylorDM , KnottJC , PhillipsGA , CastleDJ , KongDCM . Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Annals of Emergency Medicine2013;61(1):72‐81. ">Chan 2013</a>, N = 221). </p> <section id="CD002830-sec-0201"> <h6 class="title">4.4.1 "To reach initial adequate sedation"</h6> <p>There was no clear difference between droperidol and olanzapine for use of additional medication "to reach initial adequate sedation" (RR 0.68, 95% CI 0.36 to 1.28; <a href="./references#CD002830-fig-0024" title="">Analysis 4.4</a>). </p> </section> <section id="CD002830-sec-0202"> <h6 class="title">4.4.2 By 60 minutes (midazolam, droperidol, olanzapine, haloperidol)</h6> <p>We found no evidence of a clear difference between droperidol and olanzapine for use of additional medication by 60 minutes (RR 1.01, 95% CI 0.63 to 1.64; <a href="./references#CD002830-fig-0024" title="">Analysis 4.4</a>). </p> </section> <section id="CD002830-sec-0203"> <h6 class="title">4.4.3 From 60 minutes after initial adequate sedation until emergency department discharge (various psychotropic drugs) </h6> <p>We found evidence of a clear difference, favouring droperidol for use of additional medication from 60 minutes after initial adequate sedation until emergency department discharge (RR 0.56, 95% CI 0.36 to 0.87; <a href="./references#CD002830-fig-0024" title="">Analysis 4.4</a>). </p> </section> </section> <section id="CD002830-sec-0204"> <h5 class="title">4.5 Adverse effects</h5> <p>One study provided adverse effect data (<a href="./references#CD002830-bbs2-0002" title="ChanE , TaylorD , KongD , KnottJ , PhillipsG , CastleD . IV droperidol or olanzapine as adjuncts to midazolam for the acutely agitated patient: a multi‐centre, randomised, double‐blind, placebo‐controlled, clinical trial. Schizophrenia Research2012;136:S259. ChanEW , TaylorDM , KnottJC , PhillipsGA , CastleDJ , KongDCM . Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Annals of Emergency Medicine2013;61(1):72‐81. ">Chan 2013</a>, N = 221). We divided the data into five subsets. </p> <section id="CD002830-sec-0205"> <h6 class="title">4.5.1 Cardiovascular ‐ arrhythmia</h6> <p>There was no clear difference between droperidol and olanzapine for arrhythmia (RR 0.32, 95% CI 0.01 to 7.88; <a href="./references#CD002830-fig-0025" title="">Analysis 4.5</a>). </p> </section> <section id="CD002830-sec-0206"> <h6 class="title">4.5.2 Cardiovascular ‐ hypotension</h6> <p>There was no clear difference between droperidol and olanzapine for hypotension (RR 1.30, 95% CI 0.30 to 5.66; <a href="./references#CD002830-fig-0025" title="">Analysis 4.5</a>). </p> </section> <section id="CD002830-sec-0207"> <h6 class="title">4.5.3 Central nervous system ‐ decreased Glasgow Coma Score (score of 6)</h6> <p>There were no reports of decreased GCS (score of 6) in either the droperidol or olanzapine group (<a href="./references#CD002830-fig-0025" title="">Analysis 4.5</a>). </p> </section> <section id="CD002830-sec-0208"> <h6 class="title">4.5.4 Respiratory ‐ airway obstruction</h6> <p>We found no evidence of a clear difference between droperidol and olanzapine (RR 0.97, 95% CI 0.20 to 4.72; <a href="./references#CD002830-fig-0025" title="">Analysis 4.5</a>). </p> </section> <section id="CD002830-sec-0209"> <h6 class="title">4.5.5 Respiratory ‐ oxygen desaturation</h6> <p>We found no evidence of a clear difference between droperidol and olanzapine (RR 1.75, 95% CI 0.61 to 5.06; <a href="./references#CD002830-fig-0025" title="">Analysis 4.5</a>). </p> </section> </section> <section id="CD002830-sec-0210"> <h5 class="title">4.6 Service use: 1. person able to be discharged home</h5> <p>One study provided data for discharge (<a href="./references#CD002830-bbs2-0002" title="ChanE , TaylorD , KongD , KnottJ , PhillipsG , CastleD . IV droperidol or olanzapine as adjuncts to midazolam for the acutely agitated patient: a multi‐centre, randomised, double‐blind, placebo‐controlled, clinical trial. Schizophrenia Research2012;136:S259. ChanEW , TaylorDM , KnottJC , PhillipsGA , CastleDJ , KongDCM . Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Annals of Emergency Medicine2013;61(1):72‐81. ">Chan 2013</a>, N = 221). There are no subsets in this outcome. We found no evidence of a clear difference between droperidol and olanzapine (RR 1.06, 95% CI 0.83 to 1.34; <a href="./references#CD002830-fig-0026" title="">Analysis 4.6</a>). </p> </section> <section id="CD002830-sec-0211"> <h5 class="title">4.7 Service use: 2. emergency department length of stay</h5> <p>One study provided data for length of stay in emergency department (N = 221). There was no suggestion of clear difference between droperidol and olanzapine (median stay was around 11 hours for both groups; <a href="./references#CD002830-fig-0027" title="">Analysis 4.7</a>). </p> </section> </section> <section id="CD002830-sec-0212"> <h4 class="title">5 Missing outcomes</h4> <p>We found no data for satisfaction with treatment, acceptance of treamtent, quality of life or economic outcomes. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD002830-sec-0213" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD002830-sec-0213"></div> <section id="CD002830-sec-0214"> <h3 class="title" id="CD002830-sec-0214">Summary of main results</h3> <section id="CD002830-sec-0215"> <h4 class="title">1 Comparison 1: droperidol versus placebo</h4> <section id="CD002830-sec-0216"> <h5 class="title">1.1 Tranquillisation or asleep: tranquillised/sleep/global state/service use</h5> <p>By 30 minutes, data that we categorise as being of 'high quality' derived from a single trial of over 200 people suggested that droperidol was more acutely tranquillising than placebo (<a href="./references#CD002830-fig-0004" title="">Analysis 1.1</a>). This would fit with clinical experience. This finding also fits with the clear demonstration within the same study of reduced risk of needing additional medication (<a href="./references#CD002830-fig-0007" title="">Analysis 1.4</a>). For the outcome of being ready for discharge, there was no clear difference between groups (RR 1.16, 95% CI 0.9 to 1.48). </p> </section> <section id="CD002830-sec-0217"> <h5 class="title">1.2 Adverse effects</h5> <p>The one relevant trial (N = 227) found no evidence that droperidol caused more cardiovascular arrhythmia and respiratory airway obstruction than placebo. Droperidol has become less accessible because it has been reported that people who receive droperidol are at higher risk of QT prolongation (<a href="./references#CD002830-bbs2-0079" title="EricWooltorton . Droperidol: cardiovascular toxicity and deaths [Droperidol: cardiovascular toxicity and deaths]. Canadian Medical Association Journal2002; Vol. 166, issue 7. ">Wooltorton 2002</a>). We found no evidence for concern in these short trials for people with acute aggressive behaviour. </p> </section> <section id="CD002830-sec-0218"> <h5 class="title">1.3 Missing outcomes</h5> <p>It seems worth noting that the one study we found did not report any key outcomes for mental state and none for costs. The global state reported were very useful and, perhaps, trialists considered them to be adequate for the purposes of this question. However, some type of economic consideration of the outcomes is always important and omission of this from a trial conducted in 2012 to 2013 leaves managers and policy makers less informed than they could have been. </p> </section> </section> <section id="CD002830-sec-0219"> <h4 class="title">2 Comparison 2: droperidol versus haloperidol</h4> <section id="CD002830-sec-0220"> <h5 class="title">2.1 Tranquillisation or asleep: tranquillised/sleep/global state/mental state</h5> <p>By 30 minutes, data that we categorised as being of 'high quality' from a single trial of over 200 people suggested that droperidol was more acutely tranquillising than haloperidol (<a href="./references#CD002830-fig-0011" title="">Analysis 2.1</a>). This finding also fits with the clear demonstration within the same and one other study of reduced risk of needing additional medication (<a href="./references#CD002830-fig-0013" title="">Analysis 2.3</a>). For mental state, there was no evidence of clear difference between the efficacy of droperidol and haloperidol (Scale for Quantification of Psychotic Symptom Severity: MD 0.11, 95% CI ‐0.07 to 0.29) in terms of a reduced mean score by 13 days (<a href="./references#CD002830-fig-0016" title="">Analysis 2.6</a>). This is probably no surprise as key effects of importance in this acutely aggressive situation are measured in hours and by nearly two weeks it would seem unlikely that there should be a discernible difference. </p> </section> <section id="CD002830-sec-0221"> <h5 class="title">2.2 Adverse effects</h5> <p>The one relevant trial (N = 228) found no evidence that droperidol caused more cardiovascular hypotension and cardiovascular hypotension/desaturation than haloperidol (<a href="./references#CD002830-fig-0015" title="">Analysis 2.5</a>). There was no suggestion that use of droperidol was unsafe. </p> </section> <section id="CD002830-sec-0222"> <h5 class="title">2.3 Missing outcomes</h5> <p>The one included trial did not report outcomes of service use and costs. Acknowledging their importance, global and mental state were adequately reported. However, economic consideration and service use were omitted from the study which leaves managers and policy makers less informed regarding the cost effectiveness of droperidol over haloperidol. </p> </section> </section> <section id="CD002830-sec-0223"> <h4 class="title">3 Comparison 3: droperidol versus midazolam</h4> <section id="CD002830-sec-0224"> <h5 class="title">3.1 Tranquillisation or asleep: tranquillised/asleep/global state</h5> <p>By 30 minutes, data that we categorised as being of 'high quality' derived from a single trial of more than 200 people suggested that droperidol was less acutely tranquillising than midazolam in the first few minutes (<a href="./references#CD002830-fig-0017" title="">Analysis 3.1</a>). This would fit with what is known about midazolam from other studies. This finding does not fit with the suggestion within the same study of reduced risk of needing additional medication (<a href="./references#CD002830-fig-0019" title="">Analysis 3.3</a>). </p> </section> <section id="CD002830-sec-0225"> <h5 class="title">3.2 Adverse effects</h5> <p>The one relevant trial (N = 153) reported no statistically significant differences between droperidol and midazolam ‐ but use of midazolam did result in three people (out of around 70) needing some type of 'airway management' with no such events in the droperidol group. Respiratory depression remains a known concern with midazolam (<a href="./references#CD002830-bbs2-0074" title="TREC Collaborative Group. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ2003;327(7417):708‐13. [EMBASE: 2003210869] ">TREC 2003</a>). It is entirely reversible with the use of flumazenil but even these small trials involving midazolam suggested that use of this effective compound should continue to be in units skilled in recognition of respiratory problems and their management (<a href="./references#CD002830-fig-0020" title="">Analysis 3.4</a>). </p> </section> <section id="CD002830-sec-0226"> <h5 class="title">3.3 Missing outcomes</h5> <p>The one relevant study did not report service use, mental state and economic costs. Omitting mental state from a study leaves the clinicians less informed of the relative efficacy of droperidol compared to midazolam. Likewise, not reporting important outcome of costs leaves managers and policy makers less informed regarding the cost effectiveness of droperidol over haloperidol. </p> </section> </section> <section id="CD002830-sec-0227"> <h4 class="title">4 Comparison 4: droperidol versus olanzapine</h4> <section id="CD002830-sec-0228"> <h5 class="title">4.1 Tranquillisation or asleep: tranquillised/asleep/global state/service use</h5> <p>By any time point, we found no clear differences between the older drug (droperidol) and olanzapine (<a href="./references#CD002830-fig-0021" title="">Analysis 4.1</a>). There also was a suggestion that participants allocated to droperidol needed less additional medication than people given the olanzapine (<a href="./references#CD002830-fig-0024" title="">Analysis 4.4</a>). This would fit with clinical experience and other studies of a similar nature (<a href="./references#CD002830-bbs2-0068" title="RaveendranNS , TharyanP , AlexanderJ , AdamsCE , Trec‐India II Collaborative Group. Rapid tranquillisation in psychiatric emergency settings in India: a pragmatic randomised controlled trial of intramuscular olanzapine versus intramuscular haloperidol plus promethazine. BMJ2007;335(7625):865. ">Raveendran 2007</a>). </p> </section> <section id="CD002830-sec-0229"> <h5 class="title">4.2 Adverse effects</h5> <p>The one relevant trial (N = 221) found no evidence that droperidol caused more cardiovascular arrhythmia and respiratory airway obstruction than olanzapine. The concern regarding droperidol and QT prolongation is not obviously supported by the data we found. We found no evidence for concern in this short trial for people with acute aggressive behaviour. </p> </section> <section id="CD002830-sec-0230"> <h5 class="title">4.3 Missing outcomes</h5> <p>We found no economic data. However, droperidol should be cheaper than the olanzapine preparation which may in itself increase the risk of further administration of medications. It would seem that droperidol could be both as or more effective and more cost effective. </p> </section> </section> </section> <section id="CD002830-sec-0231"> <h3 class="title" id="CD002830-sec-0231">Overall completeness and applicability of evidence</h3> <section id="CD002830-sec-0232"> <h4 class="title">1 Completeness</h4> <p>Evidence was certainly relevant, but overall data were too sparse to extensively address the objectives of this review. The search strategy identified six trials involving 733 participants comparing droperidol to placebo, non‐standard medication and standard medication. The included studies addressed most of the outcomes being investigated for this review. However, there still were a few outcomes which were not catered for by the trials. These missing outcomes, such as costs, are of prime importance when estimating the <i>cost</i> effectiveness of droperidol when compared with placebo, other 'standard' treatments or 'non‐standard' treatments. </p> </section> <section id="CD002830-sec-0233"> <h4 class="title">2 Applicability</h4> <p>The included trials were set in psychiatric hospitals, emergency departments and psychiatric crisis units. All trials included people with psychoses. <a href="./references#CD002830-bbs2-0005" title="ResnickM , BurtonBT . Droperidol versus haloperidol in the initial management of acutely agitated patients. Journal of Clinical Psychiatry1984;45(7):298‐9. ">Resnick 1984</a> did not specify beyond stating that participants were admitted involuntarily to the emergency department of a psychiatric unit. <a href="./references#CD002830-bbs2-0006" title="VanLeeuwenAMH , MoldersJ , SterkmansP , MielantsP , MartensC , ToussaintC , et al. Brief communication: droperidol in acutely agitated patients. A double blind placebo‐controlled study. Journal of Nervous and Mental Disease1977;164(4):280‐3. ">Van Leeuwen 1977</a> included people with schizophrenia, manic depression or in a 'confusional state'; however, 10 participants had no specific diagnosis. <a href="./references#CD002830-bbs2-0003" title="CocchiA , FondaP , PerosinoN . Droperidol: a double‐blind clinical study [Droperidol: studio clinico in doppio cieco]. Rivista Sperimentale di Freniatria e Medicina Legale Delle Alienazioni Mentali1971;95(6):1109‐25. ">Cocchi 1971</a> stated that all participants had schizophrenia. These inclusion criteria should make any findings applicable to the acute management of disturbed people thought to experience serious mental illnesses. It is noteworthy that along with inclusion of need for repeat injection in the included studies, outcomes such as further aggressive episodes, tranquillisation, sedation and mental state were also included. However, it is desirable to include outcomes such as quality of life, carer satisfaction, economic costs and loss to follow‐up. </p> </section> </section> <section id="CD002830-sec-0234"> <h3 class="title" id="CD002830-sec-0234">Quality of the evidence</h3> <p>See also <a href="#CD002830-sec-0129">Risk of bias in included studies</a> and <a href="./full#CD002830-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD002830-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD002830-tbl-0003">summary of findings Table 3</a>; and <a href="./full#CD002830-tbl-0004">summary of findings Table 4</a>. </p> <p>Overall the quality of the six include trials was moderate to high based on GRADE. One of the fundamental prerequisites of a randomised trial methodology is random sequence allocation which all trials employed. <a href="./references#CD002830-bbs2-0001" title="CalverL , DrinkwaterV , GuptaR , PageCB , IsbisterGK . Droperidol v. haloperidol for sedation of aggressive behaviour in acute mental health: randomized controlled trial. British Journal of Psychiatry2015;206(3):223‐8. ">Calver 2015</a> used block randomisation. <a href="./references#CD002830-bbs2-0006" title="VanLeeuwenAMH , MoldersJ , SterkmansP , MielantsP , MartensC , ToussaintC , et al. Brief communication: droperidol in acutely agitated patients. A double blind placebo‐controlled study. Journal of Nervous and Mental Disease1977;164(4):280‐3. ">Van Leeuwen 1977</a> specified that treatment was "randomly assigned" with participants listed in chronological order and assigned individually numbered vials. Therefore, it is unclear whether the people randomising participants could have ascertained the order of prescribing. <a href="./references#CD002830-bbs2-0005" title="ResnickM , BurtonBT . Droperidol versus haloperidol in the initial management of acutely agitated patients. Journal of Clinical Psychiatry1984;45(7):298‐9. ">Resnick 1984</a> did not specify the explicit means of allocation, although they stated that participants received treatment on a "randomised basis", and that the codes identifying the packages of medication were "kept in the pharmacy until the conclusion of the study". <a href="./references#CD002830-bbs2-0003" title="CocchiA , FondaP , PerosinoN . Droperidol: a double‐blind clinical study [Droperidol: studio clinico in doppio cieco]. Rivista Sperimentale di Freniatria e Medicina Legale Delle Alienazioni Mentali1971;95(6):1109‐25. ">Cocchi 1971</a> specified only that the study was randomised, with no details regarding the means of allocation. In effort to minimise bias, most of the included trials were double‐blind. All studies reported data for all outcomes listed and were therefore rated at low risk of bias with the exception of one study (<a href="./references#CD002830-bbs2-0004" title="KnottJC , TaylorD , CastleDJ . Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Annals of Emergency Medicine2006; Vol. 47, issue 1:61‐7. ">Knott 2006</a>), which we rated as having unclear risk of reporting bias. Therefore, we considered the quality of evidence high. </p> </section> <section id="CD002830-sec-0235"> <h3 class="title" id="CD002830-sec-0235">Potential biases in the review process</h3> <p>The search criteria on the Cochrane Schizophrenia Group Trials Register (December 2015) are sufficiently robust to detect relevant studies. However, it is possible that we have failed to identify small studies but we think it unlikely that we would have missed large trials. Studies published in languages other than English, and those with equivocal results, are often difficult to find (<a href="./references#CD002830-bbs2-0036" title="EggerM , SmithGD , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315:629‐34. ">Egger 1997</a>). Our search was biased by use of English phrases. However, given that the Cochrane Schizophrenia Group's Register covers many languages but is indexed in English we feel that this would not have missed many studies within the register. For example, the search uncovered two studies for which the title was only available in Chinese characters. A Chinese‐speaking colleague (Jun Xia) checked these for relevance and neither were relevant to this review. </p> <p>Furthermore, we were not blinded to the names of the authors, institutions or journal of publication which may have introduced some type of bias in the review process. </p> </section> <section id="CD002830-sec-0236"> <h3 class="title" id="CD002830-sec-0236">Agreements and disagreements with other studies or reviews</h3> <p>A previous version of this review did not identify many studies that met the inclusion criteria (<a href="./references#CD002830-bbs2-0082" title="CureS , RathboneJ , CarpenterS . Droperidol for acute psychosis. Cochrane Database of Systematic Reviews2004, Issue 4. [DOI: 10.1002/14651858.CD002830.pub2; PUBMED: 15495037] ">Cure 2004</a>). However, this updated version of the review found three more relevant studies. At this point, we are unaware of any other similar reviews or studies. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD002830-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/urn:x-wiley:14651858:media:CD002830:CD002830-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_t/tCD002830-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Droperidol structure." data-id="CD002830-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Droperidol structure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/full#CD002830-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002830-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/urn:x-wiley:14651858:media:CD002830:CD002830-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_t/tCD002830-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="2015 study flow diagram." data-id="CD002830-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>2015 study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/full#CD002830-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002830-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/urn:x-wiley:14651858:media:CD002830:CD002830-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_t/tCD002830-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD002830-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/full#CD002830-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002830-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/urn:x-wiley:14651858:media:CD002830:CD002830-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_t/tCD002830-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Droperidol versus placebo, Outcome 1 Tranquillisation or asleep: 1. tranquillised/sleep." data-id="CD002830-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Droperidol versus placebo, Outcome 1 Tranquillisation or asleep: 1. tranquillised/sleep.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/references#CD002830-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002830-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/urn:x-wiley:14651858:media:CD002830:CD002830-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_t/tCD002830-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Droperidol versus placebo, Outcome 2 Tranquillisation or asleep: 2. difficulty in achieving tranquillisation/sleep." data-id="CD002830-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Droperidol versus placebo, Outcome 2 Tranquillisation or asleep: 2. difficulty in achieving tranquillisation/sleep. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/references#CD002830-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002830-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/urn:x-wiley:14651858:media:CD002830:CD002830-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_t/tCD002830-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Droperidol versus placebo, Outcome 3 Tranquillisation or asleep: 3. time to tranquillisation/sleep (minutes)." data-id="CD002830-fig-0006" src="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Droperidol versus placebo, Outcome 3 Tranquillisation or asleep: 3. time to tranquillisation/sleep (minutes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/references#CD002830-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002830-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/urn:x-wiley:14651858:media:CD002830:CD002830-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_t/tCD002830-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Droperidol versus placebo, Outcome 4 Global state: use of additional medication." data-id="CD002830-fig-0007" src="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Droperidol versus placebo, Outcome 4 Global state: use of additional medication. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/references#CD002830-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002830-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/urn:x-wiley:14651858:media:CD002830:CD002830-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_t/tCD002830-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Droperidol versus placebo, Outcome 5 Adverse effects." data-id="CD002830-fig-0008" src="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Droperidol versus placebo, Outcome 5 Adverse effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/references#CD002830-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002830-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/urn:x-wiley:14651858:media:CD002830:CD002830-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_t/tCD002830-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Droperidol versus placebo, Outcome 6 Service use: 1 person able to be discharged home." data-id="CD002830-fig-0009" src="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Droperidol versus placebo, Outcome 6 Service use: 1 person able to be discharged home. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/references#CD002830-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002830-fig-0010"> <p> <div class="table" id="CD002830-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median (hours)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interquartile range</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chan 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Droperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.7 to 13.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chan 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.7 to 14.7</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Droperidol versus placebo, Outcome 7 Service use: 2 emergency department length of stay. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/references#CD002830-fig-0010">Navigate to figure in review</a></div> </div> <div class="figure" id="CD002830-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/urn:x-wiley:14651858:media:CD002830:CD002830-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_t/tCD002830-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Droperidol versus haloperidol, Outcome 1 Tranquillisation or asleep: 1. tranquillised/sleep within 120 minutes." data-id="CD002830-fig-0011" src="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Droperidol versus haloperidol, Outcome 1 Tranquillisation or asleep: 1. tranquillised/sleep within 120 minutes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/references#CD002830-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002830-fig-0012"> <p> <div class="table" id="CD002830-tblf-0003"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median (minutes)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interquartile range</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calver 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Droperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 to 30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calver 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 to 30</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Droperidol versus haloperidol, Outcome 2 Tranquillisation or asleep: 2. time to tranquillisation/sleep. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/references#CD002830-fig-0012">Navigate to figure in review</a></div> </div> <div class="figure" id="CD002830-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/urn:x-wiley:14651858:media:CD002830:CD002830-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_t/tCD002830-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Droperidol versus haloperidol, Outcome 3 Global state: use of additional medication." data-id="CD002830-fig-0013" src="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Droperidol versus haloperidol, Outcome 3 Global state: use of additional medication. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/references#CD002830-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002830-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/urn:x-wiley:14651858:media:CD002830:CD002830-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_t/tCD002830-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Droperidol versus haloperidol, Outcome 4 Global state: no overall improvement ‐ by 30 days." data-id="CD002830-fig-0014" src="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Droperidol versus haloperidol, Outcome 4 Global state: no overall improvement ‐ by 30 days. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/references#CD002830-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002830-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/urn:x-wiley:14651858:media:CD002830:CD002830-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_t/tCD002830-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Droperidol versus haloperidol, Outcome 5 Adverse effects." data-id="CD002830-fig-0015" src="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Droperidol versus haloperidol, Outcome 5 Adverse effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/references#CD002830-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002830-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/urn:x-wiley:14651858:media:CD002830:CD002830-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_t/tCD002830-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Droperidol versus haloperidol, Outcome 6 Mental state: Average score by 13 days (Scale for Quantification of Psychotic Symptom Severity, high = poor)." data-id="CD002830-fig-0016" src="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Droperidol versus haloperidol, Outcome 6 Mental state: Average score by 13 days (Scale for Quantification of Psychotic Symptom Severity, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/references#CD002830-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002830-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/urn:x-wiley:14651858:media:CD002830:CD002830-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_t/tCD002830-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Droperidol versus midazolam, Outcome 1 Tranquillisation or asleep: 1. tranquillised/asleep." data-id="CD002830-fig-0017" src="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Droperidol versus midazolam, Outcome 1 Tranquillisation or asleep: 1. tranquillised/asleep. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/references#CD002830-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002830-fig-0018"> <p> <div class="table" id="CD002830-tblf-0004"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median (minutes)</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Knott 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Droperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Knott 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Midazolam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.5</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Droperidol versus midazolam, Outcome 2 Tranquillisation or asleep: 2 time to tranquillisation/sleep. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/references#CD002830-fig-0018">Navigate to figure in review</a></div> </div> <div class="figure" id="CD002830-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/urn:x-wiley:14651858:media:CD002830:CD002830-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_t/tCD002830-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Droperidol versus midazolam, Outcome 3 Global state: use of additional medication." data-id="CD002830-fig-0019" src="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Droperidol versus midazolam, Outcome 3 Global state: use of additional medication. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/references#CD002830-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002830-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/urn:x-wiley:14651858:media:CD002830:CD002830-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_t/tCD002830-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Droperidol versus midazolam, Outcome 4 Adverse effects." data-id="CD002830-fig-0020" src="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Droperidol versus midazolam, Outcome 4 Adverse effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/references#CD002830-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002830-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/urn:x-wiley:14651858:media:CD002830:CD002830-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_t/tCD002830-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Droperidol versus olanzapine, Outcome 1 Tranquillisation or asleep: 1. tranquillised/asleep." data-id="CD002830-fig-0021" src="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Droperidol versus olanzapine, Outcome 1 Tranquillisation or asleep: 1. tranquillised/asleep. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/references#CD002830-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002830-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/urn:x-wiley:14651858:media:CD002830:CD002830-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_t/tCD002830-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Droperidol versus olanzapine, Outcome 2 Tranquillisation or asleep: 2. difficulty in achieving tranquillisation/sleep." data-id="CD002830-fig-0022" src="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Droperidol versus olanzapine, Outcome 2 Tranquillisation or asleep: 2. difficulty in achieving tranquillisation/sleep. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/references#CD002830-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002830-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/urn:x-wiley:14651858:media:CD002830:CD002830-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_t/tCD002830-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Droperidol versus olanzapine, Outcome 3 Tranquillisation or asleep: 3. time to tranquillisation/sleep (minutes)." data-id="CD002830-fig-0023" src="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Droperidol versus olanzapine, Outcome 3 Tranquillisation or asleep: 3. time to tranquillisation/sleep (minutes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/references#CD002830-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002830-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/urn:x-wiley:14651858:media:CD002830:CD002830-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_t/tCD002830-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Droperidol versus olanzapine, Outcome 4 Global state: use of additional medication." data-id="CD002830-fig-0024" src="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Droperidol versus olanzapine, Outcome 4 Global state: use of additional medication. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/references#CD002830-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002830-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/urn:x-wiley:14651858:media:CD002830:CD002830-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_t/tCD002830-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Droperidol versus olanzapine, Outcome 5 Adverse effects." data-id="CD002830-fig-0025" src="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Droperidol versus olanzapine, Outcome 5 Adverse effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/references#CD002830-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002830-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/urn:x-wiley:14651858:media:CD002830:CD002830-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_t/tCD002830-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Droperidol versus olanzapine, Outcome 6 Service use: 1. person able to be discharged home." data-id="CD002830-fig-0026" src="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Droperidol versus olanzapine, Outcome 6 Service use: 1. person able to be discharged home. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/references#CD002830-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/media/CDSR/CD002830/image_n/nCD002830-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002830-fig-0027"> <p> <div class="table" id="CD002830-tblf-0005"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median (hours)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interquartile range</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chan 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Droperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.7 to 13.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chan 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.2 to 14.7</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Droperidol versus olanzapine, Outcome 7 Service use: 2. emergency department length of stay. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/references#CD002830-fig-0027">Navigate to figure in review</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD002830-tbl-0011"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Design of a future study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised (clearly described).</p> <p>Blinding: single blind (outcomes assessor).</p> <p>Duration: up to 2 weeks.</p> <p>Design: parallel.</p> <p>Setting: emergency settings.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diagnosis: people whose aggressive behaviour is thought due to psychotic illness.</p> <p>N = 300.</p> <p>Age: &gt; 18 years.</p> <p>Sex: not applicable.</p> <p>Inclusion criteria: other measures failed.</p> <p>Exclusion criteria: specific contraindication to evaluated treatments.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Droperidol. N = 150.</p> <p>2. Drug intervention of choice. N = 150.</p> <p>Both drugs should be known to be effective, but the comparative effectiveness be unclear.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tranquil/asleep: binary outcomes, time.</p> <p>Behaviour: need for additional medication, additional aggressive episode.</p> <p>Adverse effects.</p> <p>Acceptability of treatment.</p> <p>Costs: cost of services, cost of care.</p> <p>Quality of life.</p> <p>Service outcomes: days in hospital, discharged, transfer to secure unit.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Notes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study should comply with <a href="http://www.consort-statement.org/" target="_blank">CONSORT</a> and <a href="http://www.alltrials.net/" target="_blank">AllTrials</a>. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Design of a future study</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/full#CD002830-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002830-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Droperidol versus placebo</span></div> <tbody> <tr class="table-header separated"> <td align="left" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b>Droperidol versus placebo</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> acute psychosis </p> <p><b>Setting:</b> inpatient </p> <p><b>Intervention:</b> droperidol </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with droperidol</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tranquillisation or asleep: tranquillised/sleep ‐ by around 30 minutes</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.18<br/> (1.05 to 1.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>227<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>'Moderate' control risk approximately that of trial population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>800 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>944 per 1000<br/> (840 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Global state: use of additional medication ‐ by 60 minutes after initial adequate sedation until ED discharge (various psychotropic drugs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.55<br/> (0.36 to 0.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>227<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>'Moderate' control risk approximately that of trial population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>400 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>220 per 1000<br/> (144 to 340) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects ‐ cardiovascular ‐ arrhythmia</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.34<br/> (0.01 to 8.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>227<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>'Moderate' control risk approximately that of trial population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000<br/> (0 to 83) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects ‐ respiratory ‐ airway obstruction</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.62<br/> (0.15 to 2.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>227<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low <sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>'Moderate' control risk approximately that of trial population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000<br/> (6 to 101) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Service use: person able to be discharged home</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.16<br/> (0.90 to 1.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>227<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>'Moderate' control risk approximately that of trial population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>580 per 1000<br/> (450 to 740) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mental state ‐ improvement</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No trial reported this important outcome.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Economic: direct costs</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No trial reported this important outcome.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>ED:</b> emergency department; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: rated 'not serious' (no downgrade) ‐ clear reporting of good methods. </p> <p><sup>2</sup> Indirectness: rated 'not serious' (no downgrade) ‐ but proxy outcome for 'Another episode of aggression by 24 hours'. </p> <p><sup>3</sup> Imprecision: rated 'serious' (downgraded by 1) ‐ few events, wide confidence intervals. </p> <p><sup>4</sup> Indirectness: rated 'serious' (downgraded by 1) ‐ respiratory obstruction proxy measure ‐ not 'death'. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Droperidol versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/full#CD002830-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002830-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Droperidol versus haloperidol</span></div> <tbody> <tr class="table-header separated"> <td align="left" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b>Droperidol versus haloperidol</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> acute psychosis </p> <p><b>Setting:</b> inpatient </p> <p><b>Intervention:</b> droperidol </p> <p><b>Comparison:</b> haloperidol </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with haloperidol</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with droperidol</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tranquillisation or asleep: tranquillised/sleep ‐ by around 30 minutes</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.01<br/> (0.93 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>228<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>'Moderate' control risk approximately that of trial population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>920 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>929 per 1000<br/> (856 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Global state: use of additional medication ‐ by 60 minutes after initial adequate sedation until ED discharge (various psychotropic drugs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.37<br/> (0.16 to 0.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>255<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>'Moderate' control risk approximately that of trial population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>160 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>59 per 1000<br/> (26 to 144) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects ‐ cardiovascular ‐ hypotension</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.80<br/> (0.30 to 26.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>228<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>'Moderate' control risk approximately that of trial population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000<br/> (3 to 265) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects ‐ cardiovascular ‐ hypotension/desaturation</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.80 (0.12 to 67.98)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>228<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low <sup>1,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>'Moderate' control risk approximately that of trial population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Service use: person able to be discharged home</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not pooled</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No trial reported this important outcome.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mental state: mean score by 13 days (Scale for Quantification of Psychotic Symptom Severity, high = poor) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: mean score by 13 days (Scale for Quantification of Psychotic Symptom Severity, high = poor) was 0 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: mean score by 13 days (Scale for Quantification of Psychotic Symptom Severity, high = poor) in the intervention group was 0.11 undefined more (0.07 fewer to 0.29 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.11</p> <p>CI ‐0.07 to 0.29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low <sup>1,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>'Moderate' control risk approximately that of trial population.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Economic: direct costs</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No trial reported this important outcome.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>ED:</b> emergency department; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: rated 'not serious' (no downgrade) ‐ clear reporting of good methods. </p> <p><sup>2</sup> Indirectness: rated 'not serious' (no downgrade) ‐ but proxy outcome for 'Another episode of aggression by 24 hours'. </p> <p><sup>3</sup> Imprecision: rated 'serious' (downgraded by 1) ‐ few events, wide confidence intervals. </p> <p><sup>4</sup> Indirectness: rated 'serious' (downgraded by 1) ‐ hypotension/desaturation proxy measure ‐ not 'death'. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Droperidol versus haloperidol</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/full#CD002830-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002830-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Droperidol versus midazolam</span></div> <tbody> <tr class="table-header separated"> <td align="left" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b>Droperidol versus midazolam</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> acute psychosis </p> <p><b>Setting:</b> inpatient </p> <p><b>Intervention:</b> droperidol </p> <p><b>Comparison:</b> midazolam </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with midazolam</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with droperidol</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tranquillisation or asleep: tranquillised/asleep ‐ by 30 minutes (at 10 minutes)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.96<br/> (0.72 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>153<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>'Moderate' control risk approximately that of trial population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>550 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>528 per 1000<br/> (396 to 704) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Global state: use of additional medication ‐ by 60 minutes after initial adequate sedation until ED discharge (various psychotropic drugs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.54 (0.24 to 1.20)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>153<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>'Moderate' control risk approximately that of trial population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>190 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>101 per 1000<br/> (42 to 224) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects ‐ respiratory ‐ airway obstruction</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.13<br/> (0.01 to 2.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>153<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low <sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>'Moderate' control risk approximately that of trial population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000<br/> (0 to 102) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects ‐ respiratory ‐ hypoxia</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.70<br/> (0.16 to 3.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>153<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>'Moderate' control risk approximately that of trial population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>35 per 1000<br/> (8 to 143) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Service use: person able to be discharged home</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No trial reported this important outcome.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mental state ‐ improvement</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No trial reported this important outcome.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Economic: direct costs</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No trial reported this important outcome.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>ED:</b> emergency department; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: rated 'not serious' (no downgrade) ‐ clear reporting of good methods. </p> <p><sup>2</sup> Imprecision: rated 'serious' (downgraded by 1) ‐ few events, wide confidence intervals. </p> <p><sup>3</sup> Indirectness: rated 'serious' (downgraded by 1) ‐ respiratory obstruction proxy measure ‐ not 'death'. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Droperidol versus midazolam</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/full#CD002830-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002830-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Droperidol versus olanzapine</span></div> <tbody> <tr class="table-header separated"> <td align="left" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b>Droperidol versus olanzapine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> acute psychosis </p> <p><b>Setting:</b> inpatient </p> <p><b>Intervention:</b> droperidol </p> <p><b>Comparison:</b> olanzapine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with olanzapine</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with droperidol</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tranquillisation or asleep: tranquillised/asleep ‐ by around 30 minutes</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.02<br/> (0.94 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>221<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>'Moderate' control risk approximately that of trial population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>900 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>918 per 1000<br/> (846 to 999) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Global state: use of additional medication ‐ by 60 minutes after initial adequate sedation until ED discharge (various psychotropic drugs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.56<br/> (0.36 to 0.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>221<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>'Moderate' control risk approximately that of trial population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>370 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>207 per 1000<br/> (133 to 322) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects ‐ cardiovascular ‐ arrhythmia</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.32<br/> (0.01 to 7.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>221<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>'Moderate' control risk approximately that of trial population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000<br/> (0 to 79) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects ‐ respiratory ‐ airway obstruction</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.97<br/> (0.20 to 4.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>221<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low <sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>'Moderate' control risk approximately that of trial population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000<br/> (6 to 142) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Service use: person able to be discharged home</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.06<br/> (0.83 to 1.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>221<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>'Moderate' control risk approximately that of trial population.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>530 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>562 per 1000<br/> (440 to 710) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mental state ‐ improvement</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No trial reported this important outcome.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Economic: direct costs</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No trial reported this important outcome.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>ED:</b> emergency department; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: rated 'not serious' (no downgrade) ‐ clear reporting of good methods. </p> <p><sup>2</sup> Imprecision: rated 'serious' (downgraded by 1) ‐ few events, wide confidence intervals. </p> <p><sup>3</sup> Indirectness: rated 'serious' (downgraded by 1) ‐ respiratory obstruction proxy measure ‐ not 'death'. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Droperidol versus olanzapine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/full#CD002830-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD002830-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Survey of 20 medical directors of emergency departments in the USA</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Favoured drug</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol + lorazepam ± benztropine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Droperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Benzodiazepine (unspecified) alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Droperidol + lorazepam + diphenhydramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol + benztropine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Survey of 20 medical directors of emergency departments in the USA</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/full#CD002830-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD002830-tbl-0006"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Preferred medication for rapid tranquillisation in Rio de Janeiro</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Drug of choice</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean dose (mg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Frequency of use</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol + promethazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (2.5 to 10) + 50 (25 to 100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol + promethazine + diazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (2.5 to 10) + 50 (25 to 100) +10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol + promethazine + chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 + 50 + 25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine + diazepam + promethazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 + 10 + 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine + promethazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 + 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diazepam + promethazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 + 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol + diazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 + 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Promethazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1%</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Preferred medication for rapid tranquillisation in Rio de Janeiro</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/full#CD002830-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD002830-tbl-0007"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Drugs for rapid tranquillisation in London survey</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Drug of choice</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean dose (mg)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diazepam*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27 (10 to 80)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 (10 to 60)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>162 (50 to 400)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Droperidol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 (10 to 20)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paraldehyde</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>U/K</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amytal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>U/K</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lorazepam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>U/K</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nitrazepam**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>U/K</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>* most frequent; **least frequent; U/K: unknown.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Drugs for rapid tranquillisation in London survey</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/full#CD002830-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD002830-tbl-0008"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Other relevant Cochrane reviews</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Focus of review</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Completed and maintained reviews</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>'As required' medication regimens for seriously mentally ill people in hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002830-bbs2-0031" title="ChakrabartiA , WhicherEV , MorrisonM , Douglas‐HallP . 'As required' medication regimens for seriously mentally ill people in hospital. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD003441.pub2] ">Chakrabarti 2007</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Benzodiazepines for psychosis‐induced aggression or agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002830-bbs2-0041" title="GilliesD , BeckA , McCloudA , RathboneJ . Benzodiazepines for psychosis‐induced aggression or agitation. Cochrane Database of Systematic Reviews2005, Issue 4. [DOI: 10.1002/14651858.CD003079.pub2] ">Gillies 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlorpromazine for psychosis‐induced aggression or agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002830-bbs2-0021" title="AhmedU , JonesH , AdamsCE . Chlorpromazine for psychosis induced aggression or agitation. Cochrane Database of Systematic Reviews2010, Issue 4. [DOI: 10.1002/14651858.CD007445.pub2; PUBMED: 20393959] ">Ahmed 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clotiapine for acute psychotic illnesses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002830-bbs2-0026" title="BerkM , RathboneJ , Mandriota‐CarpenterSL . Clotiapine for acute psychotic illnesses. Cochrane Database of Systematic Reviews2004, Issue 4. [DOI: 10.1002/14651858.CD002304.pub2; CD002304] ">Berk 2004</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Containment strategies for people with serious mental illness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002830-bbs2-0062" title="MuralidharanS , FentonM . Containment strategies for people with serious mental illness. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD002084.pub2] ">Muralidharan 2006</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Droperidol for acute psychosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This review</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002830-bbs2-0066" title="PowneyMJ , AdamsCE , JonesH . Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation). Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD009377.pub2; PUBMED: 23152276] ">Powney 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol + promethazine for psychosis‐induced aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002830-bbs2-0048" title="HufG , AlexanderJ , Allen MichaelH , Raveendran NirmalS . Haloperidol plus promethazine for psychosis‐induced aggression. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD005146.pub2; CD005146] ">Huf 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Olanzapine IM or olanzapine orodispersible tablet for acutely disturbed/agitated people with suspected serious mental illnesses </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002830-bbs2-0025" title="BelgamwarRB , FentonM . Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD003729.pub2] ">Belgamwar 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Seclusion and restraint for serious mental illnesses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002830-bbs2-0070" title="SailasE , FentonM . Seclusion and restraint for people with serious mental illnesses. Cochrane Database of Systematic Reviews2000, Issue 2. [DOI: 10.1002/14651858.CD001163] ">Sailas 2000</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002830-bbs2-0040" title="GibsonRC , FentonM , CoutinhoES , CampbellC . Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. Cochrane Database of Systematic Reviews2004, Issue 3. [DOI: 10.1002/14651858.CD000525.pub2] ">Gibson 2004</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Reviews in the process of being completed or updated</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone for psychosis‐induced aggression or agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002830-bbs2-0022" title="AhmedU , RehmanF , JonesH , AdamsCE . Risperidone for psychosis induced aggression or agitation. Cochrane Database of Systematic Reviews2011, Issue 11. [DOI: 10.1002/14651858.CD009412; CD009412] ">Ahmed 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haloperidol for long‐term aggression in psychosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002830-bbs2-0051" title="KhushuA , PowneyMJ , AdamsCE . Haloperidol for long‐term aggression in psychosis. Cochrane Database of Systematic Reviews2012, Issue 5. [DOI: 10.1002/14651858.CD009830] ">Khushu 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Loxapine inhaler for psychosis‐induced aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002830-bbs2-0076" title="VangalaR , AhmedU , AhmedR . Loxapine inhaler for psychosis‐induced aggression or agitation. Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD010190] ">Vangala 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clozapine for people with schizophrenia and recurrent physical aggression (Title)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002830-bbs2-0073" title="ToalF , RobertsK . Clozapine for people with schizophrenia and recurrent physical aggression. Cochrane Database of Systematic Reviews: Registered title. ">Toal 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine for psychosis‐induced aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002830-bbs2-0077" title="WilkieF , FentonM . Quetiapine for psychosis‐induced aggression or agitation. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD009801] ">Wilkie 2012</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>De‐escalation techniques for psychosis‐induced aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002830-bbs2-0067" title="RaoH , YeungWL , JayaramMB . De‐escalation techniques for psychosis‐induced aggression or agitation. Cochrane Database of Systematic Reviews2012, Issue 7. [DOI: 10.1002/14651858.CD009922] ">Rao 2012</a> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>IM: intramuscular.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Other relevant Cochrane reviews</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/full#CD002830-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD002830-tbl-0009"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Length of included studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Immediate (&lt; 2 hours)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Short term (&gt; 2 hours to 24 hours)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Medium term (&gt; 24 hours to 2 weeks)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Long term (&gt; 2 weeks)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002830-bbs2-0006" title="VanLeeuwenAMH , MoldersJ , SterkmansP , MielantsP , MartensC , ToussaintC , et al. Brief communication: droperidol in acutely agitated patients. A double blind placebo‐controlled study. Journal of Nervous and Mental Disease1977;164(4):280‐3. ">Van Leeuwen 1977</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ (3 and 30 min)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002830-bbs2-0002" title="ChanE , TaylorD , KongD , KnottJ , PhillipsG , CastleD . IV droperidol or olanzapine as adjuncts to midazolam for the acutely agitated patient: a multi‐centre, randomised, double‐blind, placebo‐controlled, clinical trial. Schizophrenia Research2012;136:S259. ChanEW , TaylorDM , KnottJC , PhillipsGA , CastleDJ , KongDCM . Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Annals of Emergency Medicine2013;61(1):72‐81. ">Chan 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ (5, 10 and 60 min)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002830-bbs2-0001" title="CalverL , DrinkwaterV , GuptaR , PageCB , IsbisterGK . Droperidol v. haloperidol for sedation of aggressive behaviour in acute mental health: randomized controlled trial. British Journal of Psychiatry2015;206(3):223‐8. ">Calver 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ (10 min)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ (120 min)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002830-bbs2-0004" title="KnottJC , TaylorD , CastleDJ . Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Annals of Emergency Medicine2006; Vol. 47, issue 1:61‐7. ">Knott 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ (within 60 min)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ (2 hours)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002830-bbs2-0005" title="ResnickM , BurtonBT . Droperidol versus haloperidol in the initial management of acutely agitated patients. Journal of Clinical Psychiatry1984;45(7):298‐9. ">Resnick 1984</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ (15 and 30 min)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ (24 hours)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002830-bbs2-0003" title="CocchiA , FondaP , PerosinoN . Droperidol: a double‐blind clinical study [Droperidol: studio clinico in doppio cieco]. Rivista Sperimentale di Freniatria e Medicina Legale Delle Alienazioni Mentali1971;95(6):1109‐25. ">Cocchi 1971</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>✓ (30 days)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>min: minute.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Length of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/full#CD002830-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD002830-tbl-0010"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Randomised excluded studies relevant to other reviews</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Excluded study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b> Participants</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Suggested comparison</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Existing review</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> People with serious mental illness</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> People without mental illness</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002830-bbs2-0012" title="胡光涛 , 李志宏 , 王国威 , 黄一 , 贺英 . Mesylate injection of acute agitation in schizophrenia symptoms. Efficacy of ziprasidone treatment [Google translate] [注射用甲磺酸齐拉西酮治疗精神分裂症急性激越症状疗效观察]. 中国新药与临床杂志2014;33(1):57‐60. ">Hu 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute agitation and schizophrenia.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haloperidol vs. ziprasidone for acute agitation and schizophrenia.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002830-bbs2-0066" title="PowneyMJ , AdamsCE , JonesH . Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation). Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD009377.pub2; PUBMED: 23152276] ">Powney 2012</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002830-bbs2-0007" title="CocitoE , AmbrosiniG , ArataA , BevilacquaP , TortoraE . Clinical evaluation of 112 psychiatric patients of a butyrophenone neuroleptic, dehydrobenzperidol (R 4749). Arzneimittelforschung1970;20(8):1119‐25. ">Cocito 1970</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>With psychosis in hospital, not acutely ill.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Droperidol for (non‐acute) psychosis.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD002830-bbs2-0013" title="IsbisterGK , CalverLA , PageCB , StokesB , BryantJL , DownesMA . Randomized controlled trial of intramuscular droperidol versus midazolam for violence and acute behavioral disturbance: the DORM study. Annals of Emergency Medicine2010;56(4):392‐401. ">Isbister 2010</a>; <a href="./references#CD002830-bbs2-0017" title="RosenCL , RatliffAF , WolfeRE , BranneySW , RoeEJ , PonsPT . The efficacy of intravenous droperidol in the prehospital setting. Journal of Emergency Medicine1997;15(1):13‐7. ">Rosen 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with violent and acute behavioural disturbance. No mention of any underlying psychiatric illness. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Droperidol for acute non‐psychiatric disturbance.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mostly people with trauma and medical reasons for their disturbance (total 46), 1 with 'psychiatric' diagnosis. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002830-bbs2-0015" title="RichardsJR , DerletRW , DuncanDR . Metamphetamine toxicity: treatment with a benzodiazepine versus a butyrophenone. European Journal of Emergency Medicine1997;4:130‐5. ">Richards 1997</a>; <a href="./references#CD002830-bbs2-0016" title="RichardsJR , DerletRW , DuncanDR . Chemical restraint for the agitated patient in the emergency department: lorazepam versus droperidol. Journal of Emergency Medicine1998;16(4):567‐73. ">Richards 1998</a>; </p> <p><a href="./references#CD002830-bbs2-0018" title="ThomasHJr , SchwartzE , PetrilliR . Droperidol versus haloperidol for chemical restraint of agitated and combative patients. Annals of Emergency Medicine1992;21(4):407‐13. ">Thomas 1992</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with drug‐induced toxicity, not people with severe mental illnesses.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Droperidol for drug‐induced toxicity.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002830-bbs2-0009" title="FosterPN , StickleBR , DaleM , LaurenceAS . Akathisia after low‐dose droperidol. British Journal of Anaesthesia1995;74:477P. ">Foster 1995</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Healthy women attending day hospital for minor surgery.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Droperidol for minor surgery.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Randomised excluded studies relevant to other reviews</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/full#CD002830-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002830-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Droperidol versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Tranquillisation or asleep: 1. tranquillised/sleep <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 By 5 minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.90, 1.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 By 10 minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [1.08, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 By 30 minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [1.05, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 By 60 minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [1.00, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Tranquillisation or asleep: 2. difficulty in achieving tranquillisation/sleep <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.10, 2.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Tranquillisation or asleep: 3. time to tranquillisation/sleep (minutes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐46.5 [‐86.83, ‐6.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Global state: use of additional medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 "To reach initial adequate sedation"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.28, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 By 3 minutes (haloperidol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.18, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 By 30 minutes (any psychotropic drug)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.17, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 By 60 minutes (midazolam, droperidol, olanzapine, haloperidol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.42, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 By 60 minutes after initial adequate sedation until emergency department discharge (various psychotropic drugs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.36, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Cardiovascular ‐ arrhythmia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Cardiovascular ‐ hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.20, 2.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Central nervous system ‐ oversedation (decreased Glasgow Coma Score of 6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Respiratory ‐ airway obstruction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.15, 2.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 Respiratory ‐ oxygen desaturation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.42, 2.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6 Unspecified ‐ by 3 minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Service use: 1 person able to be discharged home <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.90, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Service use: 2 emergency department length of stay <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Droperidol versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/references#CD002830-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002830-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Droperidol versus haloperidol</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Tranquillisation or asleep: 1. tranquillised/sleep within 120 minutes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.93, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Tranquillisation or asleep: 2. time to tranquillisation/sleep <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Global state: use of additional medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Midazolam administered initially</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.26 [0.69, 15.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 By 30 minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.20, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 By 60 minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.16, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 By 90 minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.02, 10.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Global state: no overall improvement ‐ by 30 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.29, 1.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Cardiovascular ‐ hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.80 [0.30, 26.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Cardiovascular ‐ hypotension/desaturation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.80 [0.12, 67.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Central nervous system ‐ extrapyramidal adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.80 [0.12, 67.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Central nervous system ‐ oversedation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.80 [0.12, 67.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 Staff injuries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.14, 2.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mental state: Average score by 13 days (Scale for Quantification of Psychotic Symptom Severity, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [‐0.07, 0.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Droperidol versus haloperidol</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/references#CD002830-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002830-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Droperidol versus midazolam</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Tranquillisation or asleep: 1. tranquillised/asleep <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 At 5 minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.21, 0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 At 10 minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.72, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Tranquillisation or asleep: 2 time to tranquillisation/sleep <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Global state: use of additional medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.24, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 By 60 minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.24, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Cardiovascular ‐ arrhythmia (bradycardia)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.81 [0.12, 67.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Cardiovascular ‐ hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.16, 3.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Central nervous system ‐ dystonic reaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.56 [0.34, 124.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Central nervous system ‐ seizure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Gastric ‐ aspiration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Gastric ‐ vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7 Respiratory ‐ airway management</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.01, 2.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8 Respiratory ‐ assistance with ventilation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9 Respiratory ‐ hypoxia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.16, 3.03]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Droperidol versus midazolam</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/references#CD002830-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002830-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Droperidol versus olanzapine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Tranquillisation or asleep: 1. tranquillised/asleep <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 At 5 minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.70, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 At 10 minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.81, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 At 30 minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.94, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 At 60 minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.93, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Tranquillisation or asleep: 2. difficulty in achieving tranquillisation/sleep <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.11, 3.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Tranquillisation or asleep: 3. time to tranquillisation/sleep (minutes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.30 [‐11.74, 26.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Global state: use of additional medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 'To reach initial adequate sedation"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.36, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 By 60 minutes (midazolam, droperidol, olanzapine, haloperidol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.63, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 From 60 minutes after initial adequate sedation until emergency department discharge (various psychotropic drugs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.36, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Cardiovascular ‐ arrhythmia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Cardiovascular ‐ hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.30, 5.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Central nervous system ‐ decreased Glasgow Coma Score of 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Respiratory ‐ airway obstruction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.20, 4.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 Respiratory ‐ oxygen desaturation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [0.61, 5.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Service use: 1. person able to be discharged home <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.83, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Service use: 2. emergency department length of stay <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Droperidol versus olanzapine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002830.pub3/references#CD002830-tbl-0015">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD002830.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD002830-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD002830-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD002830-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD002830-note-0002">Hrvatski</a> </li> <li class="section-language"> <a class="" href="pl#CD002830-note-0004">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD002830-note-0001">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002830\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002830\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002830\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002830\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002830\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002830\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002830\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002830\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002830\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002830\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002830\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002830\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002830\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002830\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002830\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002830\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002830\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002830\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=XwNPMGod&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002830.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002830.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD002830.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD002830.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002830.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740713998934"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002830.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740713998937"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002830.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d63f70d37937a',t:'MTc0MDcxMzk5OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 